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Bovine tuberculosis (TB), caused by Mycobacterium bovis, is increasing in incidence 
in the United Kingdom and detailed knowledge of host-pathogen interactions in the 
natural host is essential to facilitate disease control. Vaccination of neonatal calves 
with Bacille Calmette Guerin (BCG) induces a significant level of protection from 
infection with M. bovis. Since neonatal vaccination of humans with BCG induces 
activation of natural killer (NK) cells, and neonatal calves have high circulating 
numbers of these cells, it is proposed that NK cells are important in the response to 
BCG. Furthermore, NK cells play an important role in shaping adaptive immune 
responses through interactions with dendritic cells (DCs). The overall hypothesis of 
this project was that the enhanced efficacy of BCG in neonates is due to the increased 
number of NK cells, which through interactions with DCs can polarise Th1-type CD4+ 
and CD8+ T cell responses, both of which are involved in protection against M. bovis 
infection. Initially, the frequency and phenotype of NK cells across the blood, afferent 
lymph and the lymph nodes in steady-state conditions were compared. CD2- NK cells 
were the principal subset of NK cells migrating from the skin to the draining lymph 
node and were highly activated in afferent lymph and lymph nodes, compared with 
peripheral blood. It was also demonstrated that CD2- NK cells were the main subset 
of NK cells egressing from the lymph node via the efferent lymphatic vessel to return 
to circulation. Since many vaccines including BCG are delivered subcutaneously, NK 
cell responses in the blood and the skin draining afferent lymphatic vessel, lymph 
nodes and efferent lymphatic vessel were determined after BCG vaccination. 
Alterations in the frequency and receptor repertoire were evident following 
vaccination, supporting a role for NK cells during BCG vaccination of neonatal calves. 
To investigate the interactions of NK cells and BCG-infected DCs, in vitro co-cultures 
were established. CD2- NK cells were preferentially activated following culture with 
BCG-infected DCs and secreted high levels of IFN-γ. Overall, this thesis provides 
novel evidence that NK cells may re-circulate in steady-state conditions, play a role in 
BCG vaccination of neonatal calves, and that through interactions with BCG-infected 






Bovine tuberculosis (TB), caused by infection of cattle with Mycobacterium bovis, is 
increasing in incidence within the United Kingdom, with no vaccine currently licensed 
for use. Bacille Calmette Guerin (BCG) is the only vaccine licensed for use in humans 
against TB and is particularly effective when administered to infants. Similarly BCG 
vaccination of neonatal calves provides protection against infection. Young calves 
have an increased number of natural killer (NK) cells (white blood cells) which 
provide a rapid immune response to infection. In order to design better vaccines against 
TB, the immune response following vaccination must be understood. The hypothesis 
of this PhD project was that the enhanced efficacy of BCG in young animals is due to 
the increased number of NK cells which can contribute to protective immunity through 
interactions with dendritic cells (DCs). DCs are immune cells which are essential for 
initiation of immune responses. This project has demonstrated that NK cell frequency 
and receptor repertoire was altered following BCG vaccination of neonatal calves, 
supporting a possible role for NK cells during vaccination. Furthermore, this project 
also illustrated that a subset of NK cells can migrate from the tissues to the draining 
lymph nodes and this subset was also shown to preferentially interact with DCs 
infected with BCG. Therefore, NK cells may represent an effective target to induce 
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Ad85A  Adenovirus type 5 expressing M. tb antigen, Ag85A  
AL  Afferent Lymph  
ALDC  Afferent lymph dendritic cell 
APC  Antigen presenting cell 
APHA  Animal and Plant Health Agency 
BCG  Bacille Calmette Guerin  
BFA  Brefeldin A 
BRSV  Bovine Respiratory Syncytial Virus 
BSA   Bovine Serum Albumin 
bTB  Bovine tuberculosis 
BU  Biological unit 
bp  Base pairs 
CD  Cluster of differentiation 
CFP-10 Culture filtrate protein - 10 
CFU  Colony forming unit 
CPDA     Citrate Phosphate Dextrose Adenine 
Ct  Cycle threshold 
DCs   Dendritic cells 
DC – SIGN Dendritic cell – specific ICAM-3 grabbing non integrin 
DIVA  Differentiating infected from vaccinated animals 
DMSO Dimethyl sulfoxide 
DTH  Delayed type hypersensitivity 
EDTA  Ethylenediaminetetraacetic acid 
EL  Efferent lymph 
ESAT – 6 Early secreted antigenic target 6 
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ELISA  Enzyme - linked immunosorbent assay 
ELISPOT Enzyme-Linked ImmunoSpot 
FBS  Fetal bovine serum 
FITC  Fluorescein isothiocyanate 
FMO   Fluorescence minus one 
FSC  Forward scatter 
GM-CSF  Granulocyte-macrophage colony stimulating factor  
HEV   High endothelial venules 
HIV  Human immunodeficiency virus 
HSCs  Hematopoietic stem cells  
IC  Isotype control 
iDC  Immature dendritic cell 
IFN  Interferon 
Ig  Immunoglobulin 
IGRA  IFN-γ release assay 
IL   Interleukin  
iNOS   Inducible nitric oxide synthase 
ITIM  Immunoreceptor tyrosine-based inhibition motifs 
KIR  Killer cell immunoglobulin-like receptor 
KLRA  Killer cell lectin-like receptor subfamily A 
KLRC  Killer cell lectin like receptor 
LN  Lymph node 
LRC   Leukocyte receptor complex 
mAb  Monoclonal antibody 
M. bovis Mycobacterium bovis 
MDR  Multi-drug resistant  
MFI  Mean fluorescence intensity 
MHC   Major histocompatibility complex 
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MIC A MHC class I-related chain A  
MIC B  MHC class I-related chain B 
MIIC   MHC-II compartment  
MNC  Mononuclear cells 
MOI  Multiplicity of infection 
MVA85A  Modified vaccinia virus Ankara expressing Ag85A  
MR  Mannose receptor 
M. tb   Mycobacterium tuberculosis  
MVA  Modified vaccinia virus Ankara 
NCR   Natural cytotoxicity receptor 
NK  Natural Killer 
NKC  Natural Killer Complex 
NMS   Normal mouse serum 
NTM   Nontuberculous mycobacteria 
PAMP  Pathogen-associated molecular pattern 
PBL   Peripheral blood leukocytes 
PBMC Peripheral blood mononuclear cells 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PE   Phycoerythrin 
PIM   Phosphatidylinositol mannoside molecules 
PMA  Phorbol-myristate-acetate 
PPD  Purified protein derivative  
PRR  Pathogen recognition receptor 
PSLN  Pre-scapular lymph node 
RBCT  Randomised Badger Culling Trial 
RD1   Region of difference 1 
rhuAdV5 recombinant human replication-defective human adenovirus 5  
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ROI  Reactive oxygen intermediates 
RT  Room temperature 
S1P  Sphingosine-phosphate receptor 
SRCR  Scavenger receptor cysteine-rich  
SICCT  Single intradermal comparative cervical tuberculin  
SSC  Side scatter 
TB  Tuberculosis 
TCM  Tissue culture medium 
TCR  T cell receptor 
TDR   Totally drug resistant 
TLR  Toll-like receptor 
TNF  Tumour necrosis factor 
UK  United Kingdom 
ULBP  Unique long 16-binding proteins  
V  Volts 
WC  Workshop cluster 
WHO  World Health Organisation 
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The introduction of this thesis covers a broad range of aspects of mycobacterial 
infection and immunity with specific aspects further expanded in each of the results 
chapters. 
1.1 Human tuberculosis 
Mycobacterium tuberculosis (M. tb), a Gram-positive, acid fast, aerobic bacillus is the 
aetiological agent of human tuberculosis (TB), a chronic bacterial infection of the 
respiratory tract. M. tb, alongside M. bovis, M. bovis BCG, M. canettii, M. africanum, 
M. pinnipedii, M. microti, M. caprae and the more recently defined M. orygis (van 
Ingen et al., 2012) collectively form the M. tb complex (Wirth et al., 2008). The species 
and sub-species within this genetically related complex cause TB in a number of 
mammalian hosts, with certain members of the M. tb complex exhibiting a more 
restricted host range than others. For example, human TB is most commonly caused 
by infection with M. tb, however M. bovis can infect a wide range of mammalian host 
species (Phillips et al., 2003). In 2006, the World Health Organisation (WHO) 
developed a Stop TB strategy, which aims to dramatically reduce the global burden of 
human TB by 2015 and to eliminate TB by 2050 (http://www.who.int/tb/strategy/en/ 
last accessed 09/09/15). Despite this, TB remains the leading cause of mortality due to 
a bacterial agent worldwide. In 2013, 9 million people developed TB and 1.5 million 
people died from this disease (WHO, 2014). A recognised risk factor for human TB is 
infection with human immunodeficiency virus (HIV) and of the 1.5 million people 
who died from TB in 2013, 360,000 were HIV positive. Additional risk factors for 
active TB include: diabetes, kidney disease, alcohol or drug abuse and other forms of 
immunosuppression. Of interest, it is estimated than one third of the world’s 
population is latently infected with TB, which is a subclinical phase where the 
pathogen remains dormant (Dye et al., 1999). Of those with latent TB, only 5 to 10% 
will go on to develop active disease, which is usually a consequence of 
immunosuppression (Comstock et al., 1974, Vynnycky and Fine, 2000). Active TB 
disease can be broadly divided into three forms: pulmonary TB, extra-pulmonary TB 
and miliary TB. Individuals with pulmonary TB, defined by the presence of bacilli 
within the respiratory tract and lungs, present with a persistent cough, breathlessess, 
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fatigue, fever and weight loss. In severe cases, bacilli can spread to local lymph nodes, 
which is defined as extra-pulmonary TB or can be more widespread, defined as miliary 
TB (Harisinghani et al., 2000) .  
1.1.1 Diagnostics for human TB 
Human TB is diagnosed using a combination of acid-fast (Ziehl-Neelson) staining of 
sputum samples and chest X-ray screening in developing countries (Parsons et al., 
2011). In developed countries, TB is identified using a tuberculin skin test (also called 
the Mantoux tuberculin skin test) whereby purified protein derivative (PPD) from M. 
tb is injected into the skin and the delayed type hypersensitivity response (DTH) is 
assessed 48 to 72 hours later. Secondly, IFN-γ release assays (IGRAs) such as the 
QuantiFERON®–TB Gold In-Tube test and T-SPOT®.TB test can be used as an 
alternative to the tuberculin skin test. The QuantiFERON®–TB Gold In-Tube test and 
the T-SPOT®.TB test measure the production of antigen-specific IFN-γ to M.tb-
specific antigens using a whole blood assay and Enzyme-linked ImmunoSpot 
(ELISPOT) assay respectively. Sensitivity and specificity of these IGRAs ranged from 
73-83% and 49-58% respectively (WHO, 2011).  
1.1.2 Treatment for human TB 
Active TB disease is treated with a combination of isoniazid, rifampicin, pyrazinamide 
and ethambutol for a minimum of 6 months or 12 months for pulmonary TB and extra-
pulmonary TB respectively (www.nhs.uk last accessed 09/09/15). However, the 
emergence of multidrug-resistant strains which are resistant to isoniazid and rifampicin 
has resulted in the development of multidrug-resistant TB (MDR-TB) and in 2013, 
480,000 people were diagnosed with MDR-TB 
(http://www.who.int/tb/challenges/mdr/mdr_tb_factsheet.pdf last accessed 09/09/15). 
Furthermore, the prevalence of cases of extensively drug-resistant TB (XDR-TB) and 
totally drug-resistant TB (TDR-TB) are increasing. The existence of these resistant 
strains further complicates the treatment of TB infection in humans and threatens the 




1.2 Bovine TB 
Infection of cattle with M. bovis causes bovine TB (bTB) which is a major animal 
health problem. In the 1930s, approximately 15 to 20% of cattle in the United Kingdom 
(UK) were infected with M. bovis. The introduction of a nationwide bTB eradication 
programme in the 1960s resulted in a significant reduction in the prevalence of TB in 
cattle with 0.49% of all herds having a reactor in 1979 (Krebs JR, 1997). Nevertheless, 
despite continued routine testing, the incidence of bTB has increased in the UK since 
the early 1980s, particularly in regions of South West of England and South Wales 
(Figure 1.1). In 2010, 25,000 cattle were slaughtered at a cost of £91 million. It is 
estimated that bTB will cost the UK economy up to £1 billion over the next 10 years 
if effective control strategies are not implemented. Furthermore, bTB is a zoonotic 
disease and therefore poses a threat to human health (Cosivi et al., 1998). Prior to the 
introduction of milk pasteurisation in the 1930s, the majority of TB cases in humans 
were due to infection with M. bovis through consumption of infected milk (de la Rua-
Domenech, 2006). However, a recent study assessed the global occurrence of zoonotic 
TB caused by M. bovis and concluded that the incidence of human TB as a result of 
zoonotic M. bovis infection was low (Muller et al., 2013).  
Reasons for the increasing incidence of bTB in the UK are not clear, however it is 
likely to be due to a combination of problems with the available diagnostic tests 
(section 1.2.1) and wildlife reservoirs of infection. Wildlife reservoirs of infection pose 
significant risks for transmission of M. bovis infection to cattle. These include Eurasian 
badgers (Meles meles) in the UK and Ireland, brushtail possums (Trichosurus 
vulpecula) in New Zealand and white-tailed deer (Odocoileus virginianus) in the 
United States (Robinson et al., 2012). In 1997, an independent scientific commission 
set up by the UK government and chaired by Sir John Krebs, concluded that badgers 
were a significant source of M. bovis infection in cattle (Krebs JR, 1997). Furthermore, 
since the introduction of the badger protection act, the number of badgers has increased 
(http://www.legislation.gov.uk/ukpga/1992/51/contents last accessed 09/09/15). 
During the Randomised Badger Culling Trial (RBCT), which took place in England 
between 1998 and 2005, proactive culling of badgers reduced the incidence of bTB in 
cattle herds located within those areas where badgers were culled (Donnelly et al., 
2007). However, in areas adjacent to the culling zones there was an increase in the 
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number of herd breakdowns, thought to be attributed to the dissemination of infected 
badgers, defined as the ‘perturbation effect’ (Wilson et al., 2011). Even if culling was 
deemed to be effective, it is not a feasible single solution for bTB control due to 
economical and ethical reasons. Other reasons which may explain the spread of bTB 
include housing of infected animals in confined spaces, movement of infected animals 
resulting in transmission of bTB across different regions and international trading of 




Figure 1.1 Bovine TB has increased in incidence across England and Wales 
from 1986 to 2010. 
The incidence of bovine TB has increased in incidence since the mid-1980s to 2010 
particularly in areas of South West of England and Wales. Data courtesy of Animal 
Plant and Health Agency (APHA). Copyright: University of Exeter. 
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1.2.1 Current bovine TB control measures  
The principal test to diagnose bTB is the single intradermal comparative cervical 
tuberculin (SICCT) test, commonly known as the tuberculin skin test, which measures 
the cell-mediated immune response to purified protein derivatives from M. avium 
(PPD-a) and M. bovis (PPD-b) (Monaghan et al., 1994). Using the standard test 
interpretation, animals are considered to be infected with M. bovis if the reaction to 
PPD-b, administered subcutaneously, is 4mm greater than the reaction to PPD-a. If the 
standard test result is positive or inconclusive then the severe test interpretation is 
employed, whereby animals are deemed positive for bTB if the reaction to PPD-b is 
2mm greater than the reaction to PPD-a. Animals which test positive in the SICCT 
(TB reactors) are slaughtered and the herd is placed under TB restrictions with 
repeated testing every 60 days until a clear herd test is achieved. In certain 
circumstances, an ancillary blood test can be employed alongside the skin test, for 
example when TB reactors have already been confirmed on the herd that is being 
tested. Samples of whole blood are stimulated with PPD-b for 24 hours and the 
production of antigen-specific IFN-γ present in the plasma supernatant is detected by 
ELISA (Wood and Jones, 2001). The SICCT is highly specific, with specificity 
estimated to be greater than 99.9%; however sensitivity is moderate, ranging from 50 
to 60%. Sensitivity of the IFN-γ test (90%) is greater than the SICCT but the specificity 
of the IFN-γ test (96.7%) is insufficient for this to be the primary screening test for 
bTB. The IFN-γ test can detect infected animals that are negative to the SICCT.  
Further complications involved in the diagnosis of bTB are that infection of cattle with 
Mycobacterium avium subspecies paratuberculosis, the causative agent of Johne’s 
disease (Wadhwa et al., 2012), Bovine Viral Diarrhoea Virus or Fasciola hepatica 
conflicts the interpretation of the bTB diagnostic tests (Charleston et al., 2001, Flynn 
et al., 2007, Claridge et al., 2012). In addition, it is widely acknowledged that the IFN-
γ test cannot be used in young animals due to non-specific production of IFN-γ in non-
infected animals, caused by activation of NK cells (Olsen et al., 2005) or exposure to 
environmental, non-tuberculous mycobacteria (NTM) (Waters et al., 2006b).  
To reduce the movement of infected cattle and subsequent spread of disease, 




tb-testing-of-cattle-in-great-britain last accessed 09/09/15). Pre-movement testing 
began in England and Wales in 2006 with pre-movement tests required 60 days before 
cattle movement and post-movement tests needing to be completed 60 to 120 days 
after movement of cattle. This should reduce the risk of further spread of bTB in 
England and Wales and allow Scotland to remain bTB free.  
1.2.2 Treatment for bovine TB 
bTB is rarely treated in domestic livestock and most M. bovis-infected animals will be 
slaughtered. Occasionally if animals belong to a rare or endangered species, or if they 
are considered to be zoological exhibits, then anti-mycobacterial therapy will be 
utilised.  
1.3 Vaccination against TB 
Vaccination is based on the induction of immunological memory and effective 
vaccines induce long-lived immune responses. The Krebs report highlighted the 
importance of developing a cattle vaccine and an associated diagnostic test (Krebs JR, 
1997) which together, would greatly improve the control of bTB. However, despite 
extensive research into vaccination strategies, the development of novel vaccines to 
protect against TB in humans and cattle has proven extremely difficult (Hope and 
Vordermeier, 2005, Wilkie and McShane, 2015). Currently within the UK there are no 
licensed vaccines available for use in cattle and only one licensed vaccine for human 
TB. 
1.3.1 Bacille Calmette Guerin (BCG) Vaccine 
Bacille Calmette-Guerin (BCG), a live attenuated form of M. bovis, is the only TB 
vaccine available for use in humans. It is one of the world’s most widely used vaccines 
and is administered to approximately 120 million children each year (Ritz and Curtis, 
2009). Albert Calmette and Camille Guerin sub-cultured a virulent strain of bovine 
tubercle bacillus (M. bovis) on ox bile, glycerine and potato-soaked medium which 
resulted in attenuation of M. bovis. The potential use of BCG as a vaccine against M. 
tb infection in humans was demonstrated when Calmette and Guerin vaccinated 9 cows 
with BCG and showed that they were protected from challenge with M. bovis. The first 
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dose of BCG was administered to a newborn child in 1921. This original strain of BCG 
has been distributed to several laboratories worldwide and passaged under different 
conditions resulting in many daughter strains, including BCG Pasteur, BCG Tokyo 
and BCG Russia. These daughter strains differ in the deletions present and levels of 
attenuation which affect the virulence of each strain. For example region of difference 
1 (RD1) is deleted in all BCG strains but BCG Pasteur is also missing RD2 and RD14 
(reviewed in (Joung and Ryoo, 2013)). BCG confers variable protection against 
pulmonary TB, particularly when administered to adolescents or adults, with efficacy 
ranging from 0 to 80% (Fine, 1995, Colditz et al., 1995). Hypotheses which explain 
the variable efficacy of BCG in humans include: geographical location, exposure to 
environmental mycobacteria prior to vaccination which may stimulate an 
inappropriately biased immune response and distinct daughter strains of BCG that 
differ in their capabilities to stimulate protective immune responses (Andersen and 
Doherty, 2005). Routine BCG vaccination of adolescents stopped in the UK in 2005 
and is currently only administered to babies from high risk families 
(http://www.bcgatlas.org/ last accessed 09/09/15). 
In addition to the development of a cattle vaccine and an associated Differentiating 
Infected from Vaccinated Animals (DIVA) diagnostic test, the Krebs report also stated 
that a vaccine for badgers may improve control of bTB (Krebs JR, 1997). BCG was 
licensed for use in badgers in 2010 after 10 years of research into its efficacy and 
safety. It was subsequently demonstrated that BCG vaccination of free-living badgers 
reduced the incidence of positive serological tests by 73.8% (Chambers et al., 2011). 
1.3.1.1. Neonatal vaccination of humans and cattle with BCG 
Despite the variable efficacy observed following administration of BCG to adolescents 
or adults, BCG is particularly effective when delivered to infants and subsequently 
protects children against severe forms of childhood TB, such as TB meningitis and 
miliary TB (Trunz et al., 2006, Bonifachich et al., 2006). Similar to humans but unlike 
mice, cattle are born with a competent but immature immune system and therefore 
respond well to neonatal vaccination. Additionally, vaccination of neonatal calves 
overcomes the negative effects associated with exposure to environmental 
mycobacteria prior to vaccination. A number of studies have demonstrated that 
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experimental vaccination of neonatal calves with BCG imparts significant protection 
against challenge with M. bovis by reducing TB lesions in the lung and respiratory 
tract associated lymph nodes. Furthermore, neonatal vaccination with BCG reduces 
the number of M. bovis bacteria present in the tissues (Buddle et al., 1995a, Hope et 
al., 2005, Hope et al., 2011). A study investigating the duration of immunity induced 
by BCG vaccination of neonates showed that protection from M. bovis was evident 12 
months post-vaccination, but not after 24 months (Thom et al., 2012). Revaccination 
of BCG-vaccinated calves at 24 months results in enhanced protection upon challenge 
with M. bovis (Parlane et al., 2014), providing evidence that homologous BCG 
revaccination is effective to boost waning immunity. Nevertheless, BCG sensitises 
cattle to the SICCT and therefore current legislation prevents BCG vaccination of 
cattle in the UK due to the inability of the available diagnostic tests to discriminate 
between infected and vaccinated cattle. Neonatal vaccination with BCG has also been 
shown to be partially protective against M. bovis infection in natural transmission 
settings during field studies in Ethiopia and Mexico with the duration of immunity 
lasting between 12 and 23 months (Ameni et al., 2010, Lopez-Valencia et al., 2010). 
Even though BCG has been shown to be effective to protect cattle against TB, similar 
to humans, the efficacy of BCG in cattle is variable across studies (reviewed in (Waters 
et al., 2012)). Possible reasons for the variable efficacy of BCG in cattle across a range 
of ages are firstly, BCG provides greater protection in Bos indicus breeds of cattle 
compared with Bos taurus (Ellwood and Waddington, 1972) therefore host genetic 
background may be important. For example, in well-controlled infection experiments 
where cattle are exposed to the same dose of M. bovis, there is a wide range of 
pathology scores observed likely reflecting host genetic differences. Secondly, 
different daughter strains of BCG may induce variable protection; however it has been 
shown that BCG strains Danish and Pasteur confer similar levels of protection (Hope 
et al., 2011, Wedlock et al., 2007). Finally, exposure to environmental mycobacteria 
prior to BCG vaccination may stimulate an inappropriately biased immune response.  
1.3.1.2. DIVA tests 
More sensitive and specific diagnostic tests, which can also differentiate infected from 
vaccinated animals (DIVA tests), are required to improve control of bTB. The 
specificity of the IFN-γ test can be improved via the inclusion of early secretory 
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antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) (Jones et al., 
2010a) which are contained within RD1 that is deleted from all strains of BCG. A 
cocktail of ESAT-6, CFP-10 and Rv3615c (Rv3615c is not located on RD1 but 
secretion of Rv3165c is dependent on the Esx-1 secretion system which is contained 
within RD1 (Millington et al., 2011)) can be successfully used as a DIVA skin test 
(Whelan et al., 2010). Addition of a fourth antigen, Rv3020c further improved the 
sensitivity of the skin test (Jones et al., 2012). Rv3020c is present in both M. bovis and 
BCG genomes therefore the mechanisms underlying the improved sensitivity are 
unclear (Jones et al., 2010b). ESAT-6, CFP-10, Rv3615c and Rv3020c were identified 
as being effective DIVA test antigens by screening potential M. bovis specific antigens 
(Jones et al., 2010a, Jones et al., 2010b). 
Alternatively, it was demonstrated that following stimulation of whole blood with 
PPD-b for 4 hours, M. bovis-infected cattle produced antigen-specific IFN-γ, whereas 
IFN-γ was not detected in the plasma supernatant of BCG-vaccinated cattle until 24 
hours after stimulation (Sopp et al., 2008). This provides a simple and rapid method to 
distinguish M. bovis-infected from BCG-vaccinated cattle. Furthermore, active TB in 
humans can also be detected by this method (Sopp et al., 2008). Similarly, M. bovis-
infected cattle produce antigen-specific IL-2 after stimulation with mycobacterial 
antigens (PPD-b, ESAT-6 and CFP-10) but BCG-vaccinated cattle do not, thus this 
test could also be applied to discriminate infected from vaccinated animals (DIVA 
tests) (Rhodes et al., 2013). 
1.3.2 Heterologous prime-boost strategies in humans and cattle 
Heterologous prime-boost vaccination strategies which involve priming the immune 
response with BCG and boosting with either DNA vaccines, proteins or live-attenuated 
viruses have been developed for both humans and cattle. Adenovirus type 5 expressing 
M. tb antigen, Ag85A (Ad85A) and modified vaccinia virus Ankara also expressing 
Ag85A (MVA85A) were shown to improve the efficacy of BCG alone, when utilised 
as the boosting agent in a heterologous prime-boost vaccination protocol, against M. 
bovis infection of cattle (Vordermeier et al., 2009). Boosting BCG primed animals 
with MVA85A (Vordermeier et al., 2004) and Ad85A (Vordermeier et al., 2006) 
results in the induction of strong cellular immunity by boosting IFN-γ responses to 
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Ag85A. MVA85A is one of the most clinically advanced human TB vaccination 
candidates and in 2009; MVA85A was the first subunit TB vaccine to enter into a 
phase IIb efficacy trial. Despite improved efficacy to BCG alone in four preclinical 
models (mice, cattle, guinea pigs and non-human primates), MVA85A did not improve 
the protection over BCG alone against TB disease or M. tb infection in BCG-
vaccinated South African infants (Tameris et al., 2013). Reasons for this may be: a 
high burden of TB in the study site, environmental influences, co-infection with other 
infectious agents or the vaccine may be more efficacious in adolescents or in adults 
rather than infants. In order to design better vaccines and diagnostic tests it is vital to 
understand the pathology and immunology of human and bovine TB. 
1.4 Pathogenesis of human and bovine TB 
Cattle are a natural host for M. bovis and the immunology and pathology of bTB is 
similar to human TB, therefore studies of M. bovis infection in cattle may impart 
knowledge of TB in humans (Waters et al., 2011). Bacilli contained within aerosols 
infect humans and cattle primarily via the respiratory route however bacilli can also 
invade the host via other routes such as mucous membranes or breaks in the skin. M. 
bovis is highly virulent in cattle with as low as a single organism sufficient to establish 
infection (Dean et al., 2005). Bacilli employ an array of immune evasion strategies to 
enable intracellular survival and persistence. For example: (1) prevention of 
phagosome maturation and subsequent fusion with lysosomes to form phagolysosomes 
(2) inhibition of autophagy, apoptosis, IFN-γ receptor signalling and antigen 
processing and presentation to T cells (3) hindrance of escape from phagosome to 
cytoplasm and (4) inhibition of toxic oxygen and nitrogen intermediates (reviewed by 
(Ottenhoff, 2012)).  
M. bovis bacilli persist within granulomas which are present as early as 7 to 15 days 
post-experimental infection with M. bovis and granuloma formation is employed by 
the host to limit proliferation of mycobacteria (Palmer et al., 2007). Granulomas are 
better studied in cattle due to the availability of tissues; however granulomas in 
infected cattle are similar to those present in infected humans. Granulomas are divided 
into Stage I, Stage II, Stage III and Stage IV and granulomas of all developmental 
stages can be present in the same section of tissue from 60 days post experimental 
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infection of cattle with M. bovis. Stage I granulomas are characterised by an 
accumulation of epithelioid macrophages with low numbers of Langhan’s 
multinucleated giant cells, lymphocytes (mainly CD4+ T cells) and neutrophils. Stage 
II granulomas contain a central infiltrate of lymphocytes and neutrophils and unlike 
Stage I granulomas, have a thin fibrous capsule and a central area of necrosis. Stage 
III granulomas contain a thick fibrous capsule and a significant amount of central 
necrosis. Low numbers of CD8+ T cells, γδ T cells and B cells can be found in Stage 
I-III granulomas. Finally, Stage IV granulomas are characterised by the presence of 
multiple, merged granulomas with extensive necrosis and contain the highest number 
of bacilli (Palmer et al., 2007). Granulomas are most commonly found in the tissues 
and associated lymph nodes of the respiratory tract, head and thorax in naturally 
infected cattle (Neill et al., 1994).  
1.5 Innate immune response to mycobacteria 
The immune response to M. tb and M. bovis infection is not completely understood 
therefore greater understanding of the immune response to mycobacteria is essential 
to develop improved vaccines and diagnostic tests, to pinpoint correlates of protection 
and ultimately improve control of TB in both humans and cattle. 
1.5.1 Macrophages 
Macrophages are a diverse population of specialized phagocytic cells which are 
essential for host defense, homeostasis and wound repair. They are derived from bone 
marrow precursors and circulating blood monocytes, which differentiate into resident 
macrophages or dendritic cells (DCs) upon tissue entry (Verschoor et al., 2012). 
Macrophages are considered the major host cells for mycobacteria in vivo and due to 
the respiratory route of entry employed by mycobacteria, alveolar macrophages play a 
pivotal role during anti-mycobacterial immune responses (Pollock and Neill, 2002). 
Macrophages express an array of cell surface receptors that recognize mycobacteria 
including: Toll-like receptors (Means et al., 1999); the macrophage mannose receptor 
that recognizes mannosylated glycoproteins; Fc receptors binding opsonized cells and 
complement receptors (Ernst, 1998). Signaling pathways are activated as a result of 
mycobacterial recognition. Within bovine alveolar macrophages, up-regulation of 
genes associated with the transcription factor NFκB are evident early post-M. bovis 
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infection (Widdison et al., 2011). Macrophages ingest mycobacteria by phagocytosis 
and the bacilli are subsequently targeted to the phagosome where fusion with the 
lysosome occurs, resulting in bacterial destruction. However, mycobacteria can also 
evade the immune response and prevent phagolysosome fusion within macrophages. 
Nevertheless, activation of macrophages by IFN-γ from T cells and NK cells can 
partially block the arrest of phagolysosome fusion. Similarly, IFN-γ stimulates 
autophagy within M. tb-infected macrophages which also prevents arrest of 
phagolysosome fusion, thus inhibiting survival of bacteria (Gutierrez et al., 2004). 
Activated macrophages release reactive oxygen or nitrogen intermediates. For 
example, bovine alveolar macrophages stimulated with M. bovis express inducible 
nitric oxide synthase (iNOS) that catalyses the production of nitric oxide (NO) which 
aids macrophage killing of mycobacteria (Widdison et al., 2007). Inflammatory 
chemokines are also produced by M. bovis-infected macrophages which attract 
lymphocytes to the lungs and contribute to granuloma formation (Widdison et al., 
2011).  
 
1.5.2 Dendritic cells  
DCs are a heterogeneous population of potent antigen-presenting cells (APC) which 
are essential mediators of immunity (Banchereau and Steinman, 1998) and tolerance 
(Steinman et al., 2003). Stem cell precursors in the bone marrow give rise to circulating 
myeloid or lymphoid precursors that enter tissues and reside as immature DCs. 
Monocytes, macrophages and DCs share a common progenitor (Fogg et al., 2006). 
Flt3L drives differentiation of DCs (Schmid et al., 2010) and loss of Flt3L (McKenna 
et al., 2000), Flt3 (Waskow et al., 2008) or downstream signalling molecule STAT3 
(Laouar et al., 2003) reduces the number of DCs in vivo. DCs are predominantly found 
underlying body surfaces including the skin, intestine and the trachea. Immature DCs 
are specialised to capture antigen by a number of different routes including 
phagocytosis, macropinocytosis and endocytosis via clathrin-coated pits or caveolae 
(Werling et al., 1999). M. tb gains entry to human monocyte-derived DCs through 
binding to DC-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-
SIGN) (Tailleux et al., 2003). Likewise, binding of BCG- fluorescein isothiocyanate 
(FITC) to bovine DCs was reduced in the presence of a polyclonal antibody to DC-
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SIGN revealing a role for DC-SIGN in uptake of BCG by bovine DCs (Yamakawa et 
al., 2008). TLR2, TLR4 and TLR9 have also been associated with the uptake and 
recognition of mycobacteria by DCs (Means et al., 1999, Tsuji et al., 2000, von 
Meyenn et al., 2006). DCs act as sentinels and respond to infection, inflammatory 
signals or tissue damage by migrating away from the periphery towards draining 
lymph nodes where they present antigen and initiate primary T cell mediated immune 
responses which is a unique feature of DCs (Steinman, 1991). M.tb-infected DCs 
migrate to the lung draining lymph nodes by 8 to 12 days post-infection (O'Garra et 
al., 2013). CCR7 expression by antigen-exposed DCs allows migration from the 
periphery to the draining lymph node via afferent lymphatic vessels, in response to the 
chemo attractants CCL19 and CCL21 (Rot and von Andrian, 2004). During migration, 
DCs undergo maturation which is characterised by reduced endocytosis and an 
augmented expression of major histocompatibility complex (MHC) molecules, 
costimulatory molecules and adhesion molecules. Following infection of human DCs 
with M. tb, expression of CD54, CD40, CD80 and MHC class I molecules were 
increased. In addition to increased expression of various cell surface molecules, DCs 
exposed to M. tb bacilli produce pro-inflammatory cytokines which induce T cell 
immune responses, such as TNF-α, IL-1 and IL-12 (Henderson et al., 1997). Likewise 
monocyte-derived DCs from cattle infected with M. bovis and BCG Pasteur up-
regulated MHC class II, CD40 and CD80 in conjunction with increased production of 
TNF-α, IL-10 and IL-12, therefore suggesting increased capacity to stimulate antigen-
specific T cells (Hope et al., 2004).  
Bovine DCs comprise phenotypically distinct subsets which are of myeloid origin 
(Howard and Hope, 2000, Miyazawa et al., 2006) however a population of lymphoid 
derived plasmacytoid DCs have been identified in cattle (Reid et al., 2011). Bovine 
monocyte-derived DCs are generated in vitro from blood CD14+ monocytes which are 
cultured with recombinant bovine granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and IL-4 to obtain an immature population (Werling et al., 1999). 
Alternatively, bone marrow-derived DCs can be obtained by culturing bone marrow 
progenitor cells with Flt-3L (Hope et al., 2000b). Afferent lymph derived DCs 
(ALDCs) can be studied in cattle via cannulation of pseudo-afferent lymphatic vessels 
(Hope et al., 2006, Emery et al., 1987) which allows collection of ex vivo DCs draining 
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sites of vaccination or infection. Sub-populations of ALDCs draining the skin (Howard 
et al., 1997, Brooke et al., 1998, McKeever et al., 1991) and mucosal surfaces have 
been described which have differential capacity not only to stimulate T cell responses 
(Howard et al., 1997) but which also display divergent capacities to interact with 
mycobacteria. Monocyte-derived DCs infected with BCG induced effective memory 
CD4+ and CD8+ T cell responses (Hope et al., 2000a). However, assessment of ex 
vivo populations of DCs isolated from afferent lymphatic vessels revealed that only a 
subset could uptake and present antigens from BCG (Hope et al., 2012). This could 
impact vaccine efficacy or the induction of protective immunity to infection. 
1.5.3 Natural Killer (NK) Cells 
NK cells are large granular lymphocytes which were identified in the 1970s by their 
ability to lyse malignant or transformed cells without prior sensitisation (Kiessling et 
al., 1975). This heterogeneous cell population has diverse roles in the immune system 
and are the first line of defence in the control of viruses, bacteria and parasites 
(Junqueira-Kipnis et al., 2003, Cerwenka and Lanier, 2001, Lieke et al., 2004, 
Artavanis-Tsakonas and Riley, 2002). NK cells are derived from self-renewing 
pluripotent hematopoietic stem cells (HSCs) that reside in the bone marrow. NK cells 
have two main effector functions, firstly cytotoxicity to target cells through the release 
of preformed granules containing perforin and granulysin. For example, it was shown 
that human NK cells kill M. tb in a contact-dependent manner by releasing granules 
containing perforin and granulysin (Lu et al., 2014). Secondly, NK cells are a 
significant source of immunoregulatory cytokines, primarily IFN-γ but also TNF-α, 
GM-CSF (Fehniger et al., 1999, Cooper et al., 2001b, Boysen et al., 2006), IL-10 
(Fehniger et al., 1999, Cooper et al., 2001b) and IL-22 (Cella et al., 2009, Dhiman et 
al., 2009).  
An increasing body of evidence demonstrates that NK cells are not simply cells 
confined to the innate arm of the immune response; rather they bridge the innate and 
adaptive responses. In line with this, NK cells have a number of similar developmental 
features with cells of the adaptive immune system. NK cells, T cells and B cells are 
derived from the common lymphoid progenitor (Kondo et al., 1997) and all require 
IL-2, IL-7 and IL-15 for their development, homeostasis and survival (Di Santo, 2006). 
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In addition, NK cells undergo education in the bone marrow which is very similar to 
the process of T cell development in the thymus (Sun and Lanier, 2011, Orr and Lanier, 
2010). Furthermore, NK cells have been shown to have functional features of adaptive 
immunity including immunological memory (Sun et al., 2009, O'Leary et al., 2006, 
Cooper et al., 2009, Paust and von Andrian, 2011). The first evidence of NK cell 
memory was demonstrated in 2006 when mice devoid of T and B cells acquired 
antigen-specific immunological memory to hapten-based contact sensitizers. This was 
found to be mediated by a subset of NK cells localised in the liver (O'Leary et al., 
2006). NK cells respond to CD4+ T cell derived IL-2 after rabies vaccination of 
humans (Horowitz et al., 2010) or following infection of mice with Leishmania major 
(Bihl et al., 2010), further strengthening the role of NK cells in adaptive immune 
responses. Furthermore, discrete subsets of human NK cells have also been shown to 
express MHC class II after stimulation with IL-2, thus NK cells may present antigen 
to CD4+ T cells (Evans et al., 2011). Lastly, NK cells can bridge the innate and 
adaptive immune response through interactions with populations of accessory cells 
such as DCs. These interactions are reciprocal in nature and can polarise the outcome 
of the adaptive immune response (Cooper et al., 2004).  
1.5.3.1. Human NK cells 
NK cells comprise 10-15% of peripheral blood lymphocytes in humans (Trinchieri, 
1989). Frequencies of NK cells are highest within cord blood and then undergo a 
progressive decline during the first year of life. Human NK cells are defined by an 
absence of CD3 and can be broadly subdivided based on their differential expression 
of the cell surface markers CD56 and CD16 (FcγRIII) (Robertson and Ritz, 1990, 
Cooper et al., 2001a). Cells with a low expression of CD56 (CD56dim) and high levels 
of CD16 comprise the majority (~90%) of human NK cells present within peripheral 
blood. The remaining ~10% of NK cells are classified as CD56bright with a low or 
negative expression of CD16. Due to their high expression of CD16 which mediates 
antibody-dependent cellular cytotoxicity, CD56dim NK cells are more cytotoxic than 
CD56bright NK cells (Nagler et al., 1989). By contrast CD56bright NK cells, which are 
the predominant NK cell subset found within lymph nodes, produce increased amounts 
of immunoregulatory cytokines including IFN-γ, compared with CD56dim NK cells 
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(Cooper et al., 2001b). Furthermore, CD56bright NK cells have a higher proliferative 
capacity in response to IL-2 (Baume et al., 1992).  
1.5.3.2. Murine NK cells 
CD56 is not expressed in mice therefore subsets of NK cells are distinguished by the 
expression of NK1.1 or CD49b (Arase et al., 2001) and can be further subdivided 
based on CD27 and CD11b expression (Chiossone et al., 2009). NK cells are present 
within the lymph nodes, liver and lungs of mice with the largest absolute number of 
NK cells found within the spleen (Gregoire et al., 2007). CD27+ NK cells are the 
principal subset of NK cells found within lymph nodes and in contrast, CD27- NK 
cells are the main subset in the blood and spleen (Inngjerdingen et al., 2011). Most 
laboratory mice have very few lymph node derived NK cells which is in contrast with 
feral mice who have a high frequency of primed NK cells within peripheral lymph 
nodes (Boysen et al., 2011).  
NK cells are responsive during mycobacterial infection of humans and mice in vivo 
and important functional roles for NK cells in response to mycobacteria have been 
described (reviewed in (Esin and Batoni, 2015)). NK cells are recruited to the site of 
mycobacterial infection during pulmonary (Portevin et al., 2012) and extra-pulmonary 
TB in humans (Schierloh et al., 2009). Furthermore, a potential role for NK cell and 
γδ T cell derived IFN-γ during BCG immunisation of infants has been recently defined 
(Zufferey et al., 2013). Following infection of mice with M. tb or BCG, increased 
numbers of activated NK cells are recruited to the lungs where they secrete IFN-γ, 
however depletion of NK cells has no effect on the bacterial load within the lungs 
suggesting a level of redundancy (Junqueira-Kipnis et al., 2003). In BCG-immunised 
mice, NK cells control bacterial replication and enhance T cell responses through their 
secretion of IFN-γ and IL-22 (Dhiman et al., 2012). Taken together, this highlights the 
importance of innate effector cells such as NK cells, during anti-mycobacterial 
immune responses. 
1.5.3.3. Bovine NK cells 
NK cells are located within the spleen, lung, liver and lymph nodes of cattle (Storset 
et al., 2004, Boysen et al., 2008). Within bovine peripheral blood, NK cells represent 
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0.5%-10% of the total lymphocyte population with an increased prevalence in neonatal 
calves, particularly those aged between 8-120 days old (Kulberg et al., 2004, Graham 
et al., 2009). The high number of NK cells found in neonates is thought to be a 
mechanism whereby the innate immune response is able to compensate for the 
immature state of the adaptive immune system. Similar to mice, bovine NK cells do 
not transcribe CD56 (Endsley et al., 2006). NKp46 (NCR1; CD335), a natural 
cytotoxicity receptor expressed exclusively by NK cells, is recognised as a pan-species 
marker used to identify NK cells (Walzer et al., 2007c). The development of a 
monoclonal antibody (mAb) specific to this receptor has allowed NK cells to be 
studied in cattle (Storset et al., 2004). Prior to this, a population of NK-like CD8+ cells 
were described in cattle but these could not be definitively identified as NK cells until 
the mAb specific for NKp46 was developed (Hope et al., 2002b). Populations of 
bovine NK cells which lack NKp46 expression have also been detected, and are 
thought to exist in an immature state (Graham et al., 2009). Similar to humans, bovine 
NK cells lack expression of CD3 and can be subdivided into two subsets based on their 
differential expression of CD2, an adhesion molecule expressed by T cells and NK 
cells (Storset et al., 2004). As observed in mice (Nakamura et al., 1990) and humans 
(Chan et al., 1989), CD2 expression appears to be redundant for the function of bovine 
NK cells. The majority of peripheral blood derived NK cells are CD2+ and a small 
population have low or no expression of CD2 (referred to as CD2- herein). In contrast 
to peripheral blood, CD2- NK cells are the predominant subset found within lymph 
nodes and this subset has also been defined as the major NK cell subset present within 
skin draining afferent lymphatic vessels (Lund et al., 2013). CD2- NK cells have a 
higher expression of the activation markers CD25 and CD44, an increased proliferative 
capacity and enhanced ability to produce IFN-γ in comparison to their CD2+ 
counterparts. However, both subsets have equal cytotoxic capacities (Boysen et al., 
2006). Parallels have been drawn between the CD2- subset of bovine NK cells and the 
CD56bright CD16- subset of human NK cells (illustrated in Figure 1.2). 
There is considerable evidence in the literature that bovine NK cells play key roles in 
the immune response to mycobacteria. For example, bovine NK cells stimulated with 
IL-2, IL-15, IL-2/12 or IL-12/15 restrict the replication of BCG within monocyte-
derived and alveolar macrophages (Endsley et al., 2006). As mentioned in section 
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1.5.3, NK cells are found at the interface between innate and adaptive immunity and 
accordingly, can interact with populations of accessory cells such as macrophages or 
DCs. Bovine NK cells proliferate and produce IFN-γ in response to interactions with 
M. bovis-infected macrophages, which enhances IL-12 and NO production by 
activated macrophages (Denis et al., 2007). Similarly, through interactions with BCG-
infected splenic DCs, bovine NK cells acquire cytotoxic activity and produce IFN-γ 
(Bastos et al., 2008). More recently, reciprocal interactions between NK cells and DCs 
in the context of M. bovis were demonstrated, with preferential stimulation of the CD2- 




Figure 1.2 Similarities and differences between bovine CD2- NK cells and 
human CD56bright NK cells 
CD2- bovine NK cells and CD56bright human NK cells are both localised in afferent 
lymph and lymph nodes. Furthermore, both subsets express CD25, CD44, CXCR4 and 
CCR7, proliferate after culture with IL-2 and produce IFN-γ. These subsets differ in 
their cytotoxic capabilities as CD2- NK cells are cytotoxic, however CD56bright NK 





1.5.4 NK cell receptors 
Unlike B and T cells, NK cells do not express receptors that require somatic gene 
rearrangements to generate receptor diversity (Lanier, 2005). Instead, NK cell function 
and maintenance of self-tolerance is determined by a complex interplay between a 
plethora of activating and inhibitory NK cell receptors (Long et al., 2013). These germ-
line encoded receptors recognise MHC class I molecules, MHC class I-like molecules, 
stress-related molecules, costimulatory ligands and cytokines (Vivier and Ugolini, 
2011, Ljunggren and Karre, 1990, Lanier, 1997). By using mass cytometry, it was 
demonstrated that host genetic background determines the expression of inhibitory 
receptors and the repertoire of activating receptors is influenced by the environment. 
This suggests that inhibitory receptors may be the key receptors involved in 
maintenance of self-tolerance and the response to pathogens may be controlled by 
activating receptors (Horowitz et al., 2013). NK cells can also eliminate target cells 
that fail to express self-MHC class I molecules during a phenomenon known as the 
‘missing self’ hypothesis (Ljunggren and Karre, 1990) (Figure 1.3C). This paradigm 
has since been updated as it is now clear that in addition to the inhibitory signals, 
activating signals are also necessary for NK cell killing (Lanier, 2005). NK cell 
receptors contain extracellular domains which recognise MHC class I molecules and 
can be structurally divided into those containing either C-type lectin-like domains or 
Ig-like domains which are encoded within the NK complex (NKC) and leukocyte 
receptor complex (LRC) respectively. Both of these groups contain receptors capable 






Figure 1.3 The balance between activating and inhibitory receptors expressed 
by NK cells 
NK cells expressing activating and inhibitory receptors which do not detect activating 
ligands or MHC class I on a target cell remain unresponsive (A). If NK cell inhibitory 
receptors recognise MHC class I on a target cell, NK cells do not respond (B). 
However, if MHC class I is downregulated by a target cell then activating receptors 
are ligated and the NK cell attacks the target cell (C). Finally, if the target cell 
expresses ligands for both activating and inhibitory receptors, the outcome is 






1.5.4.1. Inhibitory receptors 
Inhibitory receptors which recognise MHC class I comprise the Killer Cell 
Immunoglobulin-Like Receptors (KIRs) in humans and primates, Ly49 (KLRA) 
receptors in rodents and CD94/NKG2 receptors. To date, cattle have the most 
expanded NK cell receptor gene family and are the only species to have significantly 
expanded the KIR and CD94/NKG2 genes (Figure 1.4) (Guethlein et al., 2007, 
McQueen et al., 2002, Storset et al., 2003, Birch and Ellis, 2007, Dobromylskyj et al., 
2009). Unlike non-primate mammals whereby the LRC contains one or no KIR genes 
(Hammond et al., 2009, Futas and Horin, 2013, Gagnier et al., 2003, Sambrook et al., 
2006, Takahashi et al., 2004), cattle KIR have evolved independently with two distinct 
lineages denoted by L and X: 3DL and 3DX (Guethlein et al., 2007). The 3DL lineage 
KIR gene is a single, conserved KIR gene and the second lineage consists of multiple 
3DX lineage KIR genes. This is in contrast with humans and higher primates which 
have expanded 3DL lineage KIR genes but have a single, conserved 3DX lineage KIR 
gene (Guethlein et al., 2007, Sanderson et al., 2014). KIR receptors, which belong to 
the Ig superfamily, can transmit activating signals through their short cytoplasmic tail 
which contains a charged amino acid residue that conveys activating signals upon 
binding to DAP12. However, KIR receptors primarily deliver inhibitory signals 
through the presence of two immunoreceptor tyrosine-based inhibition motifs (ITIMs) 
(Thielens et al., 2012). Mice lack KIR genes but express C-type lectin Ly49 receptors 
which are functionally similar to the human KIR receptors (Lanier, 2005). To date, 18 
KIR genes have been identified in cattle which are mainly inhibitory (Sanderson et al., 
2014).  
Ly49 (KLRA) receptors contain C-type lectin-like domains and are expressed on the 
surface of NK cells as disulphide-linked homodimers (Wong et al., 1991). They 
recognise MHC class I and MHC class I-like molecules and consist of both activating 
and inhibitory receptors. To date, no functional Ly49 genes have been identified in 
humans, however 23 Ly49 genes and 6 Ly49 genes have been identified in mice and 
horses respectively (Berry et al., 2014, Takahashi et al., 2004). A single copy Ly49 
gene exists in cattle, which is highly polymorphic (McQueen et al., 2002, 
Dobromylskyj et al., 2009).  
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CD94-NKG2 receptor complexes are also C-type lectin-like receptors which consist 
of disulphide-linked heterodimers of CD94 and NKG2 molecules with CD94 required 
for surface expression of NKG2 family members (Lazetic et al., 1996). In humans, 
CD94 forms a heterodimer with NKG2A or NKG2C to transmit inhibitory or 
activating signals respectively. Both CD94/NKG2A and CD94/NKG2C bind to HLA-
E (Braud et al., 1998). Similar to KIR lineage 3DX, NKG2 and CD94 are significantly 
expanded in cattle and contain 2 CD94 genes, 7 NKG2A genes and 2 NKG2C genes 
(Figure 1.3) (Birch and Ellis, 2007). It is has not been defined if CD94 forms 




Figure 1.4 Comparison between NK cell receptor genes in LRC and NKC across 
species 
Blue = gene presence, pink = significant expansion, blank = gene is absent in the 





1.5.4.2. Activating receptors 
The natural cytotoxicity receptors (NCRs) comprise a family of activating receptors 
belonging to the Ig superfamily. In the late 1990s it was discovered that human NK 
cells express three NCRs: NKp46 (NCR1; CD335) (Sivori et al., 1997), NKp44 
(NCR2; CD336) (Vitale et al., 1998) and NKp30 (NCR3; CD337) (Pende et al., 1999). 
Resting human NK cells constitutively express NKp46 and NKp30, however NKp44 
expression is induced following activation (Vitale et al., 1998). NKp44 is not present 
in mice or cattle (Cantoni et al., 1999, Hammond, 2012) and mice also lack expression 
of NKp30 (Hollyoake et al., 2005). NKp30 is the most diverse of all the NCRs and is 
involved in human NK cell lysis of immature DCs (Ferlazzo et al., 2002). Bovine 
NKp30 has been demonstrated to be expressed following cytokine stimulation 
(Hammond, 2012).  
NK cells can be activated directly by pathogens such as mycobacteria through direct 
interactions with NCRs. For example, expression of NKp44 by human CD56bright NK 
cells allows BCG to bind directly to NK cells and induce proliferation, cytotoxicity 
and production of IFN-γ (Esin et al., 2008, Esin et al., 2004). Similarly, NKp44 
expressed by human NK cells is able to interact directly with components of the M. tb 
cell wall (Esin et al., 2013). In contrast with NKp44 which can bind directly to M. tb 
cell wall components, NKp46 binds to vimentin expressed by M. tb-infected 
monocytes, resulting in lysis of M. tb-infected monocytes (Garg et al., 2006, 
Vankayalapati et al., 2002, Vankayalapati et al., 2005).  
Another activating receptor is NKG2D which is expressed as a disulphide-linked 
homodimer on the surface of NK cells. Ligands of human NKG2D are the stress-
induced molecules MHC class I-related chain A and B (MICA/MICB) and the unique 
long 16-binding proteins (ULBP) (Bottino et al., 2005). NKG2D expression by human 
NK cells permits lysis of M. tb-infected alveolar macrophages through recognition of 
ULPB (Vankayalapati et al., 2005).  
1.5.5 NKT cells 
NKT cells are a small subset of lymphocytes which have shared attributes of both NK 
cells and T cells. Classical T cells recognise MHC-presented peptides, however NKT 
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cells recognise lipids/glycolipids presented by CD1d molecules and a common NKT 
ligand is α-galactosylceramide (αGalCer). Following activation, NKT cells can 
produce significant amounts of Th1 (IFN-γ) and Th2 (IL-4 and IL-13) cytokines. NKT 
cells are well characterised in humans and mice, however their presence in cattle 
remains controversial. CD1d presents antigens to NKT cells in humans and mice but 
initially it was thought CD1d-restricted NKT cells did not exist in cattle due the 
presence of a non-functional CD1d gene (Van Rhijn et al., 2006). However, it has since 
been demonstrated that the bovine CD1d gene is expressed and translated in vivo 
(Nguyen et al., 2013). Furthermore, a population of bovine lymphocytes co-expressing 
NKp46 and CD3 were described, suggesting a population of NKT-like cells exists in 
bovine peripheral blood (Connelley et al., 2014). Recently, it was shown that bovine 
NKT-like cells can be activated by highly purified phosphatidylinositol mannoside 
(PIM) molecules isolated from M. tb, thus showing evidence for lipid-specific NKT 
activation for the first time in cattle (Pirson et al., 2015). 
1.5.6 γδ T cells 
γδ T cells, which have a T cell receptor (TCR) consisting of one γ and one δ chain,  
constitute a minor fraction of the lymphocyte population in humans and mice and 
represent approximately 10% of the circulating lymphocytes present. However, γδ T 
cells are a major subset of lymphocytes in ruminants, constituting approximately 60% 
of circulating T cells in young animals (Davis et al., 1996). In parallel with NK cells, 
numbers of γδ T cells are elevated in young calves and decline with age (Kulberg et 
al., 2004). Bovine γδ T cells are divided into distinct subsets based upon their 
expression of isoforms of Workshop Cluster 1 (WC1), a transmembrane glycoprotein 
and member of the scavenger receptor cysteine rich (SCRC) superfamily. The majority 
of blood derived γδ T cells express WC1 (Rogers et al., 2005) and lack expression of 
CD2 and CD8. A smaller proportion of circulating γδ T cells are WC1- CD8+ cells. 
Recently, it was proposed that bovine circulating γδ T cells are a major regulatory T 
cell population through their expression of IL-10 which supports the role of γδ T cells 
as key players in immune regulation in humans and mice (Guzman et al., 2014).  
Considerable evidence exists to suggest that γδ T cells play a key role in the immune 
response to mycobacterial infection. Following BCG vaccination of calves, the 
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percentage of WC1+ γδ T cells present in the peripheral blood increased at 2 weeks 
post-vaccination alongside increased production of IFN-γ (Buza et al., 2009). 
Similarly, the percentage of IFN-γ producing WC1+ γδ T cells were elevated in the 
tissues of the lungs and upper respiratory tract following intranasal BCG vaccination 
(Price et al., 2010). In terms of virulent M. bovis infection, the frequency of peripheral 
blood derived WC1+ γδ T cells declines following M. bovis infection of cattle, thought 
to be attributed to their movement out of the circulation to the site of infection (Pollock 
et al., 1996). Furthermore, depletion of WC1+ γδ T cells from the circulation and 
respiratory tract of calves, prior to infection with M. bovis, had no effect on disease 
severity or granuloma formation. However, these studies revealed a role for WC1+ γδ 
T cells in the polarisation of a Th1 immune response during M. bovis infection 
(Kennedy et al., 2002).  
In conjunction with NK cells, WC1+ γδ T cells also bridge innate and adaptive immune 
responses through interactions with APCs. During in vitro studies, WC1+ γδ T cells 
exhibited enhanced expression of CD25 and MHC class II in parallel with increased 
production of IFN-γ after co-culture with M. bovis-infected DCs. Levels of IL-12 
secreted by M. bovis-infected DCs were also augmented after culture with WC1+ γδ 
T cells highlighting the reciprocal nature of the interaction between WC1+ γδ T cells 
and M. bovis-infected DCs (Price and Hope, 2009).  
1.6 Adaptive immune response to mycobacteria 
M. tb has the ability to delay onset of adaptive immune responses in mice or humans 
(Ottenhoff, 2012) and similarly, adaptive responses are delayed following M. bovis 
infection of cattle (Waters et al., 2009). The adaptive immune response is initiated 
when mature, mycobacteria-infected DCs arrive in the lung draining lymph nodes 
around day 11 post-infection where recognition of T cells can occur (Flynn, 2004).  
1.6.1 αβ T cells 
1.6.1.1. CD4+ T cells 
T cells bearing the αβ TCR are divided into CD4+ and CD8+ subsets based on their 
expression of the co-receptors CD4 and CD8 respectively. CD4+ T cells recognise 
antigen presented by MHC class II molecules, whereas MHC class I molecules present 
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antigen to CD8+ T cells. Both CD4+ and CD8+ T cells contribute to the anti-
mycobacterial immune response. CD4+ T cells increase within the circulation of 
calves around 4-6 weeks post-BCG vaccination (Buza et al., 2009) and a similar 
increase was also evident following infection with M. bovis (Pollock et al., 1996). 
CD4+ T cells also proliferate and produce IFN-γ in response to BCG-infected DCs 
(Hope et al., 2000a). A major function of CD4+ T cells is as helper lymphocytes and 
upon antigen recognition, naïve CD4+ T cells can differentiate into various subsets of 
CD4+ T helper cells. This differentiation is dictated in part by the cytokine milieu 
present at the time of differentiation and these cytokines are produced by populations 
of innate immune cells (Zhou et al., 2009). For example, the presence of IL-12 and 
IFN-γ in the local environment results in the development of a Th1 immune response 
which are characterised by the production of TNF-α, IL-2 and IFN-γ (Figure 1.5). Th1 
CD4+ T cells play a major role in the defence against mycobacteria and M. tb-infected 
DCs bias the polarisation of CD4+ Th1 cells in mice through the secretion of IL-12 
(Hickman et al., 2002). The importance of Th1 CD4+ T cell responses during anti-
mycobacterial immunity is highlighted by the inability of CD4+ T cell deficient mice 
to control bacterial growth within the lungs and the enhanced susceptibility of HIV+ 
individuals to TB due to the absence of Th1 CD4+ T cells (Estaquier et al., 1995, 
Mogues et al., 2001). Protective immunity against M. bovis infection in cattle is also 
driven by Th1 immune responses which are characterised by early and persistent 
production of IFN-γ (Buddle et al., 2005). Th17 immune responses have also been 
implicated during anti-mycobacterial immunity in humans (Jurado et al., 2012), mice 
(Khader and Cooper, 2008) and cattle (Vordermeier et al., 2009). Expression of IL-17 
mRNA was induced after in vitro stimulation of PBMCs with PPD-b or Ag85A in both 
BCG/Ag85A vaccinated cattle and M. bovis infected cattle. Furthermore, IL-17 
responses to Ag85A in BCG/Ag85A vaccinated animals negatively correlated with 
disease pathology therefore vaccine-induced IL-17 responses may be protective 
(Vordermeier et al., 2009). Conversely, increased IL-17 production was associated 
with pathology in M. bovis-infected cattle (Blanco et al., 2011). Further research is 
required to decipher the key components of the CD4+ T cell response induced by 
mycobacteria and the specific CD4+ T helper cell associated cytokines which may 





Figure 1.5 Polarisation of CD4+ T helper subsets.  
Naïve CD4+ T cells can differentiate into many subsets of T helper cells which is 
determined in part by the cytokine milieu present at the time of differentiation. These 
subsets of T helper cells have different effector functions mediated by a wide range of 











1.6.1.2. CD8+ T cells 
CD8+ T cells also contribute to anti-mycobacterial immunity (North and Jung, 2004) 
and are cytotoxic, proliferate and produce IFN-γ upon activation. CD8+ T cells 
increase following M. bovis infection of calves (Pollock et al., 1996) and the proportion 
of CD8+ T cells is elevated 8-10 weeks post-BCG vaccination of calves (Buza et al., 
2009). Similar to CD4+ T cells, CD8+ T cells produce IFN-γ following BCG 
vaccination (Hope et al., 2000a). However, in vivo depletion of CD8+ T cells prior to 
challenge with M. bovis, resulted in lower lesion scores in the head lymph nodes of 
depleted calves compared with control calves indicating that CD8+ T cells may 
contribute to the immunopathology of bTB (Villarreal-Ramos et al., 2003). 
1.6.2 B cells 
According to the Th1/Th2 paradigm, Th1 cells and Th2 cells protect the host from 
intracellular and extracellular pathogens respectively (Mosmann and Coffman, 1989). 
Th2 polarisation of the immune response is driven by the presence of an IL-4 rich 
cytokine milieu which results in antibody secretion by B cells and production of 
cytokines including IL-4, IL-5 and IL-13 (illustrated in Figure 1.4). As Mycobacteria 
spp are intracellular pathogens, B cell immune responses were thought not to be 
important for protective immunity. However, it is become apparent that many diseases 
elicit mixed cellular and humoral responses, thus challenging the traditional view of 
the Th1/Th2 paradigm. For example, the protective role of humoral responses to 
intracellular pathogens such as Plasmodium, Chlamydia, Schistosoma and 
Cryptococcus neoformans has been established (Abebe and Bjune, 2009).  
The importance of antibody in protection of mice and humans following M. tb 
infection of has been demonstrated (Maglione et al., 2007, Lopez et al., 2009). 
Similarly in cattle, antibodies specific for mycobacteria were present in the sera from 
4 weeks post-M. bovis infection (Waters et al., 2006a). The presence of B cells within 
granulomas from M. bovis-infected cattle has also been demonstrated, particularly in 
Stage III and IV granulomas (Aranday-Cortes et al., 2013). Nevertheless, the role of B 




1.7 Hypothesis and Objectives 
Mycobacteria cause significant disease affecting both humans and animals and the 
incidence of human and bovine TB remains high due to the lack of effective vaccines 
and associated sensitive and specific diagnostic tests. In order to design better vaccines 
and induce optimal priming of protection, it is crucial that the immune response 
elicited by mycobacteria is fully understood. A key to effective immune response 
induction is the innate immune response and subsequent interactions with the adaptive 
immune response. NK cells are the focus of this thesis as they are involved during 
immunisation of infants with BCG (Zufferey et al., 2013) and have an increased 
frequency and activity in neonatal calves (Kulberg et al., 2004, Graham et al., 2009). 
Furthermore, they can bridge innate and adaptive immunity through interactions with 
DCs, which can affect the subsequent adaptive immune response. The overarching 
hypothesis being addressed in this thesis is that the enhanced efficacy of BCG in 
neonatal calves is due to the increased number of NK cells which through 
interactions with DCs prime Th1-type CD4+ and CD8+ T cell responses. This 
project comprised three main objectives which are detailed in Chapters 3, 4 and 5 
respectively: 
1) Compare the frequency and phenotype of NK cells across peripheral blood, afferent 
lymph, lymph nodes and efferent lymph in steady-state conditions 
2) Determine the effect of BCG vaccination on NK cells derived from peripheral 
blood, afferent lymph, lymph nodes and efferent lymph 






































2. Materials and Methods 
 
2.1 Media and Suppliers  
Details of all media used and suppliers of reagents and equipment are listed in 
appendix 8.1 and appendix 8.7 respectively. 
2.2 Animals 
Experiments were performed using male British Holstein-Friesian (Bos taurus) calves 
obtained from the Langhill herd, University of Edinburgh which has been certified free 
of bTB for over 10 years. All calves were housed at Dryden Farm, University of 
Edinburgh according to Home Office guidelines and with approval from The Roslin 
Institute Local Ethics Committee. Calves were under 3 months of age unless otherwise 
indicated. Age-matched calves were used as controls.  
2.2.1 Subcutaneous BCG vaccination 
BCG Vaccine Danish strain 1331 was prepared by reconstituting lyophilised BCG 
with 1ml of diluted Sauton medium. During BCG vaccination experiments, calves 
were vaccinated with 0.5ml of BCG Danish (5x human dose), administered 
subcutaneously in the left shoulder. Age-matched control calves were unvaccinated. 
A sample of the inoculum was plated onto 7H11 agar to determine titre immediately 
after administration. 
Blood samples were collected at various intervals pre- and post-BCG vaccination for 
up to 12 weeks. To confirm that calves were responding to vaccination, cultures of 
whole blood were stimulated with PPD-b (10µg/ml) or left unstimulated for 18 hours 
at 37°C with 5% CO2. Whole blood cultures were centrifuged at 650g, 4°C for 5 
minutes and plasma supernatants were harvested and stored at -20°C prior to analysis. 
Supernatants were analysed for the presence of IFN-γ by Enzyme Linked 
Immunosorbent Assay (ELISA) (section 2.15).  
To study in vivo NK cell responses within skin draining afferent lymphatic vessels 
(section 2.2.2) in the context of BCG vaccination, 0.5ml of reconstituted BCG Danish 
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was delivered subcutaneously to the left shoulder of 6 month old pseudo-afferent 
lymphatic cannulated calves and afferent lymph was collected at various time points 
pre- and post-vaccination. To assess recruitment of NK cells to the lymph nodes 
draining the site of vaccination in vivo, 0.5ml of reconstituted BCG Danish was 
administered subcutaneously to the left shoulder of 6 month old calves and prescapular 
lymph nodes (PSLN) were then excised 24 or 48 hours post-vaccination. PSLN from 
the right shoulder (non-vaccinated) of each calf served as an internal control.  
2.2.2 Afferent Lymphatic Cannulation 
Surgical cannulation of skin draining afferent lymphatic vessels of male British 
Holstein-Friesian (Bos taurus) calves aged 3-6 months old was kindly performed by 
Dr Charlotte Bell using a protocol described in detail elsewhere (Hope et al., 2006) 
and as illustrated in Figure 2.1. Briefly, prior to cannulation of the afferent lymphatic 
vessels, the left and right PSLNs were identified and excised. Approximately 8 weeks 
later, following re-anastomosis of the small afferent lymphatic vessels to the larger 
efferent lymphatic vessel, a sterilised surgical cannula was inserted into this ‘pseudo-
afferent’ lymphatic vessel. Lymph was collected into a T75 tissue culture flask, which 
was secured to the side of the calf using a harness, and contained 1ml of sodium 
benzylepenicillin dissolved in heparin (3g sodium benzylepenicillin dissolved in 
5000i.u/ml heparin). Flasks were changed twice daily, or as required, for up to 28 days 
post-cannulation. Paired samples of peripheral blood were collected by jugular 
venepunture into 10ml vacutainers containing sodium heparin (10U/ml). PBMCs were 






Figure 2.1 Illustration represents the steps involved to cannulate the skin 
draining afferent lymphatic vessels.  
To cannulate the ‘pseudo-afferent’ lymphatic cannulation vessel, the lymph node was 
excised and approximately 8 weeks later following re-anastomosis of the small 
afferent lymphatic vessels to the larger efferent lymphatic vessel, a cannula was 
inserted into the ‘pseudo-afferent’ lymphatic vessel. Lymph was then be collected into 
a flask which was attached to the side of the calf and contains cells which are 
trafficking to lymph nodes via the afferent lymphatic vessel. Adapted from (Neeland 















2.2.3 Efferent Lymphatic Cannulation 
Samples of frozen efferent lymph from naïve efferent lymphatic cannulated calves 
were kindly provided by Dr Bernardo Villareal-Ramos (APHA). Efferent lymphatic 
vessels of male British Holstein-Friesian (Bos taurus) calves aged 3-6 months old were 
surgically cannulated by Dr Bryan Charleston using a method described previously 
(Vrieling et al., 2012). Following surgical cannulation, efferent lymph was collected 
into flasks containing sodium benzylepenicillin dissolved in heparin as described in 
section 2.2.2. Paired samples of peripheral blood were collected by jugular 
venepunture into 10ml vacutainers containing sodium heparin (10U/ml). PBMCs were 
then isolated as detailed in section 2.3.1. Three efferent lymphatic cannulated calves 
(aged 6 months) were vaccinated subcutaneously with 0.5ml reconstituted BCG 
Danish and efferent lymph was collected at various time points pre- and post-
vaccination. 
2.3 Isolation of cells 
2.3.1 Peripheral blood mononuclear cells (PBMCs) 
50ml volumes of blood were collected by jugular venepuncture into syringes 
containing sodium heparin (10U/ml) or for larger blood volumes (between 300-
500ml), blood was collected into bags containing citrate phosphate dextrose adenine 
(CPDA), and PBMCs were separated by density gradient centrifugation. Depending 
on the age of the calf, blood was diluted either 1:2 (if less than 3 months old) or 1:3 
with phosphate buffered saline (PBS) and layered onto Histopaque 1083. Gradients 
were centrifuged at 1200g, 20°C for 35 minutes with the brake disabled and the buffy 
coat containing PBMCs was retrieved. Cells were washed three times with PBS, once 
at 650g, 4°C for 10 minutes and twice at 400g, 4°C for 8 minutes. Contaminating 
erythrocytes were removed by adding 3ml of 0.1M ammonium chloride lysis buffer 
for 5 minutes followed by washing with PBS at 400g, 4°C for 8 minutes. Viable cells 
were counted using trypan blue exclusion in a haemocytometer and PBMCs were 
resuspended in an appropriate volume of tissue culture medium (TCM) prior to use. 




2.3.2 Mononuclear cells (MNCs) from PSLNs 
 
PSLNs were collected into ice cold PBS, sliced in half, and inner regions were scored 
using a scalpel to aid removal of the cells from the tissue. Cells were gently teased 
away from the capsule using a blunt scalpel, collected into PBS and filtered through a 
sterile 40µM cell strainer. The cell suspension was diluted in PBS and MNCs were 
obtained by density gradient centrifugation using Histopaque 1083 (described in detail 
in section 2.3.1). MNCs were resuspended in TCM and viable cells were counted using 
trypan blue exclusion in a haemocytometer. Fresh cells were analysed by flow 
cytometry. 
2.3.3 MNCs from afferent lymph 
Whole lymph was centrifuged at 400g, 4°C for 5 minutes to pellet the cells. Cells were 
then resuspended in TCM and viable cells were counted using trypan blue exclusion 
in a haemocytometer. Fresh cells were analysed by flow cytometry. 
2.3.4 MNCs from the skin 
Small sections of shaved skin were digested in RPMI containing dispase I (20µg/ml) 
and collagenase (75U/ml) for 90 minutes at 37°C in a shaking incubator. The digest 
was then homogenised and filtered through a 40µM cell strainer. Cells were 
centrifuged at 400g, 4°C for 5 minutes to pellet cells, resuspended in TCM and viable 
cells (1 x 106) were counted using trypan blue exclusion in a haemocytometer. Fresh 
cells were analysed by flow cytometry. 
2.3.5 CD14+ monocytes and culture of monocyte-derived DCs 
MACS MicroBeads conjugated to a mouse anti-human CD14 antibody, which has 
been shown to be cross-reactive with bovine monocytes (Werling et al., 1999) were 
used to isolate CD14+ monocytes. PBMCs were incubated with 2.5μl beads/107 cells 
for 10 minutes at room temperature. Following labelling of PBMCs, cells were washed 
twice with PBS at 400g, 4°C for 5 minutes and resuspended with 2.5ml FACSFlow/1% 
Bovine Serum Albumin (BSA). CD14+ monocytes were positively selected using a 
MidiMACS LS column and washed twice with PBS (400g for 5 minutes at 4°C). 
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CD14+ monocytes were diluted to 1 x 106 cells/ml in TCM and 3 x 106 monocytes 
were seeded in 6-well plates with a 1:300 dilution of COS cell derived recombinant 
bovine GM-CSF and IL-4 (generated as detailed in section 2.16). CD14+ monocytes 
were incubated for 3 days at 37°C with 5% CO2 to obtain immature monocyte-derived 
DCs. All monocyte-derived DCs were used fresh. 
2.3.6 NK cells 
PBMCs were diluted to 5 x 107 cells/ml in PBS/2mM ethylenediaminetetraacetic acid 
(EDTA)/0.5% BSA and 3μg/ml of mouse anti-ovine NKp46 (clone EC1.1, IgG1) was 
added. PBMCs were rolled gently for 30 minutes at 4°C, washed twice with PBS/2mM 
EDTA/0.5% BSA (400g for 10 minutes at 4°C) and resuspended to 5 x 107 cells/ml in 
PBS/2mM EDTA/0.5% BSA. Immunomagnetic pan-mouse IgG Dynabeads were 
prepared by washing the required volume (10μl beads per 107 cells) with 1ml 
PBS/2mM EDTA/0.5% BSA. Beads were added directly to labelled PBMCs diluted 
in PBS/2mM EDTA/0.5% BSA and rolled for a further 30 minutes at 4°C. The volume 
of cell suspension was doubled with PBS/2mM EDTA/0.5% BSA and transferred to 
15ml falcon tubes. Falcon tubes were placed in a DynaMag-15 for 2 minutes and 
unbound cells were poured off. NKp46+ cells were washed a further 3 times with 5ml 
PBS/2mM EDTA/0.5% BSA, removed from the magnet and resuspended in TCM. 5 
x 105 cells/ml were seeded in 24-well plates and incubated at 37°C with 5% CO2. NK 
cells were harvested from the plates 24 hours later, mixed thoroughly and placed in a 
DynaMag-15 for 2 minutes to remove the magnetic beads. Resulting NK cells were 
collected and washed once with PBS (400g for 5 minutes at 4°C), resuspended in TCM 
and counted using trypan blue exclusion and a haemocytometer. All NK cells were 
used fresh and an average of 2.5 x 106 cells were obtained from 300-500ml of blood. 
 
2.3.7 Cryopreservation 
Cells were frozen by resuspending cells at 5 x 107 cells/ml in FCS containing 10% 
dimethyl sulfoxide (DMSO). 1ml volumes were then transferred into cryovials and 
placed in a freezing container containing isopropanol and stored at -80°C. Aliquots 
were thawed immediately after removal from the freezer using a 37°C water bath and 
washed twice with PBS prior to use. 
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2.4 Labelling BCG with FITC 
BCG was reconstituted as previously described (section 2.2.1), mixed with an equal 
volume of 0.2mg/ml FITC and incubated for 3 hours at 4°C, protected from light. 
Bacteria were washed with PBS at 800g, 4°C for 20 minutes and this was repeated 3 
times. Fluorescently labelled bacteria were then resuspended in an appropriate volume 
of RPMI + 10% Foetal Bovine Serum (FBS) prior to infection of DCs (section 2.5). 
2.5 Infection of DCs with BCG/BCG-FITC 
Immature monocyte-derived DCs were harvested by firstly removing floating cells 
which were stored on ice prior to combining with adherent cells. Adherent cells were 
incubated with 1ml non-enzymatic cell dissociation fluid for 30 minutes at 37°C with 
5% CO2. Floating and adherent cells were pooled and washed once with PBS (400g 
for 5 minutes at 4°C) and resuspended in RPMI + 10% FCS. BCG was reconstituted 
as described (section 2.2.1), washed once with PBS at 400g, 4°C for 5 minutes and 
resuspended in RPMI + 10% FCS. DCs were pelleted and resuspended in 1ml of BCG 
or BCG-FITC at a multiplicity of infection (MOI) of 5 for 24 hours at 37°C with 5% 
CO2. This MOI was selected after determining the percentage of DCs that took up 
BCG-FITC and the viability of DCs after infection of DCs with BCG at MOIs of 1, 3 
and 5 (Figure 5.2.2 and 5.2.3). 
 
2.6 Exposure of DCs to Zylexis™ 
Zylexis™ is an immunomodulatory compound produced by the industrial partner of 
this PhD project, Zoetis. It is used to non-specifically stimulate the immune response 
of horses therefore it was tested within co-cultures of bovine NK cells and monocyte-
derived DCs to determine if it could act as an immunomodulator in this context. 
Immature DCs were harvested as described in section 2.5. Zylexis™ was reconstituted 
in distilled water, washed once with PBS at 400g, 4°C for 5 minutes and resuspended 
in RPMI + 10% FCS. DCs were pelleted and resuspended in 1ml of Zylexis™ at a 
multiplicity of infection (MOI) of 1 for 24 hours at 37°C with 5% CO2. This MOI was 
defined by determining cell viability after exposing DCs to Zylexis™ at MOIs of 1, 5 
and 10.  
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2.7 Co-culture of NK cells with BCG-infected DCs 
BCG-infected DCs or uninfected DCs were diluted to 4 x 105 cells/ml in RPMI + 10% 
FCS and seeded in a 96 well ‘U’ bottom plate at 100µl cells per well for 24 hours at 
37°C with 5% CO2. NK cells were diluted to 2 x 10
6 cells/ml in RPMI + 10% FCS and 
added to the wells containing DCs at 100µl cells per well (at a previously determined 
optimal NK cell : DC ratio of 5:1 (Siddiqui and Hope, 2012)). NK cells and DCs were 
incubated for 18 hours at 37°C with 5% CO2. Following co-culture, cells were pelleted 
and supernatants were collected and stored at -20°C prior to analysis of cytokine 
production by ELISA (section 2.15). Expression of NKp46, CD3, CD2, CD25 and 
NKp30 by NK cells, and MHC class I, MHC class II, CD40, CD80, CD86 and CCR7 
by DCs were analysed using multi-colour flow cytometry (as described in section 
2.13). NK cells cultured alone, with BCG (MOI of 5) or supplemented with 
recombinant bovine IL-12 (20BU/ml) and recombinant human IL-18 (20ng/ml) were 
the control conditions.  
2.8 Co-culture of NK cells with Zylexis™-exposed DCs  
Co-cultures of NK cells and Zylexis™-exposed DCs were performed as described in 
section 2.7.  
2.9 RNA extraction 
Prior to RNA extraction, 1 x 106 isolated NK cells were lysed using RLT buffer 
containing 2-mercaptoethanol and stored at -80°C. Lysed cells were thawed and 
homogenised using a Qiashredders column. RNA was extracted using RNeasy mini 
kits, which included a DNase digestion step to remove contaminating genomic DNA, 
according to the manufacturer’s instructions. RNA was eluted into RNase-free water 
and the quality and concentration of the RNA was assessed using the Nanodrop 
spectrophotometer ND-1000. RNA was stored at -80°C until use.  
2.10 Reverse transcription  
RNA was reverse transcribed using the Superscript III Reverse Transcriptase system 
according to the manufacturer’s instructions. The quality of cDNA was assessed by 
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detecting the presence of the housekeeping gene GAPDH by PCR (primers illustrated 
in appendix 8.4). 
2.11 Polymerase Chain Reaction (PCR) 
To assess the expression of KLRC1.1, KLRC2.1 and KLRC2.2 by isolated NK cells at 
various time points post-BCG vaccination, PCR reactions for were performed using 
the primers illustrated in appendix 8.4. Mastermixes (same composition for each gene) 
contained: 1µl cDNA, 1.25µl forward and 1.25µl reverse primers, 0.5µl dNTPs, 0.25µl 
Taq polymerase, 2.5µl 10x PCR reaction buffer, 1.25µl MgCl2 and reactions were 
made up to a volume of 25µl with distilled water. Reactions were run according to the 
programmes illustrated below using cDNA positive for the gene of interest as the 
positive control and water as the negative control. 
95°C 2 minutes 
95°C 30 seconds 
 56°C 30 seconds   x 35 cycles 
72°C 1 minute 
72°C 7 minutes 
PCR products were mixed with 5µl loading dye and loaded on a 2% agarose gel 
containing 10.5µl SYBR Safe at 115 volts (V) for 2 hours. 5µl of 1Kb PLUS DNA 
ladder diluted 1:5 with loading dye was run alongside the PCR products to define size. 
Expected band sizes for each gene were as follows: KLRC1.1 (140bp), KLRC2.1 
(140bp) and KLRC2.2 (180bp). 
 
2.12 Quantitative real – time PCR 
To assess expression of NKp30 (NCR3) by NK cells prepared at various time points 
pre- and post-BCG vaccination and NK cells from age-matched, non-vaccinated 
control calves, qPCR assays were performed for these target genes alongside the 
reference genes, ATP5B and EIF2B2. These reference genes were decided as the most 
suitable after testing five reference genes (Alasdair Allan, PhD thesis, Royal 
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Veterinary College, 2015). Primer sequences are illustrated in appendix 8.5. 
Mastermixes (compositions detailed in appendix 8.5) were prepared for each gene and 
contained: Luminaris Colour HiGreen Low ROX qPCR master mix, cDNA, forward 
primer, reverse primer and were made up to a volume of 20µl with distilled water. 
Each sample was tested in duplicate. qPCR was performed using the Viia 7 Real Time 
PCR system with cDNA positive for the gene of interest as the positive control, cDNA 
amplified with Taq polymerase as the reverse transcription control and water as the 
negative control.  
2.13 Multi-colour immunofluorescent staining 
Flow cytometry of cell surface molecules was performed on PBMCs, MNCs, NK cells, 
and DCs. For 4 colour direct/indirect staining, 106 cells were added to wells of a 96 
well ‘U’ bottom plate and centrifuged at 650g for 2 minutes. Primary antibodies, 
diluted in PBS/1% BSA/0.1% sodium azide were added and cells were incubated for 
15 minutes at room temperature, protected from light. Following two washes with 
PBS/1% BSA/0.1% sodium azide (650g for 2 minutes); fluorochrome-labelled 
isotype-specific secondary antibodies were added for 15 minutes in the dark. After one 
wash with PBS/1% BSA/0.1% sodium azide (650g for 2 minutes), 10% normal mouse 
serum was added to cells for 15 minutes to prevent non-specific binding. Lastly, one 
or two directly conjugated antibodies were added and after a final two washes at 650g 
for 2 minutes, cells were resuspended in FACSFlow. An equal volume of Sytox Blue, 
to discriminate live cells, was added prior to visualisation and collection of 50,000 
events using the BD LSRFortessa and FACSDiva Software. Data was analysed using 
FlowJo v10 software. Appendix 8.2 and 8.3 illustrate the mAbs and fluorochromes 
used respectively. 
2.14 Intracellular cytokine staining 
107 PBMCs/MNCs were resuspended in RPMI 1640 + 10% FCS with 20 x 
PMA/Ionomycin/Brefeldin A and incubated for 4 hours at 37°C with 5% CO2. 
Following stimulation, Zombie Aqua Fixable Viability Kit was added at a 1:200 
dilution in 100ul PBS per 106 cells for 15 minutes protected from light. PBMCs were 
washed twice with PBS and fixed by the addition of 2% paraformaldehyde for 30 
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minutes at room temperature. Cells were then washed with PBS and permeabilised by 
adding 1x Permeabilisation Solution. Cells were resuspended overnight in PBS/1% 
BSA/0.1% sodium azide prior to staining of surface and intracellular molecules.  
2.15 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISAs were performed to detect the presence of bovine IL-12 (Hope et al., 2002a) 
and IFN- (Collins et al., 1999). Appendix 8.6 illustrates the capture antibodies, 
detection antibodies and cytokine standards used. 96-well transparent, flat-bottomed 
plates were coated with capture antibody diluted in carbonate/bicarbonate buffer, 
sealed and left overnight at room temperature. Following six washes with PBS/Tween-
20 using the Skan Washer 400 plate washer, non-specific binding of the antibody was 
blocked by adding 1mg/ml sodium casein in PBS for 1 hour at room temperature. 
Plates were then washed six times with PBS/Tween-20. Recombinant cytokines were 
serially diluted (2-fold for IFN-γ and 3-fold for IL-12) and 100μl of each dilution and 
100μl of sample were plated in duplicate and incubated for 1 hour at room temperature. 
Plates were washed a further six times with PBS/Tween-20 and incubated for 1 hour 
with biotinylated detection antibody, diluted to the appropriate concentration in 
1mg/ml sodium casein in PBS. Following additional washing, Streptavidin-HRP 
Peroxidase, diluted 1:500 with 1mg/ml sodium casein/Tween-20, was added for 45 
minutes at room temperature. After a final six washes, the plates were developed in 
the dark using 100μl/well of 3,3´,5,5´-tetramethylbenzidine (TMB) substrate solution 
and the reaction was stopped using 50μl/well of 1M sulphuric acid. Absorbance was 
measured at 450nm subtracted from 690nm using the Synergy HT Multi-Mode 
Microplate Reader and Gen 5 software.  
2.16 Generating recombinant bovine GM-CSF and IL-4 
Recombinant bovine GM-CSF and IL-4 were obtained from stably-transfected 
Chinese Hamster Ovary (CHO) cell lines, which were kindly provided by Professor 
Gary Entrican and Sean Wattegedera (Moredun Research Institute). Cloned lines of 
transfected CHO cells were maintained in Glasgow’s Modified Eagle’s Medium 
(GMEM) supplemented with sodium pyruvate, non-essential amino acids and USDA-
approved dialysed foetal calf serum (FBS). For cytokine production, CHO cells were 
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cultured in FBS-free GMEM and supernatants containing GM-CSF or IL-4 were 
collected and stored at -20°C (Entrican et al., 1996).  
2.17 Data analysis 
Data analysis was performed using Microsoft Excel 2010 and GraphPad Prism 6. 
Statistical analysis was completed using Minitab v16. Distribution of data was 
assessed using a normality test with data with p<0.05 deemed to be of a non-normal 
distribution. Non-normal data was log transformed. Statistical methods used are 
detailed in individual figure legends and included paired t test, 2-sample t test and 























NK cells are widely distributed in lymphoid and non-lymphoid tissues however little 
is known about the recirculation of NK cells between blood and tissues. Therefore, the 
percentage of NK cells and their phenotype across peripheral blood, afferent lymph 
and lymph nodes in steady-state conditions was investigated using the pseudo-afferent 
lymphatic cannulation model. CD2+ CD25lo NK cells were the predominant subset of 
NK cells within the blood. In contrast, CD2- CD25hi NK cells were the main subset 
present within the skin draining afferent lymphatic vessels and lymph nodes indicating 
that CD2- NK cells are the principal NK cell subset trafficking to LNs via the afferent 
lymphatic vessel. Furthermore, NK cells were present in efferent lymph and therefore 
suggests that NK cells, particularly the CD2- subset, can egress from lymph nodes and 
return to circulation in steady-state conditions. Thus, NK cells may represent a 















3. The frequency and phenotype of peripheral blood, afferent lymph, 
lymph node and efferent lymph derived NK cells 
 
3.1 Introduction 
NK cells are highly motile lymphocytes that are widely distributed in lymphoid and 
non-lymphoid tissues (Gregoire et al., 2007, Connelley et al., 2011, Boysen et al., 
2008, Mair et al., 2012, Tomasello et al., 2012) allowing them to respond quickly to 
infection or inflammation through cytotoxicity and production of immunoregulatory 
cytokines. Dissecting the precise anatomical location of NK cells will reveal potential 
roles for these cells in steady-state and inflammatory conditions. Furthermore, NK 
cells interact with an array of accessory cell populations including DCs and therefore, 
it is important to decipher where these interactions may take place in vivo, as such 
innate immune cell interactions are pivotal in driving the nature of the adaptive 
immune response. 
 
Lymphocytes continuously circulate between the blood and tissues such as the skin 
via the lymphatics and lymph nodes in steady-state conditions. This continuous 
recirculation is required for immune surveillance (Gowans, 1959). Lymphocytes can 
enter lymph nodes via two routes, firstly from the circulation through high endothelial 
venules (HEVs) and secondly, they can migrate from the tissues through afferent 
lymphatic vessels. Lymphocytes can then egress from the lymph nodes via the efferent 
lymphatic vessel and return to circulation via the thoracic duct (Masopust and 
Schenkel, 2013). In contrast to the re-circulatory nature of αβ T cells, very little is 
known about NK cell recirculation (Carrega and Ferlazzo, 2012). It has been 
demonstrated in mice that NK cells migrate from the circulation to lymph nodes via 
HEVs (Martin-Fontecha et al., 2004, Bajenoff et al., 2006). NK cells are present in 
human afferent lymphatic vessels (Yawalkar et al., 2000, Hunger et al., 1999, Carrega 
et al., 2014) and to date, one study has shown that NK cells are found in human efferent 
lymph (Romagnani et al., 2007). It was demonstrated recently that bovine NK cells 
are present in the skin draining afferent lymphatic vessels of cattle in steady-state 
conditions. In this study, the frequency, phenotype and function of NK cells from 
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peripheral blood and afferent lymph of different animals were compared using the 
pseudo-afferent lymphatic cannulation model (Lund et al., 2013).  
 
Surgical cannulation of afferent and efferent lymphatic vessels has been used to study 
innate immune responses during vaccination and infection in animal models. In 
contrast to efferent lymphatic vessels, afferent lymphatic vessels are difficult to 
surgically access, even in large animals, therefore to access cells trafficking through 
skin draining afferent lymphatic vessels, the pseudo-afferent lymphatic cannulation 
model can be utilised as previously described (Hope et al., 2006) and as detailed in 
Figure 2.1. Briefly, approximately eight weeks prior to cannulation of the afferent 
lymphatic vessels, the left and right PSLNs are identified and excised. Following re-
anastomosis of the small afferent lymphatic vessels to the larger efferent lymphatic 
vessel, which takes place over a period of six-eight weeks, a sterilised surgical cannula 
is inserted into this ‘pseudo-afferent’ lymphatic vessel, to allow collection of afferent 
lymph that contains cells which would have been migrating into the lymph nodes in 
vivo. This method is well established in cattle, sheep, pigs and rats (Hope et al., 2006, 
Schwartz-Cornil et al., 2006, Johnson and Jackson, 2008, Liu et al., 1998). 
 
Many vaccines (including BCG) are delivered subcutaneously. Our knowledge of why 
vaccines work whereas others fail at a mechanistic level remains limited. Priming of 
the adaptive immune response in mammals occurs in organised lymphoid tissue, hence 
investigation of the local immune response occurring at the site of vaccination and in 
the draining lymph nodes will help improve vaccine design and delivery. The work 
presented in this Chapter assessed the frequency and phenotype of bovine NK cells in 
steady-state conditions across peripheral blood (PB), afferent lymph (AL) and lymph 
nodes (LNs). To do this, the pseudo-afferent lymphatic cannulation model was utilised, 
with a total of seven calves. LNs were analysed at the time of excision, and PB and 
AL from the same animal was collected post-surgical cannulation and analysed in 
parallel. Furthermore, samples of efferent lymph (EL) from five naïve efferent 
lymphatic cannulated calves were kindly provided by Dr Bernardo Villareal-Ramos 
(APHA) to determine if NK cells were present in bovine EL.  
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The hypothesis of this study was that the frequency and phenotype of bovine NK 
cells in steady-state conditions is reflective of their anatomic localisation. 
Understanding the frequency and phenotype of innate lymphocytes such as NK cells 
will inform on the design of appropriate vaccines/adjuvants/immunomodulators and 
will also help to decipher the innate interactions that drive the bias of the adaptive 






















3.2.1 Percentage of NK cells present in PB, AL and LNs 
Firstly, to determine if NK cells were present in skin draining afferent lymphatic 
vessels and at what frequency compared with those present in PB and LNs, the 
abundance of NKp46+ CD3- NK cells within PB, AL and LNs of seven calves was 
investigated. Lymphocytes were labelled with mAbs to NKp46 and CD3 and analysed 
by flow cytometry. The gating strategy used to identify lymphocytes throughout this 
thesis is illustrated in Figure 3.1.1. NKp46+ CD3- NK cells represented 5.1% (2.05 - 
10.3%; SD = 3.1), 4.8% (1.39 - 7.68%; SD = 1.9), and 6% (3.03 - 11.7%; SD = 2.9) 
of lymphocytes in PB, AL and the LNs respectively. No significant differences were 
evident between the percentages of NK cells present across the three compartments 
(Figure 3.1.3). 
3.2.2  NK cell subsets present in PB, AL and LNs 
Similar to human (Cooper et al., 2001a) and murine (Chiossone et al., 2009) NK cells, 
bovine NK cells exist as distinct subsets and consequently NKp46+ NK cells can be 
subdivided into two subsets based on their differential expression of CD2 (Boysen et 
al., 2006). Therefore, to investigate the distribution of CD2+ and CD2- subsets of NK 
cells across PB, AL and LNs, lymphocytes were labelled with mAbs to NKp46 and 
CD2 and analysed by flow cytometry. CD2+ NK cells were the predominant subset in 
PB; however CD2- NK cells were the principal NK cell subset found in the skin 
draining afferent lymphatic vessels and LNs. Furthermore, CD2- NK cells were 
present in AL (p<0.001) and LNs (p<0.001) at a significantly higher proportion 













Figure 3.1 Percentage of NK cells present in PB, AL and LNs 
Lymphocytes derived from PB (fresh), AL (fresh) and the LNs (fresh) of seven calves 
were labelled with mAbs to NKp46 and CD3 and analysed by flow cytometry. Single 
cells were gated, followed by lymphocytes and then live lymphocytes were selected as 
those cells which were negative for the dead cell discriminator, Sytox Blue (Figure 
3.1.1). FACS plots from one representative animal illustrate the expression of NKp46 
and CD3 by PB, AL and LN derived lymphocytes (Figure 3.1.2). Quadrants were set 
based on Fluorescence Minus One (FMO) controls. Pooled data from seven calves 
indicate the percentage of NKp46+ CD3- NK cells present in PB (circles), AL 
(squares) and LNs (triangles) (Figure 3.1.3). Data were normally distributed (p>0.05) 










Figure 3.2 NK cell subsets present in PB, AL and LNs  
Lymphocytes derived from PB (fresh), AL (fresh) and the LNs (fresh) of seven calves 
were labelled with mAbs to NKp46 and CD2 and analysed by flow cytometry. FACS 
plots from one representative animal illustrate the expression of NKp46 and CD2 by 
PB, AL and LN derived lymphocytes (Figure 3.2.1). Quadrants were set based on 
FMO controls. Pooled data from seven calves illustrates the average percentage of 
CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD within the total gated 
NKp46+ NK cell population from PB, AL or the LNs (Figure 3.2.2). Data were 





3.2.3 Activation of NK cells derived from PB, AL and LNs 
The activation status of NK cells derived from PB, AL and the LNs was analysed by 
determining the expression of the activation marker, CD25 which is the α-chain of the 
IL-2 receptor. Lymphocytes were labelled with mAbs to NKp46, CD2 and CD25 and 
analysed by flow cytometry. In contrast to PB where 26.3% (13.3 - 46.2%; SD = 10.9) 
of NK cells were CD25+, the percentage of CD25+ NK cells was significantly 
increased in AL (p<0.001) and LNs (p<0.001), with 85.8% (66.1 - 95.2%; SD = 12.2) 
and 81.4% (74.8 - 87.9%; SD = 5.1) of AL and LN derived NK cells expressing CD25 
respectively (Figure 3.3.2). A similar increase in the expression levels of CD25, 
represented by Mean Fluorescence Intensity (MFI), was also noted and CD25 
expression was significantly enhanced on AL (p=<0.001) and LN (p=0.013) derived 
NK cells, compared with NK cells from PB (Figure 3.3.3). To define the subset of NK 
cells responsible for the increased activation of NK cells in AL and LNs, the 
percentage of CD2+ and CD2- NK cells within the CD25+ population from PB, AL 
and LNs was assessed. CD25 was equally expressed by PB derived CD2+ and CD2- 
NK cells, however the percentage of CD2- CD25+ NK cells increased significantly in 
AL (p<0.001) and the LNs (p=0.005) (Figure 3.3.4). 
3.2.4 Migratory potential of NK cells present in PB, AL and LNs 
To assess the migratory potential of NK cells, the expression of the LN homing 
molecules CD62L (L-selectin) and CCR7 were assessed by PB, AL and LN derived 
NK cells. Lymphocytes were labelled with NKp46, CD2, CD62L and CCR7 and 
analysed by flow cytometry. No significant differences between the percentages of 
CD62L+ NK cells present across PB, AL and LNs were observed (Figure 3.4.2). 
However, the percentage of CD2- NK cells expressing CD62L was significantly 
increased in AL (p=0.004) and LNs (p=0.024), compared with PB (Figure 3.4.3). 
CCR7 expression was not detected on PB and LN derived NK cells and the expression 








Figure 3.3 Activation of NK cells derived from PB, AL and LNs 
Lymphocytes from PB (fresh), AL (fresh) and the LNs (fresh) of seven calves were 
labelled with mAbs for NKp46, CD2 and CD25 and analysed by flow cytometry. 
FACS plots from one representative animal illustrate the expression of NKp46 and 
CD25 by PB, AL and LN derived lymphocytes (Figure 3.3.1). Quadrants were set 
based on FMO controls. Pooled data from seven calves illustrates the percentage of 
CD25+ NK cells within the total gated NKp46+ NK cell population from PB (circles), 
AL (squares) or the LNs (triangles) (Figure 3.3.2). Pooled data from seven calves 
indicates the MFI of CD25+ NK cells within the total gated NKp46+ NK cell 
population from PB (circles), AL (squares) or the LNs (triangles) (Figure 3.3.3). 
Pooled data from seven calves illustrates the average percentage of CD2+ (lighter bars) 
and CD2- (darker bars) NK cells ± SD within the total gated NKp46+ CD25+ 
population from PB, AL or LNs (Figure 3.3.4). Data were normally distributed 

























Figure 3.4 Migratory potential of NK cells present in PB, AL and LNs 
Lymphocytes from PB (fresh), AL (fresh) and the LNs (fresh) of seven calves were 
labelled with mAbs for NKp46, CD2, CD62L and CCR7 and analysed by flow 
cytometry. FACS plots from one representative animal illustrate the expression of 
NKp46 and CD62L by PB, AL and LN derived lymphocytes (Figure 3.4.1). Quadrants 
were set based on FMO controls. Pooled data from seven calves indicate the 
percentage of NKp46+ CD62L+ NK cells present across the three compartments 
(Figure 3.4.2). Pooled data from seven calves illustrates the average percentage of 
CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD within the total gated 
NKp46+ CD62L+ population from PB, AL or LNs (Figure 3.4.3). FACS plots 
illustrate the expression of CCR7 by AL derived NK cells from seven calves (Figure 
3.4.4). Data were normally distributed (p>0.05) and significance was assessed using 
















3.2.5 Percentage of CD4+ T cells and WC1+ γδ T cells present in PB, AL and 
LNs 
To compare the frequency of NK cells present in PB, AL and LNs with the frequency 
of other lymphocyte populations, the percentage of CD3+CD4+ T cells and 
CD3+WC1+ γδ T cells present in PB, AL and the LNs was assessed. Lymphocytes 
were labelled with mAbs to CD3/CD4 or CD3/WC1 to define CD4+ T cells and WC1+ 
γδ T cells respectively and cells were analysed by flow cytometry. CD4+ T cells 
accounted for 19.9% (13.4 - 28.6%; SD = 5.2), 27.7% (13 - 43.8%; SD = 9.2), and 
31.6% (19.4 - 52.1%; SD = 11.3) of lymphocytes present in PB, AL and LNs 
respectively, and were significantly increased in LNs compared with PB (p=0.043) 
(Figure 3.5.3). WC1+ γδ T cells represented 22.3%, 40% and 6.1% of lymphocytes 
found in PB, AL and LNs respectively, and were significantly decreased in LNs 
compared with PB (p=0.002) and AL (p=0.002). Despite the increased presence of 
WC1+ γδ T cells in AL, this was not significantly increased compared with PB 






Figure 3.5 Percentage of CD4+ T cells and WC1+ γδ T cells present in PB, AL 
and LNs 
Lymphocytes derived from PB (fresh), AL (fresh) and the LNs (fresh) of seven calves 
were labelled with mAbs for CD3, CD4 and WC1 and analysed by flow cytometry. 
FACS plots from one representative animal illustrate the expression of CD4 (Figure 
3.5.1) and WC1 (Figure 3.5.2) within the total gated CD3+ population. Gates were set 
based on FMO controls. Pooled data from seven calves display the percentage of 
CD3+CD4+ T cells (Figure 3.5.3) and CD3+WC1+ γδ T cells (Figure 3.5.4) present 
within PB (circles), AL (squares) and LNs (triangles). Data were normally distributed 

















3.2.6 Percentage of NK cells present in the skin  
Data presented thus far provides evidence that bovine NK cells are present within skin 
draining afferent lymphatic vessels in steady-state conditions. However, it is not 
known if NK cells are resident in the skin of naïve cattle and if their presence in the 
skin draining afferent lymphatic vessels reflects migration from the skin or recruitment 
from elsewhere. Therefore, small pieces of skin were enzymatically digested and 
assessed for the presence of NK cells by labelling lymphocytes with mAbs to NKp46 
and CD2 and analysing by flow cytometry. NKp46+ NK cells were present in the skin 
of three naïve calves and accounted for a mean of 2.9% (1.5 – 4.2%; SD = 1.1) of the 
lymphocytes present in the skin (Figure 3.6). CD2+ NK cells were the main subset of 
NK cells present in the skin and accounted for 83.9% (77.3 - 96.2%; SD = 8.8) of NK 
cells present (Figure 3.6).  
 
Figure 3.6 Percentage of NK cells present in the skin 
Small sections of skin were removed from calves at post mortem and enzymatically 
digested to obtain lymphocytes. 1 x 106 lymphocytes (fresh) were labelled with a mAbs 
to NKp46 and CD2 and analysed by flow cytometry. FACS plots from three calves 
(303019, 403020 and 603022) illustrate the expression of NKp46 and CD2 by skin 





3.2.7 Comparison between PB and EL derived lymphocytes  
After establishing that NK cells were present in the skin of naïve calves and are 
therefore may migrate from the skin into the draining LNs via the afferent lymphatic 
vessels, the next question which was addressed was whether bovine NK cells were 
present in the efferent lymphatic vessel and therefore able to egress from the LNs in 
steady-state conditions. Samples of EL from five naive efferent lymphatic cannulated 
calves were kindly provided by Dr Bernardo Villareal-Ramos (APHA) and matched 
PBMCs from three of these calves were also provided. Initially to ensure the cellular 
composition of the PB from the efferent lymphatic cannulated calves was similar to 
the composition of the PB from the afferent lymphatic cannulated calves (as illustrated 
in Figures 3.1 - 3.5), the frequency and phenotype of NK cells derived from matched 
PB and EL from three calves was investigated. The percentage of NKp46+ CD3- NK 
cells and the distribution of CD2+ and CD2- subsets within PB and EL were assessed 
by labelling lymphocytes with mAbs to NKp46, CD3 and CD2 and analysing by flow 
cytometry. NK cells accounted for 0.68% (0.48 - 0.94%; SD = 0.2) of lymphocytes 
present in EL, compared with 7.6% (3.23 - 15.3%; SD = 5.5) found in PB (Figure 
3.7.1). Within PB, 80.8% (74.3 - 93.2%; SD = 8.7) of NK cells present were CD2+, 
whereas 66.5% (57.5 - 79.4%; SD = 9.3) of the NK cells found in EL were CD2-. The 
percentage of CD2- NK cells was significantly increased in EL (p=0.014) compared 
with PB (Figure 3.7.2).  
The activation status of PB and EL derived NK cells were measured by assessing the 
expression of CD25. Lymphocytes were labelled with mAbs to NKp46, CD2 and 
CD25 and analysed by flow cytometry. 15.7% (8.4 - 22.3%; SD = 5.7) of NK cells 
from PB were CD25+, compared to a significantly (p=0.009) higher proportion of 
CD25+ NK cells in EL (73.7% (72.1 - 76.6%; SD = 2.1)) (Figure 3.7.3). The 
percentage of CD2- NK cells positive for CD25 was significantly increased in the EL 
compared with PB (p=0.048) (Figure 3.7.4). 
The frequency of bovine CD4+ T cells and γδ T cells within the efferent lymphatic 
vessel of the LNs draining the skin has been previously documented (Vrieling et al., 
2012). Therefore, to ensure the samples of EL obtained from APHA were similar to 
the published literature, the percentage of CD3+CD4+ T cells and CD3+WC1+ γδ T 
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cells present in PB and EL were compared. Lymphocytes were labelled with mAbs to 
CD3/CD4 or CD3/WC1 and analysed by flow cytometry. Within PB, CD4+ T cells 
accounted for 37.6% (27.2 - 53.6%; SD = 11.5) of lymphocytes present, compared 
with 14.1% (10.7 - 16.5%; SD = 2.5) found in EL (Figure 3.7.5). No significant 
differences between the percentages of CD4+ T cells present in PB and EL were noted. 
WC1+ γδ T cells represented 13% (10.4 - 14.5%; SD = 1.8) and 45% (35.4 - 50.5%; 
SD = 6.8) of lymphocytes within PB and EL respectively and WC1+ γδ T cells were 

















Figure 3.7 Comparison between PB and EL derived lymphocytes 
Lymphocytes derived from PB (frozen) and EL (frozen) of three calves were labelled 
with mAbs to NKp46, CD3, CD2, CD25, CD3, CD4 and WC1 and analysed by flow 
cytometry. Gates were set based on FMO controls. Pooled data from three calves show 
the percentage of: NKp46+ CD3- NK cells (Figure 3.7.1); CD2+ (lighter bars) and 
CD2- (darker bars) NK cells ± SD within the total gated NKp46+ NK cell population 
(Figure 3.7.2); CD25+ NK cells within the total gated NKp46+ NK cell population 
(Figure 3.7.3); CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD within the 
total gated NKp46+ CD25+ NK cell population (Figure 3.7.4); CD3+CD4+ T cells 
(Figure 3.7.5) and CD3+WC1+ γδ T cells (Figure 3.7.6) present within PB (circles) 
and EL (squares). Data were normally distributed (p>0.05) and significance was 
assessed using paired t-tests. p<0.05*, p<0.01**. 
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3.2.8 Percentage of NK cells present in PB, AL, LNs and EL 
After confirming the samples of PB from APHA (Figures 3.7.1 - 3.7.4) were of a 
similar cellular composition to the PB from the afferent lymphatic cannulated calves 
and the samples of EL were equivalent to that of the published literature (Figure 3.7.5 
and Figure 3.7.6), the frequency and phenotype of EL derived NK cells were directly 
compared with NK cells from PB, AL and LNs. NK cells represented 1% (0.48 - 
1.58%; SD = 0.4) of lymphocytes within EL and NK cell frequency was significantly 
lower in EL compared with PB (p=0.020), AL (p=0.003) and LNs (p=0.006) (Figure 
3.8.1). Similar to NK cells present in AL and LNs, 71.7% (66.8 - 76.6%; SD = 3.4) of 
EL derived NK cells were CD2- and CD2- NK cells were present at a significantly 
higher percentage in EL compared with PB (p<0.001) (Figure 3.8.2). 
3.2.9 Activation of NK cells present in PB, AL, LNs and EL 
The expression of CD25 by EL derived NK cells was compared with those from PB, 
AL and LNs. 71.2% (66.8 - 76.6%; SD = 3.4) of NK cells from EL were CD25+ 
(Figure 3.9.1) and similar to those present in AL and the LNs, the percentage of CD25+ 
NK cells (p<0.001) and the MFI of CD25+ NK cells (p=0.043) was significantly 
increased in EL compared with PB (Figure 3.9.1 and Figure 3.9.2 respectively). 
Furthermore, when assessing the subset of NK cells responsible for this enhanced 
activation of NK cells in the EL, 63.3%  (45.1 - 77.3%; SD = 12.5) of CD25+ NK cells 
were CD2-, however this was not significantly (p=0.069) different to the percentage 










Figure 3.8 Percentage of NK cells present in PB, AL, LNs and EL 
Lymphocytes derived from PB, AL, LNs (fresh) and EL (frozen) were labelled with 
mAbs for NKp46, CD3 and CD2 and analysed by flow cytometry. Pooled data from 
seven calves for PB, AL and LNs (Figure 3.1.2), and five calves for EL, show the 
average percentage of NKp46+ CD3- NK cells ± SD present within PB (circles), AL 
(squares), LNs (triangles) and EL (diamonds) (Figure 3.8.1). Pooled data from seven 
(PB, AL and LNs) and five (EL) calves illustrates the average percentage of NKp46+ 
CD2+ (lighter bars) and NKp46+ CD2- (darker bars) NK cells ± SD within the total 
gated NKp46+ NK cell population from PB, AL, LN (Figure 3.2.2),  and five calves 
for EL (Figure 3.8.2). Data were normally distributed (p>0.05) and significance was 






Figure 3.9 Activation of NK cells present in PB, AL, LNs and EL 
Lymphocytes derived from PB, AL, LNs (fresh) and EL (frozen) were labelled with 
mAbs to NKp46, CD2 and CD25 and analysed by flow cytometry. Pooled data from 
seven calves for PB, AL and LNs (Figure 3.3.2), and five calves for EL, illustrate the 
average percentage of CD25+ NK cells ± SD within the total NKp46+ population from 
PB (circles), AL (squares), LNs (triangles) and EL (diamonds) (Figure 3.9.1). Pooled 
data from seven calves for PB, AL and LNs (Figure 3.3.3), and five calves for EL, 
indicate the average MFI of CD25+ NK cells ± SD within the total NKp46+ population 
from PB (circles), AL (squares), LNs (triangles) and EL (diamonds) (Figure 3.9.2). 
Pooled data from seven (PB, AL and LNs) and five (EL) calves indicate the average 
percentage of NKp46+ CD2+ (lighter bars) and NKp46+ CD2- (darker bars) NK cells 
± SD within the total gated NKp46+ CD25+ NK cell population from PB, AL, LN 
(Figure 3.3.4) and EL (Figure 3.9.3). Data were normally distributed (p>0.05) and 




















3.2.10 Percentage of CD4+ T cells and WC1+ γδ T cells in PB, AL, LNs and EL 
The percentage of CD4+ and WC1+ γδ T cells across PB, AL, LNs and EL (frozen) 
were compared by labelling lymphocytes with mAbs to CD3/CD4 and CD3/WC1. 
CD4+ T cells accounted for 31.2% (18 - 53.6%; SD = 12.1) of lymphocytes present 
within EL, which was not significantly different to the percentage of CD4+ T cells 
found in PB, AL or LNs (Figure 3.10.1). WC1+ γδ T cells represented 46.9% (35.4 - 
52.8%; SD = 6.1) of lymphocytes within EL and were significantly increased in EL 







Figure 3.10 Percentage of CD4+ T cells and WC1+ γδ T cells in PB, AL, LNs and 
EL 
Lymphocytes derived from PB, AL, LNs (fresh) and EL (frozen) were labelled with 
mAbs for CD3/CD4 and CD3/WC1 and analysed by flow cytometry. Pooled data from 
seven calves for PB, AL and LNs (Figure 3.5.3), and five calves for EL, illustrate the 
average percentage of CD3+ CD4+ T cells ± SD present within PB (circles), AL 
(squares), LNs (triangles) and EL (diamonds) (Figure 3.10.1). Pooled data from seven 
(PB, AL and LNs) and five (EL) calves indicate the average percentage of WC1+ γδ 
T cells ± SD from PB, AL, LN (Figure 3.5.4) and EL (Figure 3.10.2). Data were 
normally distributed (p>0.05) and significance was assessed using two sample t-tests. 




The development of a mAb to bovine NKp46 has revolutionised bovine NK cell 
research (Storset et al., 2004). NK cells are widely distributed in lymphoid and non-
lymphoid tissues, but very little is known about how NK cells migrate to their 
anatomical locations and their recirculation between blood and tissues. It was 
demonstrated recently that bovine NK cells are present within the afferent lymphatic 
vessels draining the skin of cattle in the steady-state, suggesting that they can traffic 
from tissues into LNs via the lymphatics. In that study, the frequency, phenotype and 
function of NK cells from PB and AL of different calves were compared (Lund et al., 
2013). As the samples of PB and AL were not from the same animal, it is more difficult 
to draw firm conclusions about the differences between these two compartments. Data 
presented herein aimed to extend the findings by Lund et al by analysing the frequency 
and phenotype of NK cells and NK cell subsets in parallel from the PB, AL and LNs 
of the same animal, achieved by utilising the bovine pseudo-afferent lymphatic 
cannulation model (Hope et al., 2006).  
NKp46+ CD3- NK cells were present in AL draining the skin of naïve calves, at a 
slightly reduced frequency compared with those found in PB (Figure 3.1.3). This 
illustrates that bovine NK cells can traffic from tissues such as the skin to the draining 
LNs via afferent lymphatic vessels. In line with these findings, NK cells were found 
to be more abundant in PB than AL in a study involving non-matched samples of PB 
and AL (Lund et al., 2013). Furthermore in humans, NK cells were found to be present 
at significantly lower levels in the AL compared with PB (Yawalkar et al., 2000, 
Hunger et al., 1999) and recently, NK cells were shown to be present in seroma fluid 
(an accumulation of AL), representing greater than 2% of lymphocytes (Carrega et al., 
2014). In this study, bovine LNs contained the highest percentage of NK cells across 
the three compartments examined (Figure 3.1.1). This abundance of NK cells within 
bovine LNs is in line with published findings (Boysen et al., 2008) and is also similar 
to the increased number of NK cells present in human LNs in steady-state conditions 
(Fehniger et al., 2003). This is in contrast to mouse LNs where NK cells account for 
approximately 0.5% of lymphocytes present (Gregoire et al., 2007).  
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It is well established in the literature that within the PB of cattle, the majority of NK 
cells are CD2+, whereas CD2- NK cells are the predominant subset found within the 
LNs (Boysen et al., 2006). Data presented in Figure 3.2.2 support this paradigm, 
whereby the percentage of CD2- NK cells present within the PB was low, but was 
significantly increased in AL and LNs, reflecting preferential recruitment of the CD2- 
subset of NK cells from the tissues to the draining LNs in steady-state conditions. In 
studies of human seroma fluid, CD56bright NK cells were the main subset of NK cells 
present (Carrega et al., 2014) and parallels have been drawn between this subset of 
human NK cells and the CD2- subset of bovine NK cells (as illustrated in Figure 1.2).  
AL and LNs draining the skin of cattle in steady-state conditions contained highly 
activated NK cells compared with those found within PB (Figure 3.3.2 and Figure 
3.3.3). CD25 is an activation marker expressed by activated T and B cells. The 
observed activation of NK cells in AL and LNs may be caused by interactions with 
DCs or increased responsiveness to T cell derived IL-2, together resulting in the 
augmented expression of CD25 by NK cells. CD2- NK cells were more activated in 
AL and LNs than CD2+ NK cells (Figure 3.3.4). In line with this finding, bovine CD2- 
NK cells are preferably activated when stimulated with IL-2 compared with CD2+ NK 
cells (Boysen et al., 2006). In addition to CD25, the expression of a second activation 
marker CD44, was noted to be significantly increased by AL NK cells which highlights 
an overall activated phenotype within AL (Lund et al., 2013). Furthermore, CD4+ and 
CD8+ T cells expressing markers of activation including CD25, CD69 and MHC class 
II were present in AL of humans in steady-state conditions (Yawalkar et al., 2000). 
Taken together, this indicates that events occurring as a result of egress from the skin, 
results in the arrival of tissue activated NK cells in the AL and LNs. 
The migratory potential of NK cells derived from PB, AL and LNs was characterised 
by assessing CD62L and CCR7 expression. Through interactions with HEVs, NK cell 
expression of CD62L allows homing to LNs (Chen et al., 2005). There were no 
significant differences in the percentage of CD62L+ NK cells across the three 
compartments however a slightly lower percentage of CD62L+ NK cells were present 
in the LNs which correlates with the down-regulation of CD62L in IL-2 rich areas 
(Boysen et al., 2008) (Figure 3.4.2). Despite there being no significant changes in the 
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expression of CD62L by NK cells across PB, AL and LNs, differences in the 
percentage of CD2+ and CD2- NK cells expressing CD62L were evident with an 
increased percentage of CD2- CD62L+ NK cells in the AL and LNs, compared with 
PB (Figure 3.4.3). This elevated expression of CD62L by CD2- NK cells in the AL 
and LNs correlates with their prevalence within these two compartments. Bovine NK 
cells transcribe the LN homing chemokine receptor, CCR7 (Siddiqui and Hope, 2012), 
however surface CCR7 expression could not be detected by PB or LN derived NK 
cells (data not shown). Using an anti-human CCR7 antibody cross-reactive to bovine 
cells, the expression of CCR7 by AL NK cells was very variable across the seven 
calves examined (FACS plots from seven calves are illustrated in Figure 3.4.4) and 
expression was not detected by AL NK cells in previously published work (Lund et 
al., 2013). In humans, CCR7 is expressed by CD56bright NK cells but is absent from 
CD56dim NK cells which coincides with the dominance of the CD56bright subset of NK 
cells in AL and LNs (Maghazachi, 2010). Bovine γδ T cells traffic to LNs in a CCR7-
independent manner (Vrieling et al., 2012) and therefore bovine NK cells may also 
move to the LNs in a similar CCR7-independent manner. Further investigation is 
required to decipher key molecules utilised to permit NK cell migration in cattle.  
Across all three compartments, CD4+ T cells were present at the highest frequency in 
LNs (Figure 3.5.3). In contrast, LNs contained a low frequency of WC1+ γδ T cells 
compared with PB and AL (Figure 3.5.4), which has been documented previously and 
reflects minimal interactions of γδ T cells within the LNs (Vrieling et al., 2012). This 
theory is supported in sheep where ovine γδ T cells migrate through LNs with greater 
efficiency than αβ T cells and are localised to interfollicular traffic areas of the LNs 
(Young et al., 2000). Unlike γδ T cells, bovine NK cells are present at relatively high 
frequencies in the LNs (Figure 3.1.2), where they are localised to the paracortex and 
the medulla (Boysen et al., 2008) and can undergo priming as a result of interactions 
with DCs (Lucas et al., 2007).  
NK cells are resident within bovine skin and the majority were of the CD2+ NK cell 
subset (Figure 3.6). In comparison to CD2- NK cells, which transcribe lymphoid 
homing chemokine receptors, CD2+ NK cells are more likely to be non-migratory due 
to the absence of appropriate receptors that govern homing to secondary lymphoid 
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organs and this may reflect their abundance in the skin (Siddiqui and Hope, 2012). The 
skin material analysed for the presence of NK cells was not from the calves used for 
pseudo-afferent lymphatic cannulation, therefore quantifying the frequency and 
phenotype of skin NK cells from the afferent lymphatic cannulated calves would allow 
direct comparison of skin NK cells with PB, AL and LN derived NK cells in the same 
animal. In addition, histology of skin sections would confirm the presence of NK cells 
in bovine skin and their precise location. Nevertheless, this preliminary experiment 
provides some evidence that NK cells are found in the skin of calves and therefore 
suggests that NK cells can migrate from the skin, through afferent lymphatic vessels 
and into the LNs. In humans, CD56bright CD16- NK cells are present in the dermis of 
healthy skin and were also found in skin from patients with atopic eczema/dermatitis, 
where they were in close contact with CD1a+ DCs (Buentke et al., 2002, Ebert et al., 
2006).  
After establishing that NK cells can migrate from the skin via afferent lymphatic 
vessels and into the draining LNs in steady-state conditions, samples of EL were 
analysed for the presence or absence of NK cells to understand the possible re-
circulatory nature of NK cells. Initial experiments focused on comparing matched PB 
and EL from three calves. It was confirmed that PB derived NK cells from efferent 
lymphatic cannulated calves were of a similar frequency (Figure 3.7.1) and phenotype 
(Figure 3.7.3) to PB derived NK cells from afferent lymphatic cannulated calves and 
that the cellular composition (CD4+ T cells and WC1+ γδ T cells) of the EL samples 
were comparable to the published literature (Figure 3.7.5 and Figure 3.7.6) (Vrieling 
et al., 2012). Therefore, samples of EL from five naive efferent lymphatic cannulated 
calves were directly compared to PB, AL and LNs of the seven afferent lymphatic 
cannulated calves, allowing comparison across the four compartments.  
NK cells were present in EL, at lower levels than those found in PB, AL and LNs, 
providing evidence that a proportion of NK cells can exit the LNs via the efferent 
lymphatic vessel and therefore may re-circulate in steady-state conditions (Figure 
3.8.1). Similar to NK cells entering the LNs via the afferent lymphatic vessel and those 
within LNs, EL derived NK cells were predominantly CD2- (Figure 3.8.2), illustrating 
the CD2- NK cells may be the preferred subset to egress from the nodes and return to 
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circulation. To date, one study has shown that NK cells are present within human EL 
of humans which were predominantly of the CD56bright subset (Romagnani et al., 
2007). The presence of NK cells in the efferent lymphatic vessels of other species has 
not been defined. Thus, it appears that in cattle and in humans, CD2- NK cells and 
CD56bright NK cells, which are the principal subsets of NK cells within the LNs, are 
also the main subsets egressing from the LNs to return to circulation. T and B cells 
utilise sphingosine-phosphate-receptor 1 (S1P1) to egress from peripheral lymphoid 
organs (Matloubian et al., 2004, Pappu et al., 2007), however down-regulation of S1P1 
through administration of FTY720, did not deplete NK cells from the circulation of 
mice or humans (Vaessen et al., 2006, Walzer et al., 2007b). Consequently, it was 
demonstrated that NK cells express sphingosine-phosphate-receptor 5 (S1P5) which 
permits NK cell exit from the bone marrow and LNs in mice (Mayol et al., 2011, Jenne 
et al., 2009). It would be valuable to assess the expression of S1P receptors by bovine 
NK cells to understand the molecules required to exit peripheral lymphoid organs. 
In conjunction with AL and LN derived NK cells, NK cells within EL were activated 
(Figure 3.9.1 and Figure 3.9.2) which was attributed to the CD2- subset of NK cells 
(Figure 3.9.3). Similarly, human EL derived NK cells display an activated phenotype 
reflected by their increased expression of CD16 and KIR in comparison with NK cells 
in the LNs (Romagnani et al., 2007). Therefore, it is conceivable that tissue activated 
CD2- CD25+ NK cells arriving in the LNs also egress from the LNs via the efferent 
lymphatic vessel and circulate in a primed state in steady-state conditions. 
In  summary, data presented in this Chapter and illustrated in Figure 3.11, has 
demonstrated that bovine NK cells may be present in the skin of cattle in steady-state 
conditions and that the CD2- subset of NK cells are preferentially recruited from the 
tissues, through their expression of CD62L, into draining LNs via afferent lymphatic 
vessels in a highly activated state. Similarly, NK cells within bovine LNs are 
predominantly CD2- NK cells with a high expression of CD25 and CD62L, suggesting 
that NK cells could be primed in both AL and LNs. Furthermore, the presence of CD2- 
CD25+ NK cells within EL provides evidence that a proportion of NK cells do not 
terminally reside in the LNs and can egress from the nodes to return to circulation 
where they are predominantly CD2+ CD25lo. To conclude, experimental findings in 
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this Chapter provide evidence that the frequency and phenotype of NK cells in cattle 
is reflective of their anatomical location, therefore proving the hypothesis stated at the 
beginning of this Chapter. The effect of BCG vaccination on PB, AL, LN and EL 















Figure 3.11 A model to illustrate bovine NK cell re-circulation in steady-state 
conditions 
Bovine NK cells can migrate from the skin, through afferent lymphatic vessels (1) and 
into the skin draining LNs (2). NK cells can then egress from the LNs via the efferent 
lymphatic vessel (3) and return to circulation (4). NK cells derived from the afferent 
lymphatic vessel, LNs and efferent lymphatic vessel are predominantly CD2- NK cells 
which have a high expression of CD25. Conversely, NK cells present in the blood are 










             Chapter 4 
 
Abstract 
Vaccination of neonatal calves with BCG provides significant protection against 
infection with M. bovis therefore NK cell responses in the blood, afferent lymph, 
lymph node and efferent lymph draining the site of BCG vaccination were assessed. 
The percentage and receptor repertoire of NK cells were altered in the blood following 
BCG vaccination of neonatal calves. No evidence of NK cell recruitment, or changes 
in phenotype, were noted in the lymph nodes draining the site of BCG vaccination in 
both vaccinated and revaccinated calves. Preliminary experiments using pseudo-
afferent or efferent lymphatic cannulated calves vaccinated with BCG suggested 
changes in NK cell responses in the lymph following vaccination. Together, this data 


















4. The effect of BCG vaccination on peripheral blood, afferent lymph, 
lymph node and efferent lymph derived NK cells   
         
4.1 Introduction 
Vaccination is thought to be the cornerstone of future bTB disease control, alongside 
improved DIVA diagnostic tests which differentiate infected from vaccinated animals. 
However, currently there are no vaccines licensed for use in cattle. Despite over a 
century of research, BCG a live attenuated strain of M. bovis, remains the only vaccine 
available for use in humans against TB. This vaccine is particularly effective when 
delivered to infants to induce protection against tuberculous meningitis and miliary TB 
(Trunz et al., 2006, Bonifachich et al., 2006). Similarly, a number of studies have 
demonstrated that experimental vaccination of neonatal calves with BCG provides 
significant protection against M. bovis infection (Buddle et al., 1995a, Hope et al., 
2005, Hope et al., 2011). Similar to humans, neonatal vaccination strategies are 
effective in calves as they are born with a competent immune system and therefore 
respond well to vaccination at a young age. Furthermore, vaccination of neonatal 
calves overcomes the negative effects associated with pre-exposure to environmental 
mycobacteria prior to vaccination, which can result in stimulation of an inappropriate 
immune response (Brandt et al., 2002). Nevertheless, the use of BCG in the field is 
prohibited by EU legislation due to non-specific sensitisation to the tuberculin skin 
test. Despite this, BCG remains the most effective vaccine available for use and 
continued development of DIVA tests may allow it to be deployed in the UK for bTB 
control.  
BCG vaccination of infants induces activation of innate effector cells such as NK cells 
and γδ T cells (Zufferey et al., 2013), and since young calves, particularly those aged 
between 8-120 days old have increased circulating numbers of NK cells (Graham et 
al., 2009, Kulberg et al., 2004, Elhmouzi-Younes et al., 2009), it was hypothesised that 
NK cells may play a role in the enhanced efficacy of BCG in neonatal calves. 
Alongside the increased frequency, NK cells derived from neonatal calves also exhibit 
increased activity, reflected by a higher expression of perforin compared with NK cells 
from older animals and enhanced cytotoxicity after culture with IL-15 (Elhmouzi-
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Younes et al., 2009). It is proposed that the high numbers of innate effector cells (NK 
cells and γδ T cells expressing the WC1 receptor) present in young calves has evolved 
to compensate for the immature state of the adaptive immune system. The increased 
number of NK cells and WC1+ γδ T cells in young animals may be relevant to targeted 
vaccination strategies and induction of effective immune responses in neonatal calves. 
Similar to young calves, infants have elevated levels of NK cells which also decline 
with age (Erkeller-Yuksel et al., 1992, Sundstrom et al., 2007); therefore research 
focusing on the role of NK cells during mycobacterial infection or vaccination in 
neonatal calves may be applicable to studies in humans. 
There is considerable evidence to demonstrate that NK cells are responsive to 
mycobacteria in vivo and therefore to suggest that NK cells play a role in anti-
mycobacterial immunity. The role of NK cells during M. tb infection was recently 
reviewed by Esin and Batoni (Esin and Batoni, 2015). Following infection of mice 
with M. tb or BCG, increased numbers of activated NK cells are recruited to the lungs 
where they secrete IFN-γ (Junqueira-Kipnis et al., 2003). Similarly, during studies of 
active M. tb infection in humans, NK cells infiltrate the lungs where they are localised 
to granulomas (Portevin et al., 2012). Depletion of murine NK cells at the time of BCG 
vaccination results in increased immunosuppressive regulatory T cells, increased 
bacillary burden and reduced T cell responses after challenge with M. tb (Dhiman et 
al., 2012). However, the role of NK cells during BCG vaccination or M. bovis infection 
in cattle has not yet been defined.  
Even though BCG has been shown to be effective in neonatal calves (Buddle et al., 
1995b, Hope et al., 2005, Hope et al., 2011), similar to humans, the efficacy of BCG 
in calves is variable across studies (reviewed in (Waters et al., 2012)). Ideally a better 
vaccine which induces sterilising immunity whilst avoiding sensitisation to the 
tuberculin skin test would be developed. In order to do this, the immune response 
following BCG vaccination and the way in which BCG induces protection in neonates 
must be deciphered. This may pinpoint mechanisms or cellular targets for enhanced 
vaccination strategies. It was hypothesised that vaccination of neonatal calves with 
BCG would alter NK cell properties across PB, AL, LNs and EL, therefore 
indicating a role for bovine NK cells during BCG vaccination of neonatal calves and 
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potential mechanisms of action. Data presented in Chapter 3 highlighted significant 
differences in the percentage, subset distribution and phenotype of NK cells across PB, 
AL, LNs and EL in steady-state conditions. The studies presented herein aim to extend 
these findings by assessing the effect of subcutaneous BCG vaccination on the 
frequency, phenotype, function and receptor repertoire of PB derived NK cells in 
neonatal calves. Furthermore, to assess recruitment of NK cells in vivo following BCG 
vaccination, the frequency and phenotype of NK cells within the skin-draining afferent 






















4.2 Results  
4.2.1 Production of antigen-specific IFN-γ following BCG vaccination 
Six week old neonatal calves were vaccinated subcutaneously with 0.5ml BCG Danish 
SSI, administered to the left shoulder. Age-matched, control calves were left 
unvaccinated. To determine if calves were responding to BCG vaccination, whole 
blood was sampled one week prior to BCG vaccination, on the day of vaccination 
(week 0) and then at two-weekly intervals following vaccination for up to 12 weeks. 
Whole blood was stimulated with PPD-b for 18 hours and the production of antigen-
specific IFN-γ in the plasma supernatant was assessed by ELISA (section 2.15). 
Following BCG vaccination, PBMCs from BCG-vaccinated calves produced 
significantly elevated levels of antigen-specific IFN-γ at 4 weeks (p=0.025), 6 weeks 
(p=0.02) and 8 weeks (p=0.023) post-vaccination compared with week 0. Non-
vaccinated calves produced low levels of IFN-γ (Figure 4.1). 
4.2.2 Percentage of NK cells and subsets present in the blood following BCG 
vaccination 
To define the effect of BCG vaccination on NK cell frequency and the distribution of 
CD2+ and CD2- subsets within the blood, the percentage of NK cells and the 
percentage of the two subsets was monitored by labelling lymphocytes with mAbs to 
NKp46 and CD2. Cells were analysed by flow cytometry. Following BCG 
vaccination, the percentage of NK cells increased significantly on day 1 post-
vaccination, compared with pre-vaccination (Day 0) levels (p<0.001). No other 
significant alterations were noted post-BCG vaccination, or throughout the experiment 
in non-vaccinated calves (Figure 4.2). CD2+ NK cells are the principal subset of NK 
cells present in the blood (as illustrated in Figure 3.2.2), however no significant effect 
of BCG on the proportions of CD2+ and CD2- subsets of NK cells were evident 





Figure 4.1 Production of antigen-specific IFN-γ following BCG vaccination  
Whole blood from BCG-vaccinated and non-vaccinated calves was stimulated for 18 
hours with PPD-b one week prior to vaccination, the day of vaccination and then at 
two weekly intervals following BCG vaccination for 12 weeks. Plasma supernatants 
were retrieved and the presence of IFN-γ (pg/ml) was determined by ELISA (section 
2.15). Pooled data from 12 BCG vaccinated (circles) and 9 naïve (squares) calves ± 
SD illustrates the production of antigen-specific IFN-γ (pg/ml) after stimulation of 
whole blood with PPD-b at various time points post-BCG vaccination. Data were 
normally distributed (p>0.05), and significance was assessed using GLM and paired t 











Figure 4.2 Percentage of NK cells and subsets present in the blood following 
BCG vaccination 
Lymphocytes (fresh) were isolated from PB at Day 0, 1, 3, 5, 7, 14, 21 and 28 post-
BCG vaccination or from age-matched, non-vaccinated calves and labelled with mAbs 
to NKp46 and CD2 and analysed by flow cytometry. NK cells and NK cell subsets 
were identified using the gating strategies shown in Figure 3.2.1. Pooled data from 12 
BCG-vaccinated calves (circles) and 9 naïve calves (squares) represents the average 
percentage of NK cells ± SD present within the total lymphocyte population at various 
time points post-BCG vaccination. Data were non-normally distributed (p<0.05), 
therefore data was log transformed prior to assessment of significance using GLM and 













4.2.3 Phenotype of NK cells following BCG vaccination  
Similar to investigations detailed in Chapter 3, NK cell expression of CD25 was used 
as a measure of NK cell activation following BCG vaccination. Lymphocytes were 
labelled with mAbs to NKp46, CD2 and CD25 and analysed by flow cytometry. The 
percentage of CD25+ NK cells present in the blood increased on Days 1, 3, 5 and 7 
post-BCG vaccination, however these changes were not significantly different to the 
percentage of NK cells present pre-vaccination (Day 0). No significant differences in 
the activation of NK cells from non-vaccinated calves were noted (Figure 4.3). CD25 
was equally expressed by CD2+ and CD2- subsets of NK cells (as illustrated in Figure 
3.3.4), however no significant effect of BCG on the proportions of CD2+ and CD2- 
subsets of NK cells expressing CD25 were evident throughout the vaccination 
experiment (data not shown).  
4.2.4 NK cell production of IFN-γ following BCG vaccination  
An important effector function of NK cells is the secretion of immunoregulatory 
cytokines, particularly IFN-γ. Thus, to assess the ability of NK cells to produce IFN-γ 
following BCG vaccination, intracellular cytokine staining (section 2.14) was 
employed. Lymphocytes were labelled with mAbs to NKp46 and IFN-γ and cells were 
analysed by flow cytometry. Following BCG vaccination, the percentage of IFN-γ+ 
NK cells increased at both early and later time points post-vaccination. However, non-
specific production of IFN-γ by NK cells from naïve calves was also evident therefore 







Figure 4.3 Phenotype of NK cells following BCG vaccination 
Lymphocytes (fresh) were isolated from PB at Day 0, 1, 3, 5, 7, 14, 21 and 28 post-
BCG vaccination or from age-matched, non-vaccinated calves and labelled with mAbs 
to NKp46, CD2 and CD25 and analysed by flow cytometry. CD25+ NK cells were 
identified using the gating strategy illustrated in Figure 3.3.1. Pooled data from 12 
BCG-vaccinated calves (circles) and 9 non-vaccinated calves (squares) represents the 
average percentage of CD25+ NK cells ± SD within the total gated NKp46+ NK cell 
population at various time points post BCG-vaccination. Data were normally 
distributed (p>0.05) and significance was assessed using GLM and paired t tests. No 













Figure 4.4 NK cell production of IFN-γ following BCG vaccination 
Lymphocytes (fresh) were isolated from PB at Day 0, 1, 3, 5, 7, 14, 21 and 28 post-
BCG vaccination or from age-matched, non-vaccinated calves and labelled with mAbs 
to NKp46 and IFN-γ and analysed by flow cytometry. Pooled data from 12 BCG-
vaccinated calves (circles) and 9 non-vaccinated calves (squares) illustrates the 
average percentage of IFN-γ+ NK cells ± SD within the total gated NKp46+ NK cell 










4.2.5 Expression of NKp30 by NK cells following BCG vaccination 
NK cells express a diverse array of activating and inhibitory receptors which together 
control their effector function and maintain self-tolerance. To evaluate the effect of 
BCG vaccination on the receptor repertoire of NK cells, three six-week old calves were 
vaccinated subcutaneously with 0.5ml BCG Danish SSI and NK cells were isolated at 
days 0, 3, 5, 7, 14 and 28 post-BCG vaccination. In parallel, NK cells were also isolated 
from three age-matched, non-vaccinated control calves. RNA was isolated, reverse 
transcribed and NK cell expression of the activating receptor, NKp30 was assessed at 
various time points post-vaccination by qPCR. Expression of NKp30 by NK cells was 
significantly down-regulated at day 7 post-BCG vaccination (p=0.037), compared with 
Day 0, most likely due to the tight errors bars at day 7 post-BCG (Figure 4.5.1). No 
significant changes were noted in the expression of NKp30 by NK cells derived from 
non-vaccinated animals (Figure 4.5.2).  
4.2.6 NK cell expression of KLRC1.2, KLRC2.1 and KLRC2.2 following BCG 
vaccination 
To further characterise the receptor repertoire of NK cells following BCG vaccination, 
preliminary experiments sought to compare the expression of three members of the 
KLRC (NKG2) family: KLRC1.2 (NKG2A: inhibitory receptor), KLRC2.1 (NKG2C: 
activating receptor) and KLRC2.2 (NKG2C: activating receptor) between naïve and 
BCG-vaccinated calves. Whilst it was difficult to quantify the exact amount of each 
gene expressed at each day post-BCG vaccination using PCR, there appeared to be an 
overall increased expression of KLRC1.2, KLRC2.1 and KLRC2.2 in BCG-vaccinated 
calves compared with naïve calves, denoted by the stronger bands in the vaccinated 





Figure 4.5 Expression of NKp30 by NK cells following BCG vaccination  
NK cells were isolated from the PB of three BCG-vaccinated and three age-matched, 
non-vaccinated calves on day 0, 3, 5, 7, 14 and 28 post-vaccination. RNA was 
extracted, reverse transcribed and subject to quantitative PCR analysis for the 
expression of NKp30. Each sample was tested in duplicate and normalised to two 
reference genes, ATP5B and EIF2B2 and analysed using the comparative CT method. 
Data represents the fold change (Log2) of the CT values of NKp30 expression ± SD at 
day 3, 5, 7, 14 and 28 post-vaccination, compared with day 0 by NK cells from BCG-
vaccinated (Figure 4.5.1) and non-vaccinated (Figure 4.5.2) calves. Data were 














Figure 4.6 NK cell expression of KLRC1.2, KLRC2.1 and KLRC2.2 following BCG 
vaccination 
NK cells were isolated from the PB of three BCG-vaccinated and three age-matched, 
non-vaccinated calves on day 0, 3, 5, 7, 14 and 28 post-vaccination. RNA was 
extracted, reverse transcribed and subject to PCR analysis for the expression of 
KLRC1.2, KLRC2.1 and KLRC2.2. cDNA positive for the gene of interest was used as 
the positive control (+) and water as the negative control (NTC). PCR products were 
loaded on a 2% agarose gel, alongside a 1Kb PLUS DNA ladder. Expected band sizes 
for each gene were as follows: KLRC1.2 (140bp), KLRC2.1 (140bp) and KLRC2.2 


















4.2.7 Effect of BCG on LN derived NK cells 24 hours post-vaccination 
Following characterisation of the frequency, phenotype and function of PB derived 
NK cells after BCG vaccination of neonatal calves, the frequency and phenotype of 
NK cells within PSLNs draining the site of BCG vaccination were defined. To assess 
recruitment of NK cells to LNs in vivo, 0.5ml BCG Danish SSI was administered 
subcutaneously to the left shoulder of 6 month old, non-vaccinated calves (referred to 
as ‘vaccinated’ herein) or to age-matched calves which had been previously BCG-
vaccinated at 6 weeks of age (referred to as ‘revaccinated’ herein) and draining PSLNs 
were then excised 24 hours post-vaccination. PSLNs from the right shoulder (non-
vaccinated) of each calf served as an internal control.  
 
To assess if the percentage of NK cells, or the percentage of NK cell subsets, within 
the LNs was altered following BCG vaccination, lymphocytes were labelled with 
mAbs to NKp46, CD3 and CD2 analysed by flow cytometry. No significant 
differences were noted in the percentage of NK cells present (Figure 4.7.1) or the 
distribution of the CD2+ and CD2- subsets (Figure 4.7.2) between the left and right 
LNs from the vaccinated or revaccinated calves at 24 hours post-BCG vaccination. To 
assess if BCG vaccination altered the activation status of NK cells within the LNs 
draining the site of vaccination, the percentage of CD25+ NK cells present in the left 
and right PSLNs of vaccinated or revaccinated calves at 24 hours post-vaccination was 
defined by labelling lymphocytes with mAbs to NKp46, CD2 and CD25 and analysing 
by flow cytometry. Despite a high percentage of LN derived NK cells expressing 
CD25 (as illustrated in Figure 3.3), there were no significant differences evident at 24 
hours post-BCG in the left or right LNs in either vaccinated or revaccinated calves 
(Figure 4.7.3). No differences were noted in the expression of CD25, represented by 














Figure 4.7 Effect of BCG on LN derived NK cells 24 hours post-vaccination 
Lymphocytes (fresh) derived from the left (BCG) and right (control) LNs at 24 hours 
post-BCG vaccination were labelled with mAbs to NKp46, CD3 and CD2 and 
analysed by flow cytometry. Pooled data from the left (circles) and right (squares) LNs 
of four vaccinated and three revaccinated calves represents the average percentage of 
NKp46+ CD3- NK cells ± SD (Figure 4.7.1). Pooled data from the left and right LNs 
of four vaccinated and three revaccinated calves illustrates the average percentage of 
CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD within the total gated 
NKp46+ NK cell population (Figure 4.7.2). Pooled data from the left (circles) and right 
(squares) LNs of four vaccinated and three revaccinated calves illustrates the average 
percentage of CD25+ NK cells ± SD within the total gated NKp46+ NK cell population 
(Figure 4.7.3). Data were normally distributed (p>0.05) and significance was assessed 




















4.2.8 Effect of BCG on LN derived NK cells 48 hours post-vaccination 
Vaccination of calves with BCG had no significant effect on the percentage, subset 
distribution or phenotype of LN derived NK cells at 24 hours post-vaccination, 
therefore LNs were excised 48 hours following vaccination to decipher if BCG altered 
the properties of NK cells within the draining LNs at this later time point. As described 
in section 4.2.7, 0.5ml BCG Danish SSI was administered subcutaneously to the left 
shoulder of three six month old, non-vaccinated calves (‘vaccinated’) or age-matched 
calves which had been previously BCG-vaccinated at six weeks of age (‘revaccinated’) 
and draining LNs were then excised 48 hours after vaccination. LNs from the right 
shoulder (non-vaccinated) of each calf served as an internal control.  
To assess the percentage, subset distribution and activation status of NK cells in the 
draining LNs at 48 hours post-BCG, lymphocytes were labelled with mAbs to NKp46, 
CD3, CD2 and CD25 and analysed by flow cytometry. Similar to findings at 24 hours 
post-BCG (Figure 4.7), no significant differences were evident in the percentage of 
NK cells (Figure 4.8.1), distribution of CD2+ and CD2- subsets (Figure 4.8.2) and 
percentage of CD25+ NK cells (Figure 4.8.3) present in the left and right LNs in 
vaccinated and revaccinated calves 48 hours after vaccination. Furthermore, no 
differences were noted in the expression of CD25, represented by the MFI (data not 
shown). Similar to findings in Figure 3.3.4, CD2- NK cells were the predominant 
subset of NK cells expressing CD25, however no differences were noted in the 
percentage of CD2- and CD2+ NK cells expressing CD25 between the left and right 










Figure 4.8  Effect of BCG on LN derived NK cells 48 hours post-vaccination 
Lymphocytes (fresh) derived from the left (BCG) and right (control) LNs were labelled 
with mAbs to NKp46, CD3, CD2 and CD25 and analysed by flow cytometry. Pooled 
data from the left (circles) and right (squares) LNs of three vaccinated and three 
revaccinated calves indicate the average percentage of NKp46+ CD3- NK cells ± SD 
(Figure 4.8.1). Pooled data from the left and right LNs of three vaccinated and three 
revaccinated calves represents the average percentage of CD2+ (lighter bars) and CD2- 
(darker bars) NK cells ± SD within the total gated NKp46+ NK cell population (Figure 
4.8.2). Pooled data from the left (circles) and right (squares) LNs of three vaccinated 
and three revaccinated calves illustrate the average percentage of CD25+ NK cells ± 
SD within the total gated NKp46+ NK cell population (Figure 4.8.3). Data were 
normally distributed (p>0.05) and significance was assessed using two sample t-tests. 















4.2.9 Effect of BCG on LN derived T cells 48 hours post-BCG vaccination 
Data presented thus far have illustrated no significant effect of BCG on NK cell 
frequency or phenotype within the LNs draining the site of vaccination. Therefore, the 
effect of BCG vaccination on the percentage of CD4+ T cells, CD8+ T cells and WC1+ 
γδ T cells was assessed to determine if BCG affected the frequency of other 
lymphocyte populations within the LNs. Lymphocytes were labelled with CD3/CD4, 
CD3/CD8 and CD3/WC1 to identify CD4+ T cells, CD8+ T cells and WC1+ γδ T cells 
respectively. Cells were then analysed by flow cytometry. In parallel with the absence 
of effect of BCG on NK cell frequency and phenotype, the percentage of CD4+ T cells 
(Figure 4.9.1), CD8+ T cells (Figure 4.9.2) and WC1+ γδ T cells (Figure 4.9.3) were 
unchanged in the right control LNs, compared with the left LNs draining the site of 










Figure 4.9 Effect of BCG on LN derived T cells at 48 hours post-BCG vaccination 
Lymphocytes (fresh) derived from the left (BCG) and right (control) LNs were labelled 
with mAbs to CD3, CD4, CD8 and WC1 and analysed by flow cytometry. Pooled data 
from the left (circles) and right (squares) LNs of three vaccinated and three 
revaccinated calves indicate the average percentage of CD3+CD4+ T cells ± SD 
(Figure 4.9.1), CD3+CD8+ T cells ± SD (Figure 4.9.2) and CD3+WC1+ γδ T cells ± 
SD (Figure 4.9.3) present at 48 hours post-BCG vaccination. Data were normally 
distributed (p>0.05) and significance was assessed using two sample t-tests. No 



















4.2.10  Percentage and phenotype of AL derived NK cells following BCG 
vaccination 
BCG vaccination had no effect on the percentage, subset distribution or phenotype of 
NK cells within draining PSLNs either at 24 or 48 hours post-vaccination (Figures 4.7 
and 4.8), therefore the pseudo-afferent lymphatic cannulation model was utilised to 
study the effect of BCG vaccination on NK cells within draining AL in preliminary 
experiments using two pseudo-afferent lymphatic cannulated calves aged 6 months. 
0.5ml of BCG Danish SSI was inoculated subcutaneously above the cannulation site 
(section 2.2.1) and afferent lymph was collected at 0, 4, 8, 24, 48, 72, 96 and 120 hours 
post-vaccination to establish firstly, at what time point post-vaccination NK cells may 
be arriving in the LNs via afferent lymphatic vessels and secondly, whether BCG alters 
the phenotype of AL derived NK cells.  
To define the percentage, subset distribution and phenotype of AL derived NK cells 
after BCG vaccination, lymphocytes were labelled with mAbs to NKp46, CD3, CD2 
and CD25 and analysed by flow cytometry. The percentage of NK cells decreased 
within the first 4 hours post-BCG and reached the lowest percentage at 24 hours post-
BCG. NK cell frequency then increased from 24 hours post-vaccination and returned 
to baseline levels at 96 hours post-BCG (Figure 4.10.1). CD2- NK cells decreased 
within AL over the course of the experiment (Figure 4.10.2). The percentage of CD25+ 
NK cells increased within AL within the first 4 hours post-BCG and remained steady 
throughout the remainder of the experiment (Figure 4.10.3) with the percentage of 
CD2- CD25+ NK cells increasing over time (Figure 4.10.4). A similar pattern was 
seen in the percentage of CD25+ NK cells over time, as represented by the MFI (data 






Figure 4.10 Percentage and phenotype of AL derived NK cells following BCG 
vaccination 
Lymphocytes derived from AL (fresh) of two BCG-vaccinated pseudo-afferent 
lymphatic cannulated calves were labelled with mAbs for NKp46, CD3, CD2 and 
CD25 and analysed by flow cytometry. Pooled data from two calves show: the average 
percentage of NKp46+ CD3- NK cells ± SD (Figure 4.10.1); the average percentage 
of CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD within the total gated 
NKp46+ NK cell population (Figure 4.10.2); the average percentage of CD25+ NK 
cells ± SD within the total gated NKp46+ NK cell population (Figure 4.10.3); the 
average percentage of CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD 
within the total gated NKp46+ CD25+ population present within AL at hours 0, 4, 8, 
24, 48, 72, 96 and 120 hours post-BCG vaccination. Statistical analysis was not 

















4.2.11  Percentage and phenotype of EL derived NK cells following BCG 
vaccination 
Data presented previously in this thesis (Figure 3.8) demonstrated that bovine NK cells 
were present in the efferent lymphatic vessel draining the skin in steady-state 
conditions, therefore the effect of BCG vaccination on NK cells with EL was 
addressed. To assess egress of NK cells from the LNs draining the site of BCG 
vaccination, three 6 month old efferent lymphatic cannulated calves were vaccinated 
subcutaneously with BCG Danish SSI at APHA and efferent lymph was collected at 
0, 24 and 48 hours post-BCG vaccination (section 2.2.3).  
To define the percentage, subset distribution and phenotype of EL derived NK cells 
after vaccination, lymphocytes were labelled with mAbs to NKp46, CD3, CD2 and 
CD25 and analysed by flow cytometry. No significant differences were observed in 
the percentage of NK cells (Figure 4.11.1) or the percentage of NK cell subsets (Figure 
4.11.2) present within EL at 24 or 48 hours post-BCG compared with pre-vaccination. 
Despite a decrease in the percentage (Figure 4.11.3) and MFI (Figure 4.11.4) of 















Figure 4.11 Percentage and phenotype of EL derived NK cells following BCG 
vaccination 
Lymphocytes derived from EL (frozen) of three BCG-vaccinated efferent lymphatic 
cannulated calves were labelled with mAbs for NKp46, CD3, CD2 and CD25 and 
analysed by flow cytometry. Pooled data from three calves show: the average 
percentage of NKp46+ CD3- NK cells ± SD (Figure 4.11.1); the average percentage 
of CD2+ (lighter bars) and CD2- (darker bars) NK cells ± SD within the total gated 
NKp46+ NK cell population (Figure 4.11.2); the average percentage of CD25+ NK 
cells ± SD within the total gated NKp46+ NK cell population (Figure 4.11.3); the 
average MFI of CD25+ NK cells ± SD within the total gated NKp46+ NK cell 
population (Figure 4.11.4) present within EL at hours 0, 24 and 48 post-BCG 
vaccination. Data were normally distributed (p>0.05) and significance was assessed 
















The immune response following BCG vaccination of neonatal calves that results in 
protection against bTB has not yet been fully defined. The frequency of NK cells is 
augmented in neonatal calves (Graham et al., 2009, Kulberg et al., 2004) and since NK 
cells contribute to anti-mycobacterial immunity in humans and mice (Esin and Batoni, 
2015), NK cell responses post-BCG vaccination of neonatal calves were the primary 
focus of this study. Six week old neonatal calves responded to BCG vaccination by 
producing antigen-specific IFN-γ, with peak responses around four weeks post-
vaccination, confirming successful delivery of BCG (Figure 4.1). Following BCG 
vaccination of neonatal calves, there was a significant increase in the percentage of 
NK cells present in the circulation during the first 24 hours post-BCG (Figure 4.2). 
Whether this early expansion of NK cells within the blood post-vaccination is due to 
generation of NK cells from the bone marrow, or from proliferation of NK cells within 
the circulation remains to be defined. Furthermore, this increase in the percentage of 
NK cells may be due to a decrease in another cell population and to determine if this 
was the case, changes in absolute numbers would have to be defined. This early 
increase in NK cell frequency post-BCG was followed by a non-significant decrease 
in the percentage of NK cells present in the blood from day 7 post-vaccination, which 
may reflect movement of NK cells out of the circulation and to the site of vaccination. 
No differences were noted in the proportions of CD2+ and CD2- NK cells in both 
BCG-vaccinated and non-vaccinated calves (data not shown), therefore the observed 
increased in NK cells present at day 1 post-BCG was not attributed to a particular 
subset of NK cells. Zufferey et al assessed the contribution of innate effector cells such 
as NK cells and γδ T cells during the immune response elicited by BCG immunisation 
of infants (Zufferey et al., 2013). They demonstrated that NK cells were a significant 
source of BCG-specific IFN-γ following vaccination, with NK cells contributing to 
more than half of the IFN-γ-expressing cells in infants vaccinated at birth and at 2 
months of age. Following BCG vaccination of adults, the proportion of NK cell 
subsets, expression of cell surface molecules or production of IFN-γ remained 
unaltered at 2 weeks and 3 months post-BCG. However, production of pro-
inflammatory cytokines (IL-1β, IL-6 and TNF-α) was significantly increased after ex 
vivo stimulation with M.tb, Candida albicans and Staphylococcus aureus. Therefore 
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in this particular study, BCG induced non-specific priming of NK cells (Kleinnijenhuis 
et al., 2014). WC1+ γδ T cells are also present in increased levels in young calves, and 
following BCG vaccination of calves, the percentage of WC1+ γδ T cells increased in 
the PB post-BCG alongside increased production of IFN-γ (Buza et al., 2009). 
Therefore calves may respond to BCG vaccination in a similar manner to humans. 
The activation status of NK cells derived from the blood was generally low, compared 
with those NK cells found in AL, LNs and EL (as described in Figure 3.3) and BCG 
had no significant effect on the expression of CD25 by NK cells post-vaccination 
(Figure 4.3). Similarly, the function of NK cells post-BCG vaccination was difficult 
to interpret due to non-specific production of IFN-γ by NK cells from naïve calves 
(Figure 4.4). NK cells from young animals are a source of non-specific IFN-γ and for 
this reason the IFN-γ diagnostic test cannot be used in animals less than 6 months old 
(Olsen et al., 2005). 
Preliminary experiments suggested that BCG vaccination of neonatal calves altered 
NK cell receptor usage (Figure 4.5 and Figure 4.6). NK cell gene expression of NKp30 
was significantly down-regulated following BCG vaccination (Figure 4.5). Similar to 
the present study, mRNA expression of NKp30 by NK cells was significantly down-
regulated following challenge with Bovine Respiratory Syncytial Virus (BRSV) 
(Alasdair Allan, PhD thesis, Royal Veterinary College, 2015). Taken together, this 
may reflect stimulation of bovine NK cells by pathogens such as BCG and BRSV, 
resulting in down-regulation of NKp30 mRNA in vivo. NK cell function and 
maintenance of self-tolerance is determined by a complex interplay between activating 
and inhibitory receptors, therefore it would be expected that down-regulation of 
NKp30 would be coupled with up-regulation of other NK cell receptors. This 
maintains a delicate balance between activation and inhibition and also regulates the 
activity of NK cells to prevent damage from NK cell cytotoxicity or overexpression of 
cytokines. The KIR and CD94/NKG2 (KLRD/KLRC) receptor gene families are 
significantly expanded in cattle (Figure 1.3) with the CD94/NKG2 (KLRD/KLRC) 
family containing 2 CD94 genes, 7 NKG2A genes and 2 NKG2C genes. Thus, the 
expression of KLRC1.2 (NKG2A - inhibitory receptor), KLRC2.1 (NKG2C - activating 
receptor) and KLRC2.2 (NKG2C - activating receptor) by BCG-vaccinated and non-
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vaccinated calves was assessed by PCR. Preliminary results showed an overall 
increased expression of KLRC1.2 (NKG2A), KLRC2.1 (NKG2C) and KLRC2.2 
(NKG2C) in BCG-vaccinated calves, compared with non-vaccinated calves (Figure 
4.6). Again this may reflect the complex interplay of NK cell receptors expressed at 
any one time with up regulation of both inhibitory and activating genes following 
vaccination. Nevertheless, to gain a wider understanding of the NK cell receptor 
repertoire following BCG vaccination of neonatal calves and to confirm the PCR 
results described in Figure 4.6, qPCR assays would have to be designed. 
To assess the capacity of NK cells as correlates of protection during BCG-induced 
protective immunity to M. bovis infection in cattle, NK cell responses would have to 
be analysed both during BCG vaccination and then following challenge with M. bovis. 
Challenge studies in large animals are very expensive, however it was proposed 
recently that a BCG challenge model could be utilised to negate the requirement for 
costly containment level three challenge experiments (Villarreal-Ramos et al., 2014). 
The authors hypothesised that a TB vaccine capable of conferring protection against 
M. bovis should also be able to induce immunity against the live attenuated strain of 
M. bovis, BCG. Calves vaccinated subcutaneously with BCG Danish SSI were 
protected from challenge with a different strain of BCG, BCG Tokyo which was 
delivered intranodally. This BCG challenge model has also been proposed to test TB 
vaccine candidates in humans (Minassian et al., 2012, Harris et al., 2014). To 
definitively demonstrate a functional role of NK cells during BCG-induced protection, 
NK cells would have to be deleted in vivo by administration of mAb specific for 
NKp46 prior to BCG vaccination and challenge with M. bovis. Studies have depleted 
γδ T cells (Kennedy et al., 2002) or CD8+ T cells (Villarreal-Ramos et al., 2003) from 
the circulation of calves either prior to M. bovis infection or after M. bovis infection 
and then assessed the effect of depletion on infection. Both of these experimental 
approaches would serve as excellent systems to address the role of NK cells in BCG-
induced protection but, to date, neither of these approaches have been assessed in any 
published studies. 
Within the BCG vaccination experiments described thus far, BCG was delivered 
subcutaneously therefore analysis of NK cell responses occurring in the afferent 
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lymphatic vessels, PSLNs and efferent lymphatic vessel which specifically drain the 
site of vaccination may improve our knowledge of the immune response induced by 
BCG. It was demonstrated in Chapter 3 that highly activated, CD2- NK cells could 
migrate into skin draining LNs via afferent lymphatic vessels in steady-state 
conditions. Afferent lymphatic cannulation is an excellent model to study innate 
immune responses during vaccination or infection therefore this model was utilised to 
assess the recruitment of NK cells to the LNs via the afferent lymphatic vessel, in the 
context of BCG vaccination. This preliminary experiment, with two BCG-vaccinated 
pseudo-afferent lymphatic cannulated calves, showed a transient decrease in the 
percentage of NK cells present within AL at 4 hours post-BCG vaccination with the 
lowest levels of NK cells present at 24 hours post-vaccination. This decrease may be 
due to an increase in another cell population and therefore the absolute number of NK 
cells within AL following BCG vaccination would have to be defined. The percentage 
of NK cells within AL returned to pre-vaccination levels by 96 hours following 
vaccination (Figure 4.10.1). A decrease in the percentage of CD2- NK cells in AL was 
evident over time and may reflect selective movement of CD2- NK cells through AL 
and into LNs post-BCG vaccination (Figure 4.10.2). The decrease in the percentage of 
NK cells present within 4 hours post-BCG was coupled with an increase in the 
activation of AL derived NK cells within this period (Figure 4.10.3), which was 
attributed to the CD2- subset of NK cells (Figure 4.10.4). Following subcutaneous 
administration of GFP-labelled recombinant human replication-defective human 
adenovirus 5 (rhuAdV5) and water-in-oil adjuvant, the frequency of migratory DCs in 
AL increased within 4 hours and peaked at 15 hours post-inoculation, indicating that 
alterations to populations of innate immune cells occurs early post-vaccination 
(Cubillos-Zapata et al., 2011). Overall, data described in Figure 4.2.10 provide novel, 
preliminary evidence that NK cell frequency and phenotype within afferent lymph is 
altered following BCG vaccination.  
Left (BCG) and right (control) PSLNs draining the site of vaccination from vaccinated 
or revaccinated calves were removed either 24 hours or 48 hours post-BCG 
vaccination and NK cells were analysed for differences in frequency or phenotype. No 
differences in the percentage of NK cells present in the LNs draining the site of BCG 
vaccination were evident at either 24 hours or 48 hours post-vaccination in both 
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vaccinated and revaccinated calves (Figure 4.7 and Figure 4.8). Furthermore, LNs 
were also weighed and no differences were noted between the left, vaccinated LNs and 
the right, control LNs (data not shown). There may be a few possible explanations to 
describe the lack of alterations to NK cell frequency or phenotype within the nodes 
following BCG vaccination. Firstly, it may be that NK cell frequency and phenotype 
is altered at a time-point earlier or later than 24 or 48 hours post-BCG vaccination. For 
example, experiments presented in Figure 4.10.1 showed changes in AL derived NK 
cells as early as 4 hours post-BCG vaccination. During studies in mice, NK cells 
entered LNs 2 days after injection with LPS-matured DCs or adjuvants such as R848 
and Ribi. In this study, it was shown that NK cells were trafficking from the blood into 
the LNs (following intravenous injection of LPS-DCs, R848 and Ribi), however NK 
cells were not recovered from the LNs when LPS-DCs, R848 and Ribi were 
administered subcutaneously (Martin-Fontecha et al., 2004). Secondly, NK cells are 
rapidly recruited to murine LNs following vaccination or infection (Martin-Fontecha 
et al., 2004, Lucas et al., 2007) however, unlike bovine and human LNs, mouse LNs 
contain low frequencies of NK cells in steady-state conditions. Therefore, an influx of 
NK cells during inflammation may be more pronounced or easy to detect in mice, 
compared with cattle or humans. Alternatively, NK cells may be redistributed within 
LNs to areas where accessory cells such DCs are located or vaccine-induced NK cells 
may displace resident NK cells from the LNs. Both of these hypotheses would result 
in the percentage of NK cells within BCG draining LNs remaining relatively constant. 
Finally, it may be that BCG affects both the left PSLN draining the site of vaccination 
and the right PSLN and therefore may be the reason why there were no differences 
between NK cells in the left and right nodes. 
Evidence presented in Chapter 3 illustrated that NK cells are present within bovine 
efferent lymph and therefore indicated that NK cells may egress from the LNs to return 
to circulation in steady-state conditions. Following BCG vaccination, there were no 
significant differences in the percentage of NK cells present in EL at 24 or 48 hours 
post-BCG, compared with pre-vaccination (0 hours). The percentage of NK cells 
present at time 0 in the three calves tested was very variable as denoted by the large 
error bars (Figure 4.11.1). Nevertheless, the presence of NK cells within EL at 24 and 
48 hours post-BCG vaccination implies that BCG does not prevent egress of NK cells 
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from the LNs. It is thought that in response to antigen or infection that there is a 
shutdown in lymphocyte output that lasts up to 24 hours (as reviewed by (Haig et al., 
1999)), however NK cells were present in EL at both 24 and 48 hours post-vaccination. 
CD2- NK cells remained the predominant subset of NK cells present in EL throughout 
the course of the experiment (Figure 4.11.2). A non-significant decrease in the 
activation of NK cells was noted, as illustrated by both percentage of CD25+ NK cells 
and MFI (Figure 4.11.3). This experiment would need to be repeated in more calves 
to define the effect of BCG on NK cells egressing from the LNs by the efferent 
lymphatic vessel. 
Injecting fluorescently labelled NK cells would be an optimal method to track the 
movement of NK cells from the site of BCG vaccination, through skin draining 
afferent lymphatic vessels, LNs and their subsequent egress from the efferent 
lymphatic vessel. This would also allow confirmation that it is the CD2- subset of NK 
cells which are selectively moving in and out of LNs via the lymphatics.  
To conclude, BCG vaccination of neonatal calves resulted in an increased percentage 
of NK cells within the circulation, and alterations to the receptor repertoire of bovine 
NK cells. BCG had no effect on NK cells within LNs draining the site of vaccination 
at either 24 or 48 hours post-vaccination. Preliminary experiments showed alterations 
to the frequency and phenotype of NK cells within afferent lymphatic vessels 
following vaccination. Overall, data presented in this Chapter suggests a potential role 














NK cells play a role in shaping adaptive immune responses through interactions with 
DCs therefore interactions between NK cells and DCs in the context of BCG were 
investigated. DCs infected with BCG expressed significant levels of MHC class II and 
the co-stimulatory molecules CD40 and CD80, alongside augmented production of the 
Th1 polarising cytokine IL-12 when compared with uninfected DCs. As a result of in 
vitro co-culture with BCG-infected DCs, NK cells increased their expression of CD25 
and the CD2- subset of NK cells was preferentially activated. NK cell effector 
function, as measured by production of IFN-γ, was also significantly enhanced 
following co-culture with BCG-infected DCs. This chapter provides evidence to 
demonstrate that NK cells phenotypically and functionally mature after interactions 
with DCs in the context of BCG. Furthermore, through the production of IFN-γ and 
IL-12 by NK cells and DCs respectively, this interaction may drive Th1 immune 












5. Interactions between NK cells and DCs in the context of BCG 
 
 
5.1 Introduction  
NK cells are traditionally regarded as cells of the innate immune system however as 
influential drivers of the adaptive immune response, NK cells can be viewed as an 
interface between innate and adaptive immunity. Early interactions between 
populations of innate immune cells, particularly NK cells and DCs, are important 
elements for determining the nature of the adaptive immune response. NK cells can be 
directly activated by BCG. For example, BCG can bind to human NK cells via NK 
cell expression of NKp44 to induce proliferation, cytotoxicity and production of IFN-
γ (Esin et al., 2004, Esin et al., 2008). Similarly, expression of TLR2 by human NK 
cells permits direct recognition of BCG (Marcenaro et al., 2008). However, for the 
most part, NK cells require indirect activation through a complex interplay with 
populations of accessory cells, particularly DCs to become functionally mature (Lucas 
et al., 2007). The frequency, phenotype, function and receptor repertoire of NK cells 
following BCG vaccination of neonatal calves was described in Chapter 4. However, 
to fully understand NK cell responses during vaccination or infection, the role of 
accessory cells such as DCs and their relationship with NK cells must also be 
characterised.  
Interactions between NK cells and DCs were first described in vivo in 1999 when it 
was demonstrated that DCs could modulate NK cell-mediated anti-tumour responses 
in mice (Fernandez et al., 1999). The bidirectional interplay between NK cells and 
DCs has been described in human and mouse models (Moretta, 2002, Walzer et al., 
2005, Gerosa et al., 2005). This interplay has been the target for new therapies for 
cancer (Morandi et al., 2012, Shimizu and Fujii, 2009) and HIV (Altfeld et al., 2011). 
NK cells encounter DCs at sites of infection or inflammation and also within  
secondary lymphoid organs such as LNs (Cooper et al., 2004). For example, NK cells 
and DCs have been found in close contact in the lesions of patients with atopic 
eczema/dermatitis and were co-localised in the paracortex of the LNs (Ferlazzo et al., 
2004). Co-localisation of NK cells, DC and T cells has also been demonstrated in LNs 
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(Walzer et al., 2007a, Lucas et al., 2007, Bajenoff et al., 2006), indicating a role for 
innate immune cell interactions in shaping T cell responses in vivo. 
Similar to the interactions between APCs and T cells, interactions between NK cells 
and DCs are mediated by both soluble and contact-dependent signals. A central role 
for IL-12 in the cross-talk between NK cells and DCs is evident from a number of 
studies. IL-12 (IL-12p70) is a heterodimeric cytokine composed of a 40 kDa subunit 
(p40) and a 35 kDa subunit (p35) which drives Th1 polarisation of antigen-specific T 
cells, through the stimulation of IFN-γ (Macatonia et al., 1993). The importance of IL-
12 in protection against disease has been demonstrated in humans where a defective 
IL-12 receptor results in an increased susceptibility to mycobacterial infections (de 
Jong et al., 1998, Altare et al., 1998). IL-18 released by mature DCs, can potentiate 
IL-12 by inducing expression of IL-12R on NK cells (Novick et al., 2013). 
Importantly, it has been shown that the ability of DCs to produce IL-12 depends on 
rapid IFN-γ production by NK cells, resulting in a positive feedback loop involving 
secretion of IL-12 and IFN-γ from mature DCs and NK cells respectively (Gerosa et 
al., 2002, Piccioli et al., 2002). NK cells are an important early source of IFN-γ, and 
NK cell derived IFN-γ contributes to innate resistance to M. tb infection of humans 
(Feng et al., 2006). The development of protective immunity against M. bovis infection 
in cattle is driven by Th1-type immune responses which are characterised by IFN- 
production (Buddle et al., 2005). Interactions between NK cells and DCs in vivo have 
been shown in murine models to mediate the induction of Th1 responses through the 
secretion of NK cell derived IFN- (Martin-Fontecha et al., 2004).  
Cell-to-cell contact is required for cross-talk to occur by allowing formation of the 
immunological synapse for polarised delivery of cytokines and also receptor-ligand 
interactions. Interactions between CX3CL1 (fractalkine) and the receptor CX3CR1 
which are expressed by mature DCs and NK cells respectively, aid tethering of both 
cell populations and this contact stimulates the production of IFN-γ by NK cells 
(Pallandre et al., 2008). Other receptor ligand interactions which are important in the 
cross talk between NK cells and DCs are CD40-CD40L and CD28-B7. For example, 
ligation of CD40 on DCs by CD40L expressed by NK cells can augment the 
production of IL-12 (Mackey et al., 1998). 
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Interestingly, NK cells are capable of killing autologous immature DCs and this is 
proposed to permit NK cell selection of more immunogenic DCs in order to enhance 
protective immunity. Activated human NK cells kill immature DCs through the 
NKp30 receptor (Ferlazzo et al., 2002) which is mediated by a subset of 
CD94/NKG2A+ KIR- NK cells (Della Chiesa et al., 2003). Mature DCs are thought 
to be resistant to NK cell mediated cytotoxicity due to the up-regulation of MHC class 
I molecules on their surface (Carbone et al., 1999, Wilson et al., 1999, Ferlazzo et al., 
2002, Piccioli et al., 2002). NK cell mediated killing of immature DCs is proposed to 
be a mechanism by which the immune system selects immunogenic DCs for 
interactions with T cells.  
Initial investigations into bovine innate immune cell interactions in the context of 
mycobacteria showed that a population of NK-like cells from naïve calves produced 
IFN-γ after interplay with BCG-infected DCs (Hope et al., 2002b). More recently, 
interactions between NKp46+ NK cells and M. bovis-infected DCs were defined and 
showed that reciprocal interactions occur, resulting in activation of both NK cells and 
DCs (Siddiqui and Hope, 2012). 
Interactions between NK cells and DCs in the context of BCG vaccination, and the 
key mechanisms involved in this cross-talk have not been elucidated in cattle. 
Furthermore, the effect of these interactions on the adaptive immune response is 
unknown. In vitro co-cultures between BCG-infected monocyte-derived DCs and 
autologous NK cells enriched from peripheral blood were established to study the 
interaction between these two innate immune cell populations.  
The hypotheses being addressed in this chapter are that (1) NK cells require 
interactions with BCG-infected DCs to become phenotypically and functionally 
mature; and (2) the interaction between NK cells and DCs, in the context of BCG, 






5.2.1 Purification of CD14+ monocytes 
Initial investigations focussed on the effect of the vaccine strain BCG Danish on the 
phenotype and production of cytokines by monocyte-derived DCs. To generate a 
population of immature monocyte-derived DCs, CD14+ monocytes were isolated from 
the peripheral blood of calves using MACS MicroBeads conjugated to mouse anti-
human CD14 antibody and cultured for three days with recombinant bovine GM-CSF 
and IL-4. Prior to culture with GM-CSF and IL-4, the purity of monocytes was 
assessed by labelling cells with goat anti-mouse IgG conjugated to phycoerythrin (PE). 
Purities of CD14+ monocytes were consistently >98% (Figure 5.1.1). Following three 
days of culture with GM-CSF and IL-4 to obtain monocyte-derived DCs, DCs were 
identified by gating FSChigh SSChigh cells (Figure 5.1.2) which were negative for the 
dead cell discriminator, Sytox Blue (Figure 5.1.3). 
5.2.2  Infection of DCs with fluorescently labelled BCG 
To assess the percentage of DCs that took up BCG bacilli, uptake of bacteria was 
determined by labelling BCG with FITC. Monocyte-derived DCs from four calves 
were infected with fluorescently labelled BCG (MOI 5) for 42 hours which is the 
duration of the co-culture between BCG-infected DCs and NK cells. This MOI was 
selected after determining the percentage of DCs that took up BCG-FITC and the 
viability of DCs after infection of DCs with BCG at MOIs of 1, 3 and 5 (as detailed 
Figure 5.2.1 and 5.2.2). The percentage of BCG-FITC+ cells was determined by flow 
cytometry. BCG was successfully taken up by immature DCs as illustrated by the 
percentage uptake of BCG-FITC with 64.5% (48.2-75.8%; SD=14.1) of DCs 










Figure 5.1 Purification of CD14+ monocytes 
CD14+ monocytes were positively selected using MACS MicroBeads conjugated to 
mouse anti-human CD14 antibody and labelled with goat anti-mouse IgG PE antibody 
to assess purity. A representative FACS plots indicates the purity of CD14+ monocytes 
from one animal with the red histogram representing cells positive for CD14 (Figure 
5.1.1). Gates were set using unstained cells (blue histogram). Purities of CD14+ 
monocytes were consistently >98%. CD14+ monocytes were cultured for three days 
with recombinant bovine GM-CSF and IL-4 to obtain monocyte-derived DCs. DCs 
were identified by gating FSChigh SSChigh cells (Figure 5.1.2) which were negative for 






Figure 5.2 Infection of DCs with fluorescently labelled BCG 
Monocyte-derived DCs were cultured for three days and infected with FITC-labelled 
BCG (MOI 1, 3 and 5) for 42 hours. FACS plots from one representative animal 
(Figure 5.2.1) illustrate viability of DCs after infection with BCG. FACS plots from 
one representative animal (Figure 5.2.2) the uptake of BCG-FITC by uninfected DCs 
and BCG-infected DCs at MOI 1, 3 and 5. An MOI of 5 was selected and pooled data 
from four calves (Figure 5.2.3) illustrate the average percentage uptake of BCG-FITC 
± SD by uninfected DCs (lighter bar) and BCG-infected DCs (darker bar).  
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5.2.3 Expression of MHC and costimulatory molecules by BCG-infected DCs 
Following confirmation that immature DCs can uptake and be infected by BCG, the 
effect of BCG on the phenotype of DCs was investigated by comparing the expression 
of MHC class II and the costimulatory molecules CD40 and CD80 by uninfected and 
BCG-infected DCs. Monocyte-derived DCs from four calves were infected with BCG 
(MOI 5) for 42 hours and the expression of MHC class II, CD40 and CD80 were 
assessed by flow cytometry (Figure 5.3). Expression of MHC class II (p<0.001), CD40 
(p=0.032) and CD80 (p=0.044) were significantly enhanced following infection of 
DCs with BCG compared with uninfected DCs. Uninfected DCs expressed MHC class 
I and CD86, however no significant increases were observed in the expression of MHC 
class I and CD86 by BCG-infected DCs (data not shown). CCR7 expression was not 












Figure 5.3 Expression of MHC and costimulatory molecules by BCG-infected 
DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG (MOI 5) 
for 42 hours. Uninfected and BCG-infected DCs were labelled with mAbs for MHC 
class II, CD40 and CD80 and analysed by flow cytometry. FACS plots from one 
representative animal show the expression of MHC class II (Figure 5.3.1), CD40 
(Figure 5.3.2) and CD80 (Figure 5.3.3) by uninfected (blue histograms) and BCG-
infected DCs (red histograms). Positive cells were identified based on FMO controls 
(green histograms). Pooled data from four calves indicates the average MFI ± SD of 
MHC class II (Figure 5.3.4), CD40 (Figure 5.3.5) and CD80 (Figure 5.3.6) expression 
by uninfected (lighter bars) and BCG-infected DCs (darker bars). Data were normally 
distributed (p>0.05) and significant changes in the expression of MHC class II, CD40 




5.2.4 Production of IL-12 by BCG-infected DCs 
Protective immunity against M. bovis infection in cattle is driven by Th1 polarised 
immune responses (Buddle et al., 2005), therefore the production of the Th1 polarising 
cytokine, IL-12 by uninfected and BCG-infected DCs was defined. Monocyte-derived 
DCs from five calves were infected with BCG (MOI 5) for 42 hours and supernatants 
were assayed for the presence of IL-12 by ELISA (section 2.15). DCs infected with 
BCG secreted significantly higher levels of IL-12 (p=0.023) compared to uninfected 
DCs (Figure 5.4).  
 
Figure 5.4 Production of IL-12 by BCG-infected DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG (MOI 5) 
for 42 hours. Supernatants were retrieved from uninfected and BCG-infected DCs and 
assayed for cytokine production by ELISA (section 2.15). Pooled data from five calves 
represent the average levels ± SD of IL-12 BU/ml produced by uninfected (lighter 
bars) and BCG-infected DCs (darker bars). Data were normally distributed (p>0.05) 
and significance between uninfected and BCG-infected DCs was assessed using a 2-






5.2.5 Isolation of bovine peripheral blood NK cells 
To explore the interaction between NK cells and DCs in the context of BCG, in vitro 
co-cultures were established between these two populations of innate immune cells 
and the effect of this interaction on both NK cells and DCs was assessed. NK cells 
were isolated from peripheral blood using mouse anti-ovine NKp46 mAb (which 
cross-reacts with bovine) and pan anti-mouse IgG Dynabeads. Following dissociation 
of the magnetic beads, NK cell purity was confirmed by labelling cells with mouse 
anti-ovine NKp46 indirectly conjugated to goat anti-mouse IgG PE. The purity of 









Figure 5.5 Isolation of bovine peripheral blood NK cells 
NK cells were isolated by labelling lymphocytes with mouse anti-ovine NKp46 
followed by positive selection using pan-mouse IgG Dynabeads. NK cell purity was 
assessed by labelling cells with mouse anti-ovine NKp46 indirectly conjugated to goat 
anti-mouse IgG PE. Representative FACS plots illustrate the gating strategy used to 
identify bovine NK cells. Single cells were gated (Figure 5.5.1), followed by 
lymphocytes (Figure 5.5.2) which were negative for the dead cell discriminator, Sytox 
Blue (Figure 5.5.3). Figure 5.5.4 indicates the purity of NKp46+ NK cells (red 
histogram). Gates were set using unstained cells (blue histogram). Purities of 






5.2.6 Activation of NK cells following co-culture with BCG-infected DCs 
To assess the activation status of NK cells after in vitro co-culture with BCG-infected 
DCs, the expression of CD25 was examined using flow cytometry. Monocyte-derived 
DCs from five calves were infected with BCG (MOI 5) for 24 hours and cultured for 
a further 18 hours with autologous NKp46+ NK cells enriched from peripheral blood. 
NK cells cultured with media, BCG, uninfected DCs or with recombinant bovine IL-
12 and recombinant human IL-18 served as controls. CD25 expression, as represented 
by the MFI, was low when NK cells were cultured with media, with BCG and with 
uninfected DCs (Figure 5.6.2). Subsequent to co-culture with BCG-infected DCs, NK 
cell expression of CD25 was significantly increased compared with when NK cells 
were cultured with media (p=0.009), with BCG (p=0.009) and with uninfected DCs 
(p=0.012). NK cells supplemented with IL-12 and IL-18 (positive control), had a high 
expression of CD25 (Figure 5.6.2). In addition to enhanced CD25 expression (as 
assessed by MFI) a similar significant increase in the percentage of CD25+ NK cells 
present after culture with BCG-infected DCs was evident compared with the 
percentage of CD25+ NK cells present after culture of NK cells with media (p=0.005), 
BCG (p=0.004) and uninfected DCs (p=0.034) (Figure 5.6.3). Expression levels of 
NKp30 by NK cells after co-culture with BCG-infected DCs were examined and were 






Figure 5.6 Activation of NK cells following co-culture with BCG-infected DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG (MOI 5) 
for 24 hours. NKp46+ cells were enriched from peripheral blood and cultured with 
BCG-infected DCs at a ratio of 5 NK cells per DC (section 2.7). NK cells cultured 
with media, BCG, uninfected DCs or with IL-12 and IL-18 served as controls. After 
18 hours of co-culture, cells were labelled with mAbs for NKp46 and CD25 and 
analysed by flow cytometry. FACS plots from one representative animal illustrate the 
expression of CD25 by NKp46+  NK cells after culture with media, BCG, 
uninfected DCs, BCG-infected DCs or with IL-12 and IL-18 (Figure 5.6.1). Positive 
cells were identified based on FMO controls. Pooled data from five calves illustrate 
the average MFI ± SD of CD25 expression by NK cells (Figure 5.6.2). Pooled data 
from five calves displays the average percentage of CD25+ NK cells ± SD (Figure 
5.6.3). Data were normally distributed (p>0.05) and significance between co-culture 














5.2.7 Activation of NK cell subsets following co-culture with BCG-infected DCs 
To determine if the observed activation (CD25 expression) of NK cells in response to 
culture with BCG-infected DCs (Figure 5.2.6) was attributed to a particular subset of 
NK cells, multicolour flow cytometry was used to assess the expression of CD25 by 
CD2+ and CD2- subsets of NK cells. Expression was compared following culture of 
NK cells with media, BCG, uninfected DCs, BCG-infected DCs or when stimulated 
with IL-12 and IL-18. CD25 expression did not significantly differ between CD2+ and 
CD2- subsets when NK cells were cultured with media, BCG, uninfected DCs or with 
IL-12 and IL-18. However, after culture with BCG-infected DCs, CD2- NK cells had 












Figure 5.7 Activation of NK cell subsets following co-culture with BCG-infected 
DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG (MOI 5) 
for 24 hours. NKp46+ cells were enriched from peripheral blood and cultured with 
infected DCs at a ratio of 5 NK cells per DC (section 2.8). NK cells cultured with 
media, BCG, uninfected DCs or with IL-12 and IL-18 served as controls. After 18 
hours of co-culture, cells were labelled with mAbs for NKp46, CD2 and CD25 and 
analysed by flow cytometry. Positive cells were identified based on FMO controls. 
Pooled data from five calves indicate the average MFI ± SD of CD25 expression by 
CD2+ (lighter bars) and CD2- (darker bars) NK cells. Data were normally distributed 
(p>0.05) and significance between the expression of CD25 by CD2+ and CD2- NK 







5.2.8 Activation of NKp46+ CD3+ lymphocytes following co-culture with BCG-
infected DCs 
A population of NKp46+ CD3+ lymphocytes which have shared attributes of both 
bovine NK cells and T cells has recently been described (Connelley et al., 2014). As 
the enrichment technique used to isolate bovine NK cells from peripheral blood 
involves positively selecting the total NKp46+ population, the observed activation of 
NK cells as a result of in vitro co-culture with BCG-infected DCs (Figure 5.2.6) may 
be due (at least in part) to activation of these double positive cells and not solely to 
NKp46+ CD3- NK cells. To address whether NKp46+ CD3+ cells were activated after 
co-culture with BCG-infected DCs, the expression of CD25 was analysed on NKp46+ 
CD3+ and NKp46+ CD3- cells. Monocyte-derived DCs from three calves were 
infected with BCG for 24 hours and then cultured for 18 hours with autologous 
NKp46+ NK cells enriched from peripheral blood. The activation status of NKp46+ 
CD3+ and NKp46+ CD3- cells was determined by assessing the percentage of CD3+ 
or CD3- cells within the total NKp46+ CD25+ population. CD3- cells accounted for a 
significantly higher (p<0.001) percentage of the NKp46+ CD25+ population in 
comparison to CD3+ cells, with 98.4% (97.7-98.9; SD=0.51) of the NKp46+ CD25+ 






Figure 5.8 Activation of NKp46+ CD3+ lymphocytes following co-culture with 
BCG-infected DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG for 24 
hours. NKp46+ cells were enriched from peripheral blood and cultured with infected 
DCs at a ratio of 5 NK cells per DC (section 2.7). After 18 hours of co-culture, cells 
were labelled with mAbs for CD3, NKp46 and CD25 and analysed by flow cytometry. 
FACS plots from one representative animal denotes the gating strategy used to assess 
the percentage of CD3+ and CD3- cells within the total gated NKp46+ CD25+ cells. 
Gates were set using FMO controls. NKp46+ NK cells were selected (Figure 5.8.1) 
followed by CD25+ NK cells (Figure 5.8.2) and then CD3+ and CD3- cells were gated 
(Figure 5.8.3). Pooled data from three calves illustrates the percentage of CD3+ 
(lighter bar) and CD3- (darker bar) cells ± SD within the NKp46+ CD25 population 
(Figure 5.8.4). Data were normally distributed (p>0.05) and significance between 
CD3+ and CD3- cells was assessed using a 2-sample t-test; p<0.001***. 
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5.2.9 NK cell production of IFN-γ after co-culture with BCG-infected DCs 
In addition to the activation status of NK cells, the effector function of NK cells 
following co-culture with BCG-infected DCs was investigated by determining NK cell 
production of IFN-γ. Supernatants were retrieved from co-culture experiments (section 
2.7) and assayed for IFN-γ by ELISA (section 2.15). IFN-γ production was low when 
NK cells were cultured with media, with BCG or with uninfected DCs. Following co-
culture with BCG-infected DCs, NK cell production of IFN-γ was significantly 
augmented compared with NK cells cultured with media (p=0.020), NK cells cultured 
with BCG (p=0.021) and NK cells cultured with uninfected DCs (p=0.021). NK cells 
supplemented with IL-12 and IL-18 (positive control) produced high levels of IFN-γ 
(Figure 5.9).  
5.2.10 Effect of NK cell-DC co-culture on cytokine production by DCs 
It is well established in the literature that interactions between NK cells and DCs are 
reciprocal, thus the production of DC derived IL-12 was measured after co-culture 
with NK cells. Supernatants were retrieved from co-culture experiments (section 2.7) 
and assayed for IL-12 by ELISA (section 2.15). As illustrated previously, DCs secreted 
elevated levels of IL-12 upon infection with BCG compared with the low levels 
produced by uninfected DCs (Figure 5.2.4). Similar to DCs cultured with media, 
uninfected DCs cultured with NK cells produced low levels of IL-12. Addition of NK 
cells to BCG-infected DCs did not significantly increase the level of IL-12 produced 











Figure 5.9 NK cell production of IFN-γ after co-culture with BCG-infected DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG for 24 
hours. NK cells were enriched from peripheral blood and cultured with infected DCs 
at a ratio of 5 NK cells per DC (section 2.7). NK cells cultured with media, BCG alone, 
uninfected DCs or with IL-12 and IL-18 served as controls. After 18 hours of co-
culture, supernatants were assayed for IFN-γ production by ELISA (section 2.15). 
Pooled data from five calves represents the average levels ± SD of IFN-γ (pg/ml) 
produced. Data were normally distributed (p>0.05) and significance between co-





Figure 5.10 Effect of NK cell-DC co-culture on DCs 
Monocyte-derived DCs were cultured for three days and infected with BCG for 24 
hours. NK cells were enriched from peripheral blood and cultured with infected DCs 
at a ratio of 5 NK cells per DC (section 2.7). DCs cultured with media, BCG or NK 
cells served as controls. After 18 hours of co-culture, supernatants were assayed for 
production of IL-12 by ELISA (section 2.15). Pooled data from five calves represents 
the average levels ± SD of IL-12 (BU/ml). Data were normally distributed (p>0.05) 












5.2.11 Activation of NK cells following co-culture with Zylexis™-exposed DCs  
In parallel with BCG, Zylexis™, an inactivated equine Parapox Ovis Virus 
Immunomodulator, was tested within in vitro co-cultures of NK cells and DCs. 
Monocyte-derived DCs from one animal were exposed to Zylexis™ at a MOI of 1 or 
with BCG at an MOI of 5 for 24 hours and cultured for a further 18 hours with 
autologous NKp46+ NK cells enriched from peripheral blood. An optimal MOI of 1 
for the exposure of DCs to Zylexis™ was decided by determining cell viability after 
exposure of DCs with Zylexis™ at MOIs of 1, 5 and 10. NK cells cultured with media, 
Zylexis™, BCG, uninfected DCs or supplemented with IL-12 and IL-18 served as 
controls. NK cell activation, as defined by the expression of CD25, was analysed by 
flow cytometry (Figure 5.11.1). CD25 expression was low when NK cells were 
cultured with media, Zylexis™, BCG, uninfected DCs and Zylexis™-infected DCs. 
Similar to Figure 5.2.6, NK cell activation was augmented after culture with BCG-
infected DCs or when supplemented with IL-12 and IL-18. To assess if culture of NK 
cells with Zylexis™-exposed DCs altered the expression of CD25 by CD2+ or CD2- 
subsets, CD25 expression by CD2+ and CD2- NK cells was compared following 
culture with media, Zylexis™, BCG, uninfected DCs, Zylexis™-exposed DCs, BCG-
infected DCs or with IL-12 and IL-18 (Figure 5.11.2). No difference in the expression 
of CD25 by CD2+ and CD2- NK cells was evident after culture with Zylexis™-
exposed DCs. As illustrated previously (Figure 5.7), CD2- NK cells have an increased 











Figure 5.11 Activation of NK cells following co-culture with Zylexis™-exposed 
DCs  
Monocyte-derived DCs were cultured for three days and exposed to Zylexis™ (MOI 
1) or infected with BCG (MOI 5) for 24 hours. NKp46+ cells were enriched from 
peripheral blood and cultured with Zylexis™-exposed or BCG-infected DCs at a ratio 
of 5 NK cells per DC (section 2.8). NK cells cultured with media, Zylexis™, BCG, 
uninfected DCs or with IL-12 and IL-18 served as controls. After 18 hours of co-
culture, cells were labelled with mAbs for NKp46, CD2 and CD25 and analysed by 
flow cytometry. Positive cells were identified based on FMO controls. Data from one 
animal illustrates the MFI of CD25 expression by NKp46+ NK cells (Figure 5.11.1) 




5.2.12 IFN-γ production by NK cells following co-culture with Zylexis™-exposed 
DCs 
Zylexis™ had no effect on the activation of NK cells (Figure 5.11.1) however 
Zylexis™ may have induced IFN-γ production by NK cells and therefore be having a 
functional effect. To assess if co-culture with Zylexis™-exposed DCs affected the 
effector function of NK cells, the production of IFN-γ was assessed. Supernatants were 
retrieved from co-culture experiments (section 2.8) and NK cell production of IFN-γ 
was determined by ELISA (section 2.15). Similar to the low level of IFN-γ produced 
after culture of NK cells with media, Zylexis™, BCG and uninfected DCs, IFN-γ 
production was not enhanced following NK cell culture with Zylexis™-exposed DCs 
(Figure 5.12). As previously shown in Figure 5.2.9, co-culture of NK cells with BCG-













Figure 5.12 IFN-γ production by NK cells following co-culture with Zylexis™-
exposed DCs 
Monocyte-derived DCs were cultured for three days and were exposed to Zylexis™ 
(MOI 1) or infected with BCG (MOI 5) for 24 hours. NKp46+ cells were enriched 
from peripheral blood and cultured with Zylexis™-exposed or BCG-infected DCs at 
a ratio of 5 NK cells per DC (section 2.8). NK cells cultured with media, Zylexis™, 
BCG, uninfected DC or with IL-12 and IL-18 served as controls. After 18 hours of co-
culture, the amount of IFN-γ present in the supernatant was measured by ELISA 













5.3 Discussion  
To determine the effect of BCG on NK cell-DC interactions, in vitro co-cultures 
between these two innate immune cell populations were established. Prior to 
assessment of the effect of culture with BCG-infected DCs on the activation and 
effector function of NK cells, the influence of the vaccine strain BCG Danish on DC 
phenotype and cytokine production was initially determined. CD14+ monocytes 
cultured with recombinant bovine GM-CSF and IL-4 for 3 days represent a population 
of immature monocyte-derived DCs (Werling et al., 1999). In line with published data 
by Werling et al, immature, uninfected DCs in this study expressed MHC class II, 
CD40 and CD80 at low levels which were increased upon pathogenic stimuli (Figure 
5.3). Immature monocyte-derived DCs ingested BCG as illustrated by the uptake of 
fluorescently labelled bacteria (Figure 5.2.3). Receptors involved in the uptake of 
mycobacteria by human and murine DCs include dendritic cell-specific ICAM-3-
grabbing nonintegrin (DC-SIGN) (Tailleux et al., 2003), TLR2 (Means et al., 1999), 
TLR4 (Tsuji et al., 2000) and TLR9 (von Meyenn et al., 2006). Similarly, a role for 
DC-SIGN in the uptake of BCG by bovine monocyte-derived DCs was confirmed 
when it was demonstrated that blocking DC-SIGN with a polyclonal antibody reduced 
binding of GFP-labelled BCG (Yamakawa et al., 2008). Furthermore, bovine 
monocyte-derived DCs express surface TLR2 which could be a potential route for 
uptake of BCG in cattle.  
Upon antigen uptake, immature DCs undergo maturation characterised by the 
upregulation of MHC class I, MHC class II and costimulatory molecules, including 
CD40, CD80 and CD86 (Steinman, 1991). Following uptake of BCG Danish by 
bovine DCs, DCs significantly increased their expression of MHC class II, CD40 and 
CD80 reflecting maturation of DCs in response to BCG (Figure 5.3). This is in line 
with published data whereby DCs infected with BCG Pasteur showed an increased 
expression of MHC class II, CD40 and CD80 (Hope et al., 2004). Taken together, this 
provides evidence that bovine monocyte-derived DCs undergo maturation in response 
to BCG Pasteur and to the human vaccine strain BCG Danish. Non-significant 
increases were noted in the expression of MHC class I and CD86 by BCG-infected 
DCs compared with uninfected DCs (data not shown). Maturing DCs also express 
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chemokine receptors, for example, CCR7 which permits migration of DCs carrying 
antigen from the periphery to the draining LNs (Moretta, 2002). This allows entry of 
mature DCs, which are licensed to effectively stimulate naïve T cells, into the LNs. 
However, expression of CCR7 was not detected by uninfected or BCG-infected bovine 
DCs (data not shown).  
In parallel with phenotypic maturation in response to antigen uptake, DCs also secrete 
cytokines which direct appropriate adaptive immune responses, and therefore link the 
innate and the adaptive immune response. Naïve CD4+ T cells can differentiate into 
various subsets of CD4+ T helper cells which is dictated in part by the cytokine milieu 
present at the time of differentiation (Zhou et al., 2009). For example, the presence of 
IL-12 and IFN-γ in the local environment results in the development of a Th1 immune 
response whereas the presence of IL-4 directs a Th2 immune response. Given that that 
Th1 dominant response is likely to be most effective against M. bovis infection, the 
production of IL-12 by uninfected and BCG-infected DCs was quantified. BCG-
infected DCs produced significant levels of IL-12 after infection with BCG (Figure 
5.4) indicating that BCG-infected DCs could contribute significantly to the induction 
of a CD4+ Th1 immune response. Bovine DCs have been shown previously to secrete 
IL-12 after infection with M. bovis and the Pasteur strain of BCG (Hope et al., 2004). 
The results presented in Figure 5.4 demonstrate that DCs can also produce IL-12 when 
stimulated with the vaccine strain of BCG. Conversely, BCG-infected macrophages 
have been reported to produce very little IL-12 (Hope et al., 2004), suggesting that 
macrophages are unlikely to be the drivers of Th1 responses to BCG.  
After establishing that DCs mature in response to infection with BCG (Figure 5.3) and 
produced the Th1 polarising cytokine IL-12 (Figure 5.4), the effect of BCG-infected 
DCs on NK cell activation was investigated by assessing NK cell expression of CD25. 
To do this, in vitro co-cultures were established between monocyte-derived DCs 
infected with BCG and autologous peripheral blood derived NK cells at an optimal 
ratio of 5 NK cells per DC (Siddiqui and Hope, 2012). CD25 expression was 
significantly augmented when NK cells were cultured with BCG-infected DCs, 
reflecting activation of NK cells in response to co-culture with DCs in the context of 
BCG (Figure 5.6). Previous work has shown that bovine NK cells are optimally 
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stimulated with IL-12 and IL-18 (Siddiqui and Hope, 2012), therefore NK cells 
supplemented with IL-12 and IL-18 were used as a positive control. NK cells 
stimulated in this manner were highly activated. CD25 is the α chain of the IL-2R and 
together with the IL-2Rβ and γ chains allows IL-2 signalling through the IL-2R, 
therefore data presented in Figure 5.6 suggests NK cells are more responsive to IL-2 
following co-culture with BCG-infected DCs. It was also demonstrated in Figure 5.8.4 
that activation of NK cells after co-culture with BCG-infected DCs was specific to 
NKp46+ CD3- NK cells and that a recently characterised subset of lymphocytes that 
co express NKp46 and CD3 were not activated by co-culture with BCG-infected DCs 
(Connelley et al., 2014).  
 
The observed activation of NK cells after in vitro co-culture with BCG-infected DCs 
(Figure 5.6) appears to be due to preferential activation of the CD2- subset of NK cells 
illustrated by a significantly higher CD25 expression by CD2- NK cells compared with 
CD2+ NK cells (Figure 5.7). Interestingly, in the positive control whereby NK cells 
were stimulated with IL-12 and IL-18, there was not a significant difference between 
the expression of CD25 by the two subsets, indicating that the increased activation of 
CD2- NK cells after co-culture with BCG-infected DCs was specific to these 
conditions. This preferential activation of bovine CD2- NK cells was also apparent 
when NK cells were cultured with M. bovis-infected DCs (Siddiqui and Hope, 2012) 
showing that CD2- NK cells are preferntially activated when NK cells are cultured 
with DCs in vitro in the context of both BCG and M. bovis. 
 
NKp30 is a key molecule involved in NK cell killing of immature DCs in humans 
(Ferlazzo et al., 2002) therefore expression of this receptor  by NK cells was assessed 
after co-culture with BCG-infected DCs. Using a mAb to bovine NKp30, NKp30 
expression was not detected on NK cells across all culture conditions (data not shown). 
In other experiments, NKp30 was upregulated by peripheral blood NK cells after 
overnight culture with recombinant bovine IL-2 (data not shown). It is proposed that 
NK cells activated by BCG-infected DCs kill immature DCs to allow the immune 
system to select the most immunogenic DCs (Siddiqui and Hope, 2012). Activated 
human NK cells which have been exposed to M. bovis-infected DCs acquire the ability 
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to kill immature DCs whereas DCs which upregulate HLA class I molecules were 
resistant to NK cell mediated killing (Ferlazzo et al., 2003). Similarly, bovine NK cells 
increased their expression of perforin and capacity to kill P815 target cells after 
interactions with bovine M. bovis-infected DCs (Siddiqui and Hope, 2012). Further 
work is required to address this hypothesis in cattle and the key molecules involved in 
this process. 
 
Production of cytokines, primarily IFN-γ, is a key functional property of NK cells and 
in parallel with IL-12, early production of IFN-γ drives optimal Th1 polarised immune 
responses. Therefore, supernatants from co-culture experiments were assayed for the 
presence of NK cell-derived IFN-γ. IFN-γ production was significantly augmented 
when NK cells were co-cultured with BCG-infected DCs (Figure 5.9), demonstrating 
that production of IFN-γ by NK cells after co-culture with BCG-infected DCs has the 
potential to prime Th1-type immunity. It is not clear if the concentration of IFN-γ 
produced by NK cells after in vitro co-culture with BCG-infected DCs is biologically 
relevant. To test this, the ability of macrophages to kill BCG after stimulation with 
titrated IFN-γ could be tested in vitro. Murine NK cells polarise Th1 immune responses 
through interactions with DCs (Martin-Fontecha et al., 2004) and enhanced secretion 
of IFN-γ by NK cells was also noted after reciprocal interactions with M. tb-infected 
DCs (Gerosa et al., 2002). Within the present study, the subset of NK cells responsible 
for the increased IFN-γ production following co-culture with BCG-infected DCs was 
not defined. However, bovine CD2- NK cells have an increased capacity to produce 
IFN-γ compared with CD2+ NK cells (Boysen et al., 2006). Furthermore, CD2- NK 
cells are the subset responsible for production of IFN-γ after culture with M. bovis-
infected DCs (Siddiqui and Hope, 2012). Therefore, we hypothesise that CD2- NK 
cells are the major IFN-γ producers following co-culture with BCG-infected DCs. 
Studies in humans have shown that BCG can bind directly to NK cells through NK 
cell expression of TLR2 and NKp44 and induce NK cell production of IFN-γ. Data 
presented here shows no effect of BCG alone on the production of IFN-γ by NK cells 
(Figure 5.9), or on the activation of NK cells (Figure 5.6). Despite TLR2 being 
transcribed by bovine NK cells (Nazneen Siddiqui, PhD thesis, Imperial College, 
2011), expression of TLR2 was not detected on the surface of NK cells (data not 
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shown). Furthermore, NKp44 is a pseudogene in cattle (Hammond, 2012) therefore 
combined with the lack of surface TLR2, may explain why there was no direct 
recognition of BCG by bovine NK cells in this study.  
 
Data presented herein demonstrates that BCG-infected DCs provide signals to NK 
cells which induce phenotypical and functional changes; however NK cells are also 
thought to modulate the response of DCs in a reciprocal interaction. Thus, the effect 
of NK cells on the production of IL-12 by BCG-infected DCs was assessed. The 
addition of NK cells increased the amount of IL-12 produced by BCG-infected DCs 
alone; although this was not significant (Figure 5.10). NK cells express receptors for 
IL-12 (Vitale et al., 2002) and as the supernatants were retrieved 18 hours after co-
culture with BCG-infected DCs, it is possible that the presence of NK cells enhanced 
the production of IL-12 by BCG-infected DCs through the release of IFN-γ, and this 
IL-12 was subsequently utilised by NK cells expressing IL-12R. In mice, DCs that 
have been in contact with NK cells were shown to increase secretion of IL-12 (Van 
Elssen et al., 2010) and in cattle, M. bovis-infected DCs showed enhanced expression 
of MHC class II after interactions with autologous peripheral blood NK cells (Siddiqui 
and Hope, 2012). Hence, NK cells may influence the adaptive immune response by 
inducing effective APC. As a result of data presented thus far, the proposed in vitro 

















Figure 5.13. The proposed interaction between bovine BCG-infected DCs and 
NK cells in vitro. 
Immature monocyte-derived DCs take up BCG resulting in increased expression of 
MHC class II and the key costimulatory molecules, CD40 and CD80. BCG-infected 
DCs also produce elevated levels of the Th1 polarising cytokine IL-12. As a result of 
interactions with BCG-infected DCs, autologous CD2- NK cells increase their 
expression of the activation marker CD25 and functional capacity, defined by NK cell 
production of IFN-γ. Together this interaction may contribute to the development of a 
Th1 biased immune response through the secretion of IL-12 and IFN-γ by BCG-














In conjunction with Zoetis, Zylexis™ was tested in co-cultures of NK cells and DCs 
to determine if Zylexis™ could act as an immunomodulator within this system. 
Adjuvants such as R848 (TLR7 agonist) recruited NK cells to antigen stimulated LNs 
of mice, as effectively as LPS-matured DCs, where they polarised Th1 immune 
responses through the secretion of IFN-γ (Martin-Fontecha et al., 2004). Co-cultures 
were set up as described in section 2.7 and also included NK cells cultured with 
Zylexis™ and NK cells cultured with Zylexis™-exposed DCs. Zylexis™ co-cultures 
were set up in parallel with BCG co-cultures to allow direct comparison between the 
two agents. Zylexis™-exposed DCs from three calves showed no significant 
differences in the expression of MHC class II, CD40, CD80 or the production of IL-
12 compared with uninfected DCs (data not shown). Subsequently, after co-culture of 
NK cells with Zylexis™-exposed DCs, there were no significant differences in the 
expression of CD25 (Figure 5.11.1) or production of IFN-γ (Figure 5.12) by NK cells. 
However, after co-culture with BCG-infected DCs, NK cell activation and effector 
function was significantly enhanced as previously illustrated (Figures 5.6 and 5.9). 
Since Zylexis™ did not induce maturation of DCs; it is perhaps not surprising that 
culture of NK cells with Zylexis™-exposed DCs had no effect on NK cell activation 
or function. It was possible that Zylexis™ could act directly on NK cells inducing 
CD25 expression and IFN-γ production without the requirement of accessory cells 
such as DCs. Nevertheless, similar to BCG, Zylexis™ alone had no effect on NK cell 
activation (Figure 5.11) or function (Figure 5.12). It should be noted that the influence 
of Zylexis™ on DC phenotype and production of IL-12 was demonstrated in three 
calves, however co-cultures between Zylexis™-infected DCs and autologous NK cells 
were investigated using DCs and NK cells derived from one animal and therefore may 
not be fully representative. Further work is required to decipher the effect of such 
adjuvants on NK cells.  
 
The mechanisms underlying the interactions between bovine NK cells and DCs in the 
context of BCG have not yet been elucidated. Both soluble factors and contact-
dependent receptor ligand interactions are thought to be important. Since uninfected 
DCs (which have a low expression of MHC class II, CD40 and CD80, and very low 
levels of IL-12) did not stimulate NK cell activation (Figure 5.6) or production of IFN-
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γ (Figure 5.9), we hypothesised that IL-12, CD40 and CD80 were likely to be key 
molecules involved in the cross-talk between NK cells and DCs. Preliminary 
experiments utilising an IL-12 neutralising antibody CC326, (Hope et al., 2002a) and 
CD40 and CD80 blocking antibodies provided some evidence for the involvement of 
these molecules during the NK cell-DC interaction in the context of BCG, however 
these experiments require further optimisation. Despite being unable to definitively 
show that these molecules were involved in the interactions between NK cells and 
BCG-infected DCs, we were able to demonstrate that exposure of DCs to Zylexis™ 
did not increase the expression of MHC class II, CD40 or CD80, or the production of 
IL-12 and subsequently, Zylexis™-exposed DCs were not equipped to induce NK cell 
activation (Figure 5.11) or cytokine production (Figure 5.12). Overall, IL-12, CD40 
and CD80 represent suitable candidates for some of the key molecules involved in the 
crosstalk between NK cells and BCG-infected DCs. 
 
To conclude, data presented in this Chapter has demonstrated that bovine NK cells 
require interactions with BCG-infected DCs for optimal activation and production of 
IFN-γ in vitro, therefore proving the first hypothesis stated at the beginning of this 
Chapter. Furthermore, CD2- NK cells preferentially interact with DCs in the context 
of BCG highlighted by their increased activation compared with their CD2+ 
counterparts. Through the secretion of IFN-γ and IL-12 by NK cells and BCG-infected 
DCs respectively, this interaction generated a cytokine milieu which is conducive to 
the development of Th1 biased CD4+ and CD8+ T cell response, thus proving the 
second part of the hypothesis. Further studies are required to determine if the 
interaction between NK cells and BCG- or M. bovis-infected DCs primes CD8+ T cells 





































6. Final Discussion 
 
The species and subspecies of the M. tb complex infect a wide range of mammalian 
hosts, with M. tb and M. bovis being the causative agents of human and bovine TB 
respectively. Human TB remains a significant source of morbidity and mortality with 
9 million people developing TB and 1.5 million dying from this disease in 2013 
(WHO, 2014). Similarly, bTB is increasing in incidence in regions of South West of 
England and Wales, and currently costs the UK economy up to £100 million per 
annum. An effective cattle vaccine is urgently required to improve control of bTB, 
alongside diagnostic tests which can differentiate infected from vaccinated animals 
(DIVA) (Krebs JR, 1997). However, currently within the UK there are no cattle 
vaccines licensed for use. Despite over a century of research, BCG remains the only 
vaccine available for use in humans against TB and is particularly effective when 
delivered to infants (Fine, 1995). Similarly, it is well established in the literature that 
experimental vaccination of neonatal calves with BCG provides significant protection 
against M. bovis infection (Buddle et al., 1995b, Hope et al., 2005, Hope et al., 2011), 
with protection induced by BCG vaccination lasting for at least 12 months (Thom et 
al., 2012). Nevertheless, BCG interferes with the tuberculin skin test and is therefore 
not licensed for use in the UK, and similar to humans (Fine, 1995), the efficacy of 
BCG is variable across studies in calves (Waters et al., 2012). Therefore improved 
vaccines are required and in order to design better vaccines, the immune response 
following BCG vaccination must be understood. Calves are immunocompetent at birth 
therefore respond well to neonatal vaccination and vaccination of neonates overcomes 
problems associated with exposure to environmental mycobacteria prior to 
vaccination. Furthermore, neonatal calves have an increased frequency (Kulberg et al., 
2004, Graham et al., 2009) and activity (Elhmouzi-Younes et al., 2009) of NK cells 
which may explain the enhanced efficacy of BCG in neonatal calves. 
 
Research within this thesis has focussed on the potential role of NK cells and NK cell 
interactions with DCs during BCG vaccination of neonatal calves which have not been 
previously investigated. Bovine NK cells are identified by their expression of NKp46 
and the development of a mAb specific to this natural cytotoxicity receptor has 
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revolutionised bovine NK cell research (Storset et al., 2004). NK cells can be 
subdivided into CD2+ and CD2- subsets which differ in their localisation, phenotype 
and function (Boysen et al., 2006). In recent years, NK cells have been recognised as 
key players in both the innate and the adaptive immune response and accordingly, can 
interact with populations of accessory cells to drive adaptive immune responses. 
Protective immunity against M. bovis infection in cattle is hypothesised to be driven 
by Th1 immune responses (Buddle et al., 2005) which are driven by a cytokine milieu 
of IL-12 and IFN-γ. NK cells are major sources of IFN-γ and influence IL-12 
production through interactions with APCs, therefore could be central to the induction 
of Th1 biased immunity. 
 
NK cells are widely distributed in lymphoid and non-lymphoid compartments, 
allowing NK cells to respond quickly to infection and inflammation. In bovine PB, 
CD2+ NK cells constitute 70-80% of NK cells present whereas CD2- NK cells are the 
principal subset of NK cells found within bovine LNs. NK cells are hypothesised to 
enter LNs from the blood via HEVs or alternatively from tissues such as the skin via 
afferent lymphatic vessels (Martin-Fontecha et al., 2004, Bajenoff et al., 2006). Lund 
et al provided the first indication that bovine NK cells are present within skin-draining 
afferent lymphatic vessels by comparing samples of PB and AL from different animals 
(Lund et al., 2013). Those findings were extended in Chapter 3 of this thesis by 
comparing the frequency and phenotype of NK cells and NK cell subsets from PB, AL 
and LNs of the same animal. CD2- NK cells were the predominant NK cell subset 
present within AL and LNs, providing evidence that CD2- NK cells can migrate from 
the skin through afferent lymphatic vessels and into draining LNs in steady-state 
conditions. Furthermore, CD2- NK cells trafficking through AL were highly activated, 
as reflected by the expression of the activation marker CD25, and maintained this 
activated phenotype in the LNs. CD2+ NK cells were the main subset of NK cells 
resident within the skin which further strengthens the hypothesis that CD2- NK cells 
are the main migratory subset of NK cells in cattle. Furthermore, it was established in 
Chapter 3 that CD2- NK cells were the predominant subset of NK cells within the EL 
and can therefore egress from the LNs and return to the circulation where they were of 
a CD2+ CD25lo phenotype. The presence of NK cells within EL is a novel finding in 
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the bovine system, with NK cells having only been identified in human EL to date 
(Romagnani et al., 2007). Overall, findings presented in Chapter 3 provide the first 
indication that CD2- NK cells may represent a recirculating population of lymphocytes 
in cattle and as a result, may play a role in immune surveillance. Nevertheless, bilateral 
cannulation of the afferent and efferent lymphatic vessels in the same animal (as 
described by (Vrieling et al., 2012)) would establish if NK cells can re-circulate. NK 
cells would be isolated, fluorescently labelled and then injected subcutaneously back 
into the animal. The presence of labelled NK cells in both AL and EL would confirm 
that bovine NK cells can re-circulate and would reveal the kinetics of this process.  
 
Further to determining the frequency and phenotype of PB, AL, LN and EL derived 
NK cells in steady-state conditions in Chapter 3, data presented in Chapter 4 assessed 
NK cell properties in the context of BCG vaccination. Studying NK cells draining the 
site of BCG vaccination will provide information about the activation of innate 
immune cells following vaccination. NK cells increased in frequency within the 
circulation following vaccination of neonatal calves with BCG and the receptor 
repertoire of NK cells was altered, indicating that NK cells in the blood undergo 
changes post-BCG vaccination. Conversely, NK cells within the LNs draining the site 
of BCG vaccination were not altered 24 or 48 hours post vaccination. As mentioned 
in Chapter 4, depletion of NK cells using a mAb specific for NKp46 prior to BCG 
vaccination and challenge with M. bovis would be the optimal method to define the 
functional role of NK cells during BCG-induced protection. Similar studies in a mouse 
model of M. tb infection showed that depletion of NK cells had no influence on the 
bacterial load within the lungs (Junqueira-Kipnis et al., 2003). The in vivo depletion 
technique has been successfully used to define the role of γδ T cells (Kennedy et al., 
2002) and CD8+ T cells (Villarreal-Ramos et al., 2003) during M. bovis infection of 
cattle. It would also be of interest to assess the BCG-specific NK cell recall response 
by challenging NK cells from the studies described in Chapter 4 with PPD-b or BCG 
in vitro. Studies in cannulated calves provide a unique opportunity to study immune 
cells ex vivo which is particularly relevant for understanding immune responses 
following vaccination or infection. NK cell responses were studied in a small number 
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of afferent and efferent lymphatic cannulated calves and would need to be repeated to 
fully understand the mechanisms occurring at the site of BCG vaccination.   
 
A key feature of NK cells is their ability to direct adaptive immune responses through 
interactions with populations of innate immune cells. As a result of in vitro co-culture 
with BCG-infected DCs, NK cells were highly activated and produced IFN-γ. 
Interestingly, CD2- NK cells were significantly more activated than CD2+ NK cells 
after co-culture with BCG-infected DCs and are also thought to preferentially produce 
IFN-γ (Boysen et al., 2006, Siddiqui and Hope, 2012). However, NK cell activation 
and production of IFN-γ was not observed when NK cells were cultured with BCG, 
uninfected DCs or cultured with DCs that had been exposed to Zylexis™ suggesting 
that in this system, NK cells require interactions with BCG-infected DCs to become 
activated. BCG-infected DCs expressed MHC class II, CD40 and CD80 and produced 
the Th1 polarising cytokine IL-12 and therefore propose that these molecules will play 
key roles in driving NK cell activation and effector function. Furthermore, this 
interaction may drive Th1 immune responses through the production of IL-12 and IFN-
γ by BCG-infected DCs and NK cells respectively. To demonstrate a role for 
interactions between NK cells and DCs in driving Th1 immune responses in the 
context of BCG, autologous CD4+ or CD8+ T cells from BCG-vaccinated calves could 
be added into in vitro co-cultures between NK cells and DCs. Analysis of T-bet 
expression or production of IFN-γ by CD4+ T cells would decipher if NK cell-DC 
interactions were required for polarisation of Th1 responses in cattle. It has been 
demonstrated that NK cells drive Th1 polarisation of CD4+ T cells in mice (Martin-
Fontecha et al., 2004) and human CD8+ T cell activation (Vankayalapati et al., 2004).  
 
It is not known if the proposed in vitro interactions between NK cells and DCs infected 
with BCG occur in vivo in cattle. Innate immune cell interactions are expected to take 
place at sites of infection or inflammation and also within secondary lymphoid organs 
such as LNs (Cooper et al., 2004). Findings in Chapter 3 identified CD2- NK cells as 
the main NK cell subset which can migrate from skin through AL and into draining 
LNs therefore CD2- NK cells are located in AL and LNs where they may interact with 
DCs. CD2- NK cells preferentially express inflammatory and lymphoid homing 
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chemokine receptors including CXCR3, CD62L and CCR7 representing favoured 
migration of this subset of NK cells towards sites of vaccination or infection (Chapter 
3 and (Siddiqui and Hope, 2012)). Data presented within Chapter 5 provided evidence 
that CD2- NK cells are the subset of NK cells which are activated following 
interactions with BCG-infected DCs. Furthermore, evidence presented in Chapter 4 
supports a role for NK cells during BCG vaccination of neonatal calves. It may be that 
CD2- NK cells constitutively recirculate in steady-state conditions and upon BCG 
vaccination or M. bovis infection, may interact with DCs in draining LNs, and then 
exit the LNs to return to the site of vaccination or infection via the efferent lymphatic 
vessel. CD2- NK cells may also interact with BCG-infected DCs in skin draining LNs 
resulting in generation of Th1 biased CD4+ and CD8+ T cell responses. As a result of 
findings generated within this thesis, the proposed interaction between NK cells, DCs 






















Figure 6.1. The proposed interaction between NK cells, DCs and BCG  
CD2+ NK cells are the main subset of NK cells resident within bovine skin and may 
represent a non-migratory subset of NK cells (1). In steady-state conditions, CD2- NK 
cells can migrate from the skin through afferent lymphatic vessels and into LNs 
draining the skin due to their expression of LN homing molecules such as CD62L (2). 
CD2- NK cells are highly activated (as determined by expression of CD25) in AL and 
LNs compared with those found in the circulation. CD2- NK cells can then egress from 
the LNs to return to circulation via the efferent lymphatic vessel (3). Upon 
subcutaneous BCG vaccination (4), the frequency of NK cells within the circulation 
increased and changes to the receptor repertoire of NK cells were observed (5). 
Following vaccination, BCG-infected DCs may migrate to skin draining LNs where 
they preferentially interact with CD2- NK cells resulting in enhanced activation and 
effector function of NK cells and generation of a cytokine milieu conducive to the 





Interactions between NK cells and DCs have been the target for new therapies for 
cancer (Morandi et al., 2012, Shimizu and Fujii, 2009) and HIV (Altfeld et al., 2011). 
Similarly, the interaction between bovine CD2- NK cells and DCs may represent a 
target for future vaccination strategies to initiate Th1 polarised immune responses 
during BCG vaccination of neonatal calves. For example, NK cells are responsive to 
adjuvants (Magnusson et al., 2013) therefore adjuvants could be delivered alongside 
BCG to promote the co-localisation and interaction of CD2- NK cells and DCs which 
could subsequently drive NK cell activation and polarisation of Th1 immune 
responses.  
 
To conclude, this thesis has provided evidence in support of the notion that CD2- NK 
cells preferentially migrate from the tissues into draining LNs via afferent lymphatic 
vessels and can then egress from the LNs to return to circulation via the efferent 
lymphatic vessels in steady-state conditions. In addition, it was demonstrated that NK 
cells may play a role in the immune response induced by BCG vaccination of neonatal 
calves, through increased frequency of NK cells and alterations to receptor repertoire. 
Finally, this thesis has shown that CD2- NK cells were preferentially activated 
following interactions with BCG-infected DCs and that together this interaction 
generated a cytokine milieu favourable to polarisation of Th1 immune responses which 
are important in the protective immune response against M. bovis infection of cattle. 
The findings produced in this thesis are not only relevant to improving vaccination 
strategies for enhanced control of bTB but may also be important for human vaccine 
design or delivery strategies for human TB as BCG vaccination of infants involves 
induction of NK cell responses and interactions between NK cells and APCs are 
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8.1  Media  
Tissue Culture Medium  
450ml RPMI 1640 with Glutamax + 25mM HEPES 




Middlebrook 7H9 medium 
2.35g Middlebrook 7H9 broth base 
450ml distilled water 
0.5g Tween 80 
1 vial Middlebrook ADC Supplement  
 
Middlebrook 7H11 agar  
21g Middlebrook 7H11 powder  
900ml distilled water 
100ml Middlebrook OADC enrichement 
 





PBS/1% BSA/0.1% sodium azide 
500ml PBS 
0.5g BSA 






PBS/Tween 20  
1000ml PBS 




100ml 5% BSA 
4ml 0.5M EDTA 
 
20 x PMA/Ionomycin/Brefeldin A 
50μl 100μg/ml PMA 
100μl 1mg/ml Ionomycin 























8.2 Monoclonal antibodies  
Antigen Antibody Isotype Specificity Supplier 
NKp46 CD335-PE IgG1 Mouse anti-
bovine 
AbD Serotec, UK 
NKp46 EC1.1 IgG1 Mouse anti-ovine Kindly provided by 
Tim Connelley 
NKp48 AKS6 IgG2b Mouse anti-
bovine 
Kindly provided by 
Anne Storset 
CD2 CC42 - FITC IgG1 Mouse anti-
bovine 
AbD Serotec, UK 
CD2 ILA42 IgG2a Mouse anti-
bovine 
IAH, Compton 
CD3 MM1A IgG1 Mouse anti-
bovine 
VMRD, Washington 
CD25 CACT108A IgG2a Mouse anti-
bovine 
VMRD, Washington 
CD62L CC32-FITC IgG1 Mouse anti-
bovine 
AbD Serotec, UK 
CCR7 (CD197) 3D12-Alexa 
Fluor 647 
IgG2a Rat anti-human BD Pharmingen 
MHC class II 
DQ 
CC158 - PE IgG2a Mouse anti-
bovine 
AbD Serotec, UK 
CD40 ILA156 - FITC IgG1 Mouse anti-
bovine 
AbD Serotec, UK 
CD80 ILA159 IgG1 Mouse anti-
bovine 
IAH, Compton 
CD86 ILA190 IgG1 Mouse anti-
bovine 
IAH, Compton 
CD4 CC8 IgG2a Mouse anti-
bovine 
IAH, Compton 
CD8αα CC63 IgG2a Mouse anti-
bovine 
IAH, Compton 
CD8αβ CC58 IgG1 Mouse anti-
bovine 
IAH, Compton 
WC1 CC15 - FITC IgG2a Mouse anti-
bovine 
AbD Serotec, UK 







AbD Serotec, UK 
IFN-γ  CC330 IgG1 Mouse anti-
bovine 
AbD Serotec, UK 




AbD Serotec, UK 
IL-12 CC301 IgG2a Mouse anti-
bovine 
AbD Serotec, UK 
IL-12 CC326 IgG2b Mouse anti-
bovine 






Goat anti-mouse IgG RPE Southern Biotech 
Goat anti-mouse IgG1 Alexa Fluor 647 Life Technologies 
Goat anti-mouse IgG1 FITC Bio-Rad 
Goat anti-mouse IgG2a Alexa Fluor 647 Life Technologies 




8.4 PCR primers 
 Forward Primer Reverse Primer 
KLRC 1.2 TAAAAGTTCCATTTCAATGACT CCAGGATCCCAGCAATGAA 
KLRC 2.1 ACTCCAGGAAACAGCAAGTT GTTATTCTGTTCCTGTATTAGAGC 
KLRC 2.2 GGAGACAGCAAATGAGAGATTC TCGGGAGCTTTGTTACCAG 














8.5 qPCR primers and mastermix compositions  
 
 Forward Primer Reverse Primer  
NKp30 GTTGTTCATCTTTATCATCATCCG ACTCCCTTGGCTGGCATTG 
ATP5B CCTTCTGCTGTGGGTTATCA CAGGATCCGTCAAGTCATCA 
EIF2B2 GAGCATATCCACTCCAACGA CACTCTGCCACAATGACATG 
 
 NKp30 ATP5B EIF2B2 
c DNA (µl) 1 1 1 
Forward primer (µl) 0.5 2.1 2.1 
Reverse primer (µl) 0.5 2.1 2.1 
Mastermix (µl) 10 10 10 

















COS cell derived recombinant 
bovine IFN-γ (IAH, Compton) 




COS cell derived recombinant 
bovine 



























40μm cell strainers 
BD LSRFortessa 
FACS Permeabilising Solution 10X 
FACSFlow 
Middlebrook 7H11 agar 
Middlebrook OADC enrichement 
Biolegend 
Zombie Aqua Fixable Viability Kit 
Bioline 




BioTAQ DNA polymerase 
d NTP mix 
BioTek 
Synergy HT Multi-Mode Microplate Reader 
GE Healthcare UK Limiited 
Streptavidin-HRP 
GP Pharmaceuticals 
Monoparin Heparin  
Infusion Concepts 
350ml blood bags 
Invitrogen 
RPMI 1640 with Glutamax and HEPES buffer 25mM 
Superscript III Reverse Transcriptase system  
SYBR Safe DNA gel stain 
Life Technologies 
DynaMag-15 
Pan-mouse IgG Dynabeads  
MicroAmp Fast Optical 96-Well Reaction Plate q PCR plates  
Sytox Blue Nucleic Acid Stain 
Luminaris Colour HiGreen Low ROX qPCR master mix  
Miltenyi Biotech 
Human CD14 MicroBeads 
MACS LS columns 
MACS Multi stand 
















RNeasy mini kit 
Buffer RLT 
RNase-Free Dnase Set 
Sarstedt 
500ml blood bags 
Schering-Plough 
Sodium benzylepenicillin  
Sigma Aldrich 
2-Mercatoethanol  
7H9 Middlebrook Broth Base 
Bovine Serum Albumin 
Brefeldin A  
Carbonate-bicarbonate buffer capsules 
Cell Dissociation Solution Non-Enymatic 1x 
Collagenase 
Dispase 
Dimethyl sulfoxide (DMSO) 






Phorbol 12-myristate 13-acetate (PMA) 
Sodium Azide 
Sodium Casein  
3,3’,5,5’-Tetramethylbenzidine (TMB) substrate 
Tween-20 
TCS Biosciences Ltd 





21G needles  
Thermo Fisher Scientific 
0.2ml thin walled 8 tube strips 
96 well round bottom plates 
Disposable scalpels 
Heparin Sulphate 
Nunclon Delta Surface 12 well plate 
Nunclon Delta Surface 24 well plate 
Nunclon Delta Surface 6 well plate 





NUNC Maxisorp ELISA plate 
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